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Abstract
In order to protect human health and environment, safety assessment of drugs and
industrial chemicals is mandatory according to the EU legislations. In pharmaceutical
industry, lack of efficacy in addition to safety concerns in clinical trials are the main
reasons for low success rate in the development of new drugs. Animal biology based
test systems have often failed to predict the efficacy in humans and to reveal the
adverse effects. In addition to poor predictive value, ethical concerns, high costs,
time consuming protocols and low throughput have raised the need to replace animal
models and to develop more advanced test systems.
Primary cells are considered as the traditional in vitro test systems for safety and
efficacy assessment. More recently, human pluripotent stem cells have emerged as a
promising source of specific cell types with the possibility for high throughput
production with reasonably low costs. Growing data shows that instead of planar
monocultures, supportive microenvironment, essential cell types and defined culture
conditions are critical in developing more accurate in vitro models. Furthermore,
before utilization in regulatory safety and efficacy assessment, careful
characterization and validation of the developed in vitro models is necessary.
The main objective of this thesis was to develop advanced, human cell based tissue
models to supplement or, preferably, replace animal tests and to be used in
biomedical research. First, in vitro vascular models were developed for toxicity and
efficacy assessment of pro- or anti- angiogenic compounds. Careful characterization
with defined medium was performed to vasculogenesis-angiogenesis model for
further intra-laboratory validation and to study the properties of the model as a
supportive platform for tissue models. As the second main objective, we combined
the vascular model with cardiomyocytes to establish a cardiovascular model for
cardiac safety and efficacy assessment of chemicals.
The results showed that an extensive vascular-like network formation with mature
tubules was reproducible formed in vasculogenesis-angiogenesis model in six day
culture. The characterization with defined, serum-free medium showed that
vasculogenesis-angiogenesis model is ready for intra-laboratory validation. Proof-of-
concept on the enhanced viability of co-culture of cardiomyocytes and vascular-like
network was received with two different vascular platforms. Finally, completely
human cell based cardiovascular model was shown to possess more mature structure
and response to chemicals than widely used cardiomyocyte monoculture.
It can be concluded that the developed vascular and cardiovascular models provide
more advanced test systems for safety and efficacy assessment compared to widely
used monocultures with the possibility to supplement or replace part of the tests
currently performed with animal models. However, further characterization as well
as in vitro-in vivo comparison on human cardiovascular model is needed before it may
enter into validation.
Tiivistelmä
Lääkkeiden ja teollisuuskemikaalien turvallisuuden arviointi on säädetty EU:ssa
pakolliseksi ihmisten terveyden ja ympäristönsuojelun takaamiseksi.
Lääketeollisuudessa suurin ongelma uusien lääkeaineiden kehittämisessä on niiden
riittämätön teho tai lääkeaineiden ihmisille aiheuttamat haittavaikutukset. Tähän on
syynä usein se, että eläinmalleilla ei ole kyetty ennustamaan lääkeaineiden ja
kemikaalien tehoa tai turvallisuutta ihmisille.  Huonon ennustavuuden lisäksi eettiset
syyt, korkeat kustannukset ja alhainen suoritusteho ovat syitä sille, että
eläinbiologiaan perustuvat testausmallit halutaan korvata kehittyneemmillä
menetelmillä.
Primaarisolut ovat perinteisesti käytettyjä in vitro testimenetelmiä lääkeaineiden ja
kemikaalien turvallisuuden ja tehon arvioinnissa. Ihmisen pluripotenteista
kantasoluista erilaistetut solut tarjoavat uuden mahdollisuuden yksilöllisten,
spesifisten solutyyppien monistamiseen suhteellisen edullisin kustannuksin.
Viimeaikaiset tutkimukset ovat osoittaneet, että yksisoluviljelmien sijaan
kasvuympäristö, muut oleelliset solutyypit ja kontrolloidut kasvuolosuhteet ovat
kriittisiä uusien, ennustavampien in vitro mallien kehityksessä. Tämän lisäksi in vitro
mallien huolellinen karakterisointi ja validointi ovat edellytyksenä niiden
hyväksymiselle virallisiksi testimenetelmiksi viranomaisohjeistoihin.
Tämän väitöskirjatyön päätavoitteena oli kehittää ihmissolupohjaisia kudosmalleja
testimenetelmiksi, joilla voitaisiin täydentää tai korvata eläinkokeita ja saada suoraan
ihmisiin sovellettavaa tutkimustietoa. Verisuonimuodostusta jäljitteleviä in vitro
malleja kehitettiin verisuonimuodostusta lisäävien tai estävien yhdisteiden
testaamiseen. Vaskulogeneesi-angiogeneesi -verisuonimallin karakterisoinnissa
kehitettiin uusi kasvatusliuos tulevaa laboratorion sisäistä validointia varten sekä
tutkittiin mallin ominaisuuksia verisuoniverkostoa muodostavana pohjarakenteena.
Lopullisena tavoitteena oli yhdistää verisuonimalli sydänlihassoluihin ja kehittää
täysin ihmissolupohjainen sydänmalli lääkeaineiden ja kemikaalien tehon ja
turvallisuuden tutkimiseen.
Tulokset osoittivat, että vaskulogeneesi-angiogeneesi -mallissa muodostuu kypsiä
verisuonimaisia rakenteita toistettavasti kuuden viljelypäivän aikana. Uusi
kasvatusliuos tuki vaskulogeneesi-angiogeneesi -mallin kypsymistä aikuisen
kaltaiseksi ja mallin todettiin olevan valmis laboratorion sisäiseen validointiin.
Verisuonimallin ja sydänlihassolujen yhdistäminen sydänmalliksi osoitettiin
toimivaksi kahdella erilaisella verisuonimaisella pohjarakenteella. Tulokset täysin
ihmissolupohjaisesta sydänmallista osoittivat sydänlihassolujen kypsyvän aikuisen
kaltaisiksi ja vastaavan kemikaalialtistuksiin yksisoluviljelmää herkemmin. Tämän
väitöskirjatyön tulosten perusteella verisuoni- ja sydänmalli tarjoavat
kehittyneemmän testausmenetelmän yhdisteiden toksisuuden ja tehon testaamiseen
sekä mahdollisuuden korvata osa vastaavista eläinmalleilla suoritettavista testeistä.
Sydänmalli vaatii kuitenkin jatkokarakterisointia sekä in vitro-in vivo vertailua ennen
siirtymistä mallin validointiin.
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1 Introduction
Since animals, especially mammals, are similar to humans in complexity and
physiological features, animal testing has been traditionally considered as the most
appropriate way to predict human responses. Consequently, various biomedical
research areas and the majority of the regulatory guidelines for safety evaluation relies
on animal testing. (Heinonen, 2015)  However, unreliability related to the translation
of the results from animal tests to humans in addition to ethical and economical
concerns calls for more advanced test systems (Suter-Dick et al., 2015).  Beside
general toxicity assessment, high drug attrition rate during clinical phases of drug
development has led to an increasing need for test systems that predict clinical
outcome better than conventional planar cell culture systems and animal models
(Tourovskaia et al., 2014).
Lack of physiologically relevant in vitro models is a major obstacle for the
implementation of in vitro tests systems. Traditionally used primary cell cultures and
transformed cell lines often fail to adequately mimic the in vivo situation since primary
cells tend to lose their differentiated characteristics and genotypic changes take place
during the transformation of cell lines. (Suter-Dick et al., 2015). The potential of
human pluripotent stem cells (hPSC) to provide differentiated cell models for drug
development, safety assessment and regenerative medicine is widely acknowledged
(O'Connor, 2013). The utilization of hPSC in improving human safety and, at the
same time, following the 3Rs principles of refinement, reduction and replacement of
animals, highlights the significant impacts of this field. (Kolaja, 2014)
In vitro models of vasculogenesis and angiogenesis are needed for basic biomedical
research as well as for translational research including drug development with
screening of pro- and anti-angiogenic compounds (Ucuzian & Greisler, 2007,
Folkman, 2007). In addition, drug-induced vascular injury has been challenging
pharmaceutical industry causing termination of development of new drug candidates
in nonclinical safety assessment (Mikaelian et al., 2014, Morton et al., 2014).
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Presently, there are no relevant in vitro models available for screening applications to
study drug-induced vascular injury (Mikaelian et al., 2014) or embryonic vascular
development as part of developmental toxicity assessment (Heinonen, 2015).
Heart has been shown to be particularly prone to toxic effects of drugs that can cause
severe adverse effects including decreased cardiac contractility, increased arrhythmia,
ischemia and even sudden death (Redfern et al., 2003, Lasser et al., 2002, Lexchin,
2005). Hence, assessment of the risk of a drug to cause cardiac electrophysiological
disturbances is regulated as part of the standard preclinical evaluation of new
compounds (Braam et al., 2010). Since adverse cardiac effects are the main cause for
drug withdrawal from the market and delays in regulatory approval, heart is one of
the major target for pharmaceutical industry. For these reasons, relevant test systems
for cardiac toxicity assessment are urgently needed (Kettenhofen & Bohlen, 2008).
The objective of this thesis was to develop and characterize vascular model for
toxicity and efficacy assessment of pro- and anti-angiogenic compounds and to be
used as vascular platform for tissue constructs. Another main objective was to
combine the vascular model with cardiomyocytes in order to establish cardiovascular
model for cardiac safety and efficacy assessment with human relevance. In the
development of these in vitro vascular and cardiovascular models, cells mainly of
human origin were used, medium was optimized and, furthermore, characterization
on structural, gene expression and functional level was performed.
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2 Review of the literature
2.1 Development and characteristics of vasculature
Blood vessels arose during evolution to carry oxygen, essential nutrients and waste
products to distant organs. In the developing embryo, cardiovascular system is the
first organ system developed (Carmeliet, 2005).  Blood circulation is crucial to the
mammalian embryo when its growth exceeds the limits of oxygen diffusion at about
100–200 μm in size. This occurs in the 3rd week of gestation in humans and 10th
day of gestation in rats. (Knudsen & Kleinstreuer, 2011) At the same time, heart
starts to beat and vessels of the primary vascular plexus remain either as capillaries
or differentiate into arteries or veins (Buschmann & Schaper, 1999). To increase
blood transport into growing tissues capillaries sprout and branch into larger, more
complex networks. The process of vascular development is most obvious during
embryogenesis when the first primitive vascular structures develop. However, similar
remodeling processes are thought to be essential for physiological and pathological
angiogenesis in adult. (Adams & Alitalo, 2007)
There are several known mechanisms for blood vessel formation. Vasculogenesis is
the earliest morphogenetic process of vascularization and takes place during the early
embryonic development but also during adult life. (Rivron et al., 2008, Carmeliet &
Jain, 2011, Flamme et al., 1997, Drake, 2003) In vasculogenesis, angioblasts, i.e.
endothelial precursor cells that share an origin with hematopoietic progenitor cells,
differentiate into endothelial cells (EC) and assemble into a primitive vascular plexus
(Drake, 2003). Vasculogenesis can be divided into different steps including (1)
differentiation of mesodermal cells into angioblast; (2) differentiation of angioblasts
into EC; (3) formation of the primary vascular plexus and aggregates that establish
cell-cell contacts without lumen; (4) a primary endothelial tube is formed composed
of polarized EC; (5) a primary vascular network is formed out of primary endothelial
tubes and (6) pericytes and vascular smooth muscle cells are recruited to stabilize the
vascular network. (Ko et al., 2007)
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In subsequent vessel sprouting, known as angiogenesis, the preexisting vascular
network expands, invades to target tissues and gives rise to the vascular system.
(Carmeliet & Jain, 2011, Buschmann & Schaper, 1999). Angiogenesis process can be
divided into six different steps with (1) vasodilation; (2) basement membrane
degradation; (3) cell migration; (4) formation of lumen; (5) synthesis of new
basement membrane and (6) recruitment of pericytes or vascular smooth muscle
cells to stabilize the vessel. (Ko et al., 2007) During adulthood, most blood vessels
are, however, quiescent and angiogenesis occurs mainly in the cycling ovary and in
the placenta during pregnancy (Carmeliet, 2005). Tissues can also become
vascularized by other mechanisms, e.g. by vessel splitting known as intussusception
or tumor cells can take over the existing vasculature. (Carmeliet & Jain, 2011)
De novo formation of vascular structures during embryogenesis begins with the
formation of endothelial progenitor cells in the extraembryonic mesoderm allantois
(Chen & Zheng, 2014). In humans, this fetoplacental vasculogenesis starts at
approximately 21 days after conception by formation of endothelial tubes
(Kaufmann et al., 2004). Blood flow to the maternal, fetal and placental units is
established during implantation and placentation as the maternal-fetal circulation
connects within the placenta (Reynolds & Redmer, 2001). The placental vasculature
further expands and extensive vascularization from pre-existing vessels occurs in
maternal as well as in fetal site (Chen & Zheng, 2014). Blood flow gradually increases
until the mid-gestation and after that according to the rate of the growing fetus
(Reynolds & Redmer, 2001). Due to active blood vessel formation, the placenta
provides an extensive source of pro- and anti-angiogenic factors (Chen & Zheng,
2014).  In addition, umbilical cord blood has been shown to contain high number of
hematopoietic stem/progenitor cells (Huss, 2000).
2.1.1 Differentiation and maturation of vascular structures
In order to reach the complex organization, the immature vascular network, formed
by vasculogenesis or angiogenesis, must mature at the level of the vessel wall and at
the network level. Maturation of the vessel wall involves recruitment of mural cells,
development of the surrounding matrix and organ-specific differentiation of EC,
mural cells as well as interendothelial junctions, apical-basal polarity and surface
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receptors. Maturation of the network involves optimal patterning of the vascular
network by branching and expanding to meet the tissue spesific requirements. The
timing of these processes may overlap allowing the sustained development of
vasculature towards maturation. Each molecule involved in the blood vessel
formation has multiple functions in the development of a mature vascular network.
(Jain, 2003, Stratman et al., 2009, Risau, 1997).
Maturation involves a transition from an actively growing vascular structures to a
quiescent, fully formed and functional network (Adams & Alitalo, 2007). Incomplete
maturation is frequently detected in pathological conditions, particularly in the
vasculature of tumors. A prominent feature of the maturation is the recruitment of
mural cells including pericytes and vascular smooth muscle cells. Pericytes establish
direct cell–cell contact with EC and cover capillaries and immature blood vessels.
(Aguilera & Brekken, 2014) Vascular smooth muscle cells, on their behalf, cover
mature and larger vessels, such as arteries and veins, and are separated from the
endothelium by a basement membrane. These mural cell types share a mesenchymal,
fibroblast-like morphology. (Adams & Alitalo, 2007) The vessels are stabilized not
only by recruiting mural cells but also by generating extracellular matrix (Stratman &
Davis, 2012) by controlling the formation of lumen and tubule network formation
(Sacharidou et al., 2012, Davis et al., 2011).
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2.1.2 Structure of the vascular network
The adult vasculature, with a surface area of ~1,000 m2, consists of EC, extracellular
matrix (ECM) and supporting mural cells that include pericytes for capillaries and
vascular smooth muscle cells for larger vessels (Figure 1). More complex vessel
structures may also include fibroblasts. (Rivron et al., 2008, Buschmann & Schaper,
1999) The smallest microvessels are capillaries that consist of lumen with an inner
diameter of 4-10 µm and a very thin vessel wall composed of EC. (Ko et al., 2007)
Vascular network formation is discussed in detail below.
Figure 1. Structure of blood vessel with capillary lining endothelial cells, basement membrane,
extracellular matrix and pericytes. Image modified from https://en.wikipedia.org/
wiki/Extracellular_matrix
2.1.2.1 Endothelial cells
Endothelial cells are one of the main building blocks of blood vessels with the role
in isolating the blood flow from surrounding tissues. EC function as barriers in
controlling the infiltration of blood proteins and cells through the vessel wall.
(Dejana, 2004) In the angiogenesis process, some EC within the capillary wall,
known as the tip cells, are responsible for sprouting.  After stimulation with
angiogenic factors, the quiescent vessel dilates and the tip cell starts to form branch
from the pre-existing vascular structures. (Carmeliet & Jain, 2011) Importantly, EC
interact with each other and with variety of other cell types including pericytes,
smooth muscle cells and leukocytes as well as extracellular matrix in the formation
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of blood vessels and in controlling the infiltration of proteins (Hillen et al., 2006).
Turnover time of EC is usually hundreds of days which makes them one of the most
quiescent and genetically stable cells in the body. (Kalluri, 2003) EC are widely used
to study adverse aspects of EC biology and angiogenesis (Hillen et al., 2006).
Heterogeneous characteristics between EC in different organ sites and vessel types
have been detected.  For example, studies in humans and in animals have shown that
the expression level of von Willebrand Factor in the lung vasculature is higher in
larger vessels. (Pusztaszeri et al., 2006) Common EC markers include platelet
endothelial cell adhesion molecule (CD31/PECAM), vascular endothelial cadherin
(CD144), hematopoietic progenitor cell antigen (CD34), endoglin (CD105), von
Willebrand factor (vWf, Factor VIII–related antigen), ecto-5'-nucleotidase (CD73)
and intercellular adhesion molecule 2 (ICAM-2, CD102) (Garlanda & Dejana, 1997).
EC express a wide variety of ion channels and show regional heterogeneity including
differences in Ca2+ signaling as well as in immunological and in metabolic properties.
Although EC are nonexcitable cells, the abundance of ion channels in the plasma
membrane of them has raised questions about their functional role. Ion channels are
involved in controlling intercellular permeability, EC proliferation, and angiogenesis.
They might be involved also in the regulation of the traffic of macromolecules, e.g.
von Willebrand factor. (Nilius & Droogmans, 2001)
2.1.2.2 Pericytes
Microvessels are composed of EC, surrounded by basal lamina and single pericytes
whereas large vessels are covered with multiple layers of smooth muscle cells and
collagenous fibers. Smooth muscle cells in large vessels support and regulate blood
flow.  Although pericytes have been mainly associated with blood vessel stabilization
(Bergers & Song, 2005) they have several other relevant functions related to
angiogenesis (Gerhardt & Betsholtz, 2003). Pericytes sense the presence of
angiogenic stimuli as well as the hemodynamic forces. In the formation of blood
vessels, EC and pericytes form a common basement membrane. Furthermore,
mature pericytes form umbrella-like contacts with the EC in vascular structures thus
covering several capillary structures.  (Hall, 2006).  Pericytes communicate with EC
by direct physical contact through gap junctions and also with paracrine signaling
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pathways (Bergers & Song, 2005). Pericytes may contribute to morphogenetic
control of capillary diameter through their ability to contract or, perhaps more likely,
control capillary diameter by regulating EC proliferation and differentiation.
(Gerhardt & Betsholtz, 2003)
Pericytes are multipotent cells with the capacity to differentiate into vascular smooth
muscle cells, other mesenchymal cell types and also fibroblasts in vitro and in vivo. The
extent of pericyte coverage in capillaries is tissue specific ranging from 10-50 % thus
reflecting the specific functional features of the microvessels in different organs.
Pericytes are prevalent at capillary branch points whereas the part of a vessel engaged
in the transport of gases and/or nutrients is typically free of pericytes. (Gerhardt &
Betsholtz, 2003)
Pericytes express a number of markers of differentiation such as alpha smooth
muscle actin (α-SMA), desmin, chondroitin sulfate proteoglycan (NG-2) and
platelet-derived growth factor receptor β (PDGFR-β). (Hall, 2006) In addition to
these, molecular markers including the regulator of G-protein signaling RGS5 or the
reporter transgene X-LacZ4 label only part of the heterogeneous pericyte population
and are, moreover, also expressed by vascular smooth muscle cells and other cell
types. No single marker is able to identify all pericytes. Furthermore, it remains
unclear whether there are other, unidentified and perhaps tissue-specific subsets of
mural cells. (Adams & Alitalo, 2007)
2.1.2.3 Extracellular matrix
Extracellular matrix (ECM) and basement membrane have an important role in
angiogenesis as EC originate from existing blood vessels, are surrounded by matrix
and eventually maturate through basement membrane formation. (Kalluri, 2003).
ECM has a mechanical role in supporting and maintaining the tissue architecture.
Although the extracellular matrix molecules play an important role in stabilizing
blood vessel structures, the components of vascular basement membrane are
required also for the initiation of angiogenesis process. (Sottile, 2004) Moreover,
ECM regulates migration, proliferation and differentiation of EC in the formation
of vascular structures. (Iivanainen et al., 2003)
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In resting tissues, interactions between EC and ECM are stable whereas in the
presence of angiogenic stimuli EC start to degrade ECM components with matrix
metalloproteinases. This change in interaction promotes the process of new blood
vessel formation. (Sottile, 2004)  ECM is organized into two layers: 1) vascular
basement membrane located between EC and vascular smooth muscle cells or
pericytes and 2) the interstitial matrix. Basement membrane consists of molecules
including collagen IV, laminins and heparin sulfate proteoglycans (e.g. perlecans)
whereas typical components of the interstitial matrix are fibrillar collagens and
glycoproteins such as fibronectin. (Iivanainen et al., 2003) Type IV collagen is the
main component of the vascular basement membrane and the assembly of the type
IV collagen scaffold is important for basement membrane integrity and structural
organization. Type IV collagen has also been shown to promote vascular elongation,
proliferation, and stabilization in a dose-dependent manner. (Bonanno et al., 2000)
Although several cell types are responsible for producing constituents of the
basement membrane, fibroblasts are known to secrete the precursor components of
ECM. Several studies have shown that cells can sense the three-dimensional
organization of fibrillar ECM proteins, and that cell phenotype can be altered by
changing the composition or organization of matrix fibrils (Ichii et al., 2001, Sottile,
2004, Sechler & Schwarzbauer, 1998).
2.1.2.4 Junctions
Cell-cell interactions are important for the regulation of tissue integrity and for
generation of barriers between different organs (Hillen et al., 2006). Intercellular
junctions mediate adhesion and communication between EC and epithelial cells. In
the endothelium, cells are connected through tight junctions, adherence junctions
and gap junctions. (Bazzoni & Dejana, 2004) The expression and organization of
these junctions depends on the type of vessels and the permeability requirements of
the organ. During the organization of an EC monolayer into vascular structures, cell-
cell connections follow different steps of maturation. (Bazzoni & Dejana, 2004,
Dejana, 2004, Nilius & Droogmans, 2001)
Gap junctions are communication structures that control the passage of small
molecular weight compounds and ions between neighboring cells (Bazzoni &
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Dejana, 2004). They allow direct electrical and metabolic communication between
EC, between EC and SMC and also between EC and lymphocytes or monocytes.
Various isoforms of connexins are thought to be responsible for these functional
cell-cell connections. At least three isoforms including Cx-37, Cx-40, and Cx-43 are
expressed in EC. Cx-43 has shown to be more abundant in macrovascular than in
microvascular cells whereas coronary artery endothelium expresses Cx-40 and Cx-
37 but lacks Cx-43. Gap junctions can be formed between the same or different
isoforms of connexins. Expression of connexins depends on the functional state of
EC and is modulated by growth factors, inflammatory agents (TNF-α) and by
mechanical forces. (Nilius & Droogmans, 2001).
Adherence junctions and tight junctions share the same binding mechanism where
adhesion is mediated by transmembrane protein forming a zipper-like structure
along the cell border (Hillen et al., 2006). Adherence junctions play an important role
in contact inhibition of EC growth and in organization of new vessels. The major
functional purpose of tight junctions is to provide a barrier within the membrane by
regulating paracellular permeability and maintaining cell polarity by subdividing the
plasma membrane into an apical and basolateral side. (Bazzoni & Dejana, 2004) In
tight junctions, adhesion is mediated by claudins and occludins whereas at adherence
junctions adhesion is mostly promoted by vascular endothelial cadherin. Nectin
participates in the organization of tight junctions as well as adherence junctions.
Outside these junctional complexes, platelet endothelial cell adhesion molecule
(PECAM) contributes to endothelial cell–cell adhesion. (Dejana, 2004)
2.1.3 Functional properties of vasculature
Blood vessels are crucial for organ growth in the embryo and repair of wounded
tissue in adults (Carmeliet, 2005). All tissues need to be vascularized in order to
develop and survive. Capillaries are the smallest blood vessels with the inner
diameter of 4-10 µm. Vascular system contributes also to immune protection by
circulating immune cells, it controls temperature and blood pressure and, further,
provides a biochemical communication system. (Ko et al., 2007)
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Properly functioning vasculature requires branching of vascular structures. It has
been shown that vascular patterns produced in the adult are highly variable. The
lumenal surface of blood vessels is constantly exposed to hemodynamic forces,
primarily to shear stress, created by the blood flow in vivo. Hemodynamic forces
play a critical role in the remodeling of vascular network according to tissue specific
requirements. (Dor et al., 2003)
2.1.4 Regulation of blood vessel formation
Blood vessel formation is a strictly organized process including vascular initiation,
formation, maturation, remodelling and regression that are controlled and
modulated to meet the tissue requirements (Figure 2) (Staton et al., 2009). In the
regulation of blood vessel formation, important signaling factors include VEGF-A
in sprouting vessel formation, Notch/Delta signaling in specification and TGF-
beta/Angiopoietin in the stabilization of vessel structures (Knudsen & Kleinstreuer,
2011, Bikfalvi & Bicknell, 2002). Growth factors and signaling pathways related to
blood vessel formation are discussed below in detail.
2.1.4.1 VEGF
Vascular Endothelial Growth Factor (VEGF) family consists of six members:
VEGF-A, PlGF, VEGF-B, VEGF-C, VEGF-D, and orf virus VEGF (VEGF-E)
(Liekens et al., 2001). VEGF (also known as VEGF-A) is the main component of
VEGF family stimulating angiogenesis in health and in disease (Carmeliet & Jain,
2011, Tang et al., 2015). VEGF-A exerts its biologic effect through interaction with
cell surface receptors, i.e. transmembrane tyrosine kinases. VEGF receptor-1
(VEGFR-1) and VEGFR-2 are mainly expressed on vascular EC and VEGFR-2
appears to be the major receptor mediating the pro-angiogenic effects of VEGF-A.
(Otrock et al., 2007)  VEGFR-2 deficiency as well as loss of VEGF aborts vascular
development. (Carmeliet & Jain, 2011)
VEGF is expressed by many cell types and in different tissues including brain,
kidney, liver, and spleen (Liekens et al., 2001). Members of the VEGF family are
produced by human fibroblasts and are important in regulating vascular EC
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proliferation (Wong et al., 2007). In vitro, VEGF stimulates ECM degradation,
proliferation, migration, and EC tubule formation as well as expression of MMP-1
(Figure 2). In vivo, VEGF has been shown to regulate vascular permeability in the
initiation of angiogenesis. During embryogenesis, VEGF promotes differentiation
and proliferation of EC and the formation of immature vessels.  (Liekens et al., 2001,
Domigan et al., 2015) Beside growth factors, VEGF levels are also regulated by tissue
oxygen levels as hypoxia induces VEGF expression rapidly and reversibly. On the
contrary, normoxia down-regulates VEGF production and causes regression of
newly formed blood vessels. With these opposing processes, the vasculature meets
the metabolic requirements of the specific tissue. (Liekens et al., 2001)
2.1.4.2 FGF family
The fibroblast growth factor (FGF) family consists of at least 19 members (Liekens
et al., 2001) in which heparin-binding protein mitogens acidic and basic fibroblast
growth factors (aFGF and FGF-2) play an important role in angiogenesis (Figure 2)
(Otrock et al., 2007). FGF-2 induces tubule formation in collagen gels and modulates
gap junction communication as well as VEGF up-regulation in vitro. FGF-2 is
expressed at low levels in almost all tissues with high levels reached in the brain and
pituitary. It is found also in many cultured cell types, including fibroblasts, EC,
smooth muscle cells and glial cells. (Liekens et al., 2001)
ECM sequesters angiogenic factors, such as FGF-2 and heparin-binding forms of
VEGF. Although FGF-2 is not required for angiogenesis, it stimulates EC
proliferation and migration and acts synergistically with VEGF to promote
angiogenesis in vivo. Matrix-bound FGF-2 can be released by proteolysis and induce
VEGF expression by EC. Certain heparin-binding isoforms of VEGF can also
release matrix-bound FGF-2 suggesting that some of the biological effects of VEGF
may be mediated by FGF-2. (Sottile, 2004)
2.1.4.3 Angiopoietins and Tie signaling
Angiopoietins and Tie -receptors play a critical role in angiogenesis. The angiopoietin
family consists of three ligands: angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2) and
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angiopoietin-4 (Carmeliet & Jain, 2011). All three angiopoietins bind to Tie-2 while
Tie-1 remains an orphan receptor. However, an interaction between Tie-1 and Tie-
2 occurs and both receptors translocate to EC cell-cell contacts upon angiopoietin
stimulation. (D'Amico et al., 2014) Angiopoietin/Tie signaling is the prominent
system to maintain quiescent state in healthy vasculature. Angiopoietin-1 function as
a Tie-2 agonist and Ang-2 acts as a competitive antagonist in a context-dependent
manner. Ang-1 is expressed by mural and tumor cells whereas Ang-2 is expressed by
angiogenic tip cells in the initiation of angiogenic process (Figure 2). (Carmeliet &
Jain, 2011) Expression patterns of the two Tie -receptors, are similar to those of
VEGF -receptors. Tie-1 mRNA is highly expressed in embryonic vascular
endothelium, angioblasts and endocardium whereas it is weakly expressed in an adult
endocardium. (Otrock et al., 2007)
Through the Tie-2 receptor Ang-1 induces the remodeling and stabilization of the
blood vessels with interaction with the ECM. In an adult vessel, Ang-1 is associated
with Tie-2 to keep the vessels in a stable state. (Liekens et al., 2001) Ang-1 promotes
mural cell coverage and basement membrane deposition thus promoting vessel
tightness. In the presence of angiogenic stimulators, sprouting EC release Ang-2 thus
enhancing mural cell detachment, vascular permeability and EC sprouting.
(Carmeliet & Jain, 2011). Up-regulation of Ang-2, by hypoxia or VEGF, disrupts the
interaction between Ang-1 and Tie-2, resulting in destabilization of the vessels.
(Liekens et al., 2001)
2.1.4.4 Platelet-derived growth factor
To obtain an adequate function, vessels must mature and be covered with mural cells
(Carmeliet & Jain, 2011). Platelet derived growth factor β (PDGF-B) plays a critical
role in the recruitment of pericytes to newly formed vessels as well as in
differentiation of smooth muscle cells (Figure 2). (Gerhardt & Betsholtz, 2003,
Vikkula et al., 1996) In addition to PDGF-B, PDGF family is composed of two other
isoforms including PDGF-A and -C which carry out their biological activities by
receptors PDGFR-α and PDGFR-β. (Liu et al., 2014) Sprouting EC secrete PDGF-
B signaling through PDGFR-β that is expressed by mural cells during blood vessel
formation. Secretion of PDGF-B results in proliferation and migration of mural cells
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during vessel maturation. (Armulik et al., 2005) In smooth muscle cells/pericytes
PDGF-B has been shown to upregulate Ang-1 expression and to regulate
transforming growth factor-β expression (Nishishita & Lin, 2004).
PDGF also functions as one of the key players in pathological processes including
cancers and atherosclerosis by regulating cell proliferation, differentiation, apoptosis,
angiogenesis and metastasis (Liu et al., 2014). Pdgfb and pdgfrb knockouts have been
shown to lead to lethal phenotype with vascular dysfunction. The primary cause of
the phenotype is the lack of pericytes leading to endothelial hyperplasia, abnormal
junctions, and excessive luminal membrane folds. (Armulik et al., 2005)
2.1.4.5 Transforming growth factor
The maturation of blood vessels relies partly on transforming growth factor β (TGF-
β) signaling. TGF-β stimulates mural cell differentiation, proliferation and migration
as well as promotes production of ECM (Figure 2). In humans, mutations in TGF-
β receptor 2 (TGFBR2, endoglin) expressed by EC, causes arteriovenous
malformations and abnormally remodeled vessel walls (Armulik et al., 2005). TGF-
β signaling in EC contributes to vessel maturation by secretion of PAI1 by
preventing degradation of the perivascular matrix. (Potente et al., 2011) TGF-β is
produced by a variety of cell types including EC and smooth muscle cells (Nishishita
& Lin, 2004).
Several studies have shown the importance of TGF-β for vascular smooth muscle
cells differentiation in vitro. Activation of TGF-β is dependent on EC–pericyte
contact and TGF-β signaling in mesenchymal cells is required for their
differentiation into the mural cell lineage. Gap junctions between EC and pericytes
appear to be involved in the TGF-β activation, and are also required for
endothelium-induced mural differentiation, as demonstrated by studies of connexin
43 knockout mice. (Armulik et al., 2005)
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2.1.4.6 Notch/Delta signaling
In the vertebrate cardiovascular system, multiple Notch family receptors and ligands
are expressed during critical stages of embryonic and postnatal development.
Functional studies in mice and fish have shown that the formation of blood vessel
network, the proliferation of EC and the differentiation of arteries and veins are
controlled by Notch signaling.  The Notch pathway is an evolutionary highly
conserved signaling pathway with critical role in vascular morphogenesis in almost
all vertebrates. Notch receptors are transmembrane proteins with large extracellular
domains. (Roca & Adams, 2007) Four Notch molecules (Notch1–Notch4) interact
with five ligands, including Delta-like 1, Delta-like 3, Delta-like 4, Jagged1 and
Jagged2 (Yan & Plowman, 2007). Delta-like 4 and VEGF are the only known genes
where loss of a single allele results in embryonic lethality due to defective vascular
development. Hence, blockade of Delta-like 4 may impair remodeling of the tumor
vasculature by preventing the progression to stabilized vessels. (Yan & Plowman,
2007)
The Notch pathway is a regulator of cell fate specification, growth and differentiation
(Figure 2). Notch/delta is a cell-cell interaction signaling pathway helping similar
cells to integrate information. An interaction in several levels between VEGF and
Notch/delta pathways is involved in the development of vascular network. VEGF
pathway provides signals from surrounding tissues to EC and Notch/delta pathway
acts among the EC to respond appropriately to the VEGF signals. (Thurston &
Kitajewski, 2008)
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Figure 2. Growth factors related to different steps of blood vessel formation and maturation. 1) Some
endothelial cells (EC) within the vessel wall, known as tip cells, lead the growing sprout; 2) EC guidance
is controlled by VEGF-A and PDGF-B that promote the recruitment of pericytes (PC); 3) Notch and
Delta-like 4 signaling leads to formation of vascular lumen by fusion of vacuoles; 4) The recruitment of
pericytes and deposition of extracellular matrix (ECM) proteins into basement membrane (BM) promote
vessel maturation. Image modified from Adams&Alitalo (2007).
2.1.5 Disturbances in vascular development
The formation of new blood vessels is essential for organ growth and repair
(Carmeliet, 2005). However, angiogenesis is typically quiescent in the adult except in
exercise (Kivela et al., 2008), female reproductive system and in pathological
conditions (Knudsen & Kleinstreuer, 2011). Imbalance in the blood vessel formation
contributes to numerous disorders including cancer, rheumatoid arthritis, cardiac
ischemia, retinal disorders, psoriasis, inflammatory bowel disease and infertility
(endometriosis) (Liekens et al., 2001, Knudsen & Kleinstreuer, 2011). Inadequate
vessel maintenance or decreased growth causes ischemia after myocardial infarction,
and neurodegenerative or obesity-associated disorders, whereas excessive vascular
growth or abnormal remodelling promotes cancer, inflammatory disorders and
retinal disorders (Potente et al., 2011). The process leading to angiogenesis is strictly
controlled with positive (inductors) and negative (inhibitors) regulators. The
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progress of the process is defined by the balance between these regulators. The
mechanism of action of several new drugs used in cancer treatments is to prevent
angiogenesis thus inhibit the tumor growth (Staton et al., 2009).
Genetic studies have shown that perturbing embryonic vascular development may
cause adverse consequences from benign vascular malformations to embryolethality.
Defects in pathways linked to vascular development and angiogenesis, such as
VEGF, PDGFR-β, TGF-β and Tie-2, are suggested to play critical role in vascular
malformations. (Knudsen & Kleinstreuer, 2011)
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2.2 Development and characteristics of heart
Heart is the first organ to form in vertebrates and has a vital role in distributing
nutrients and oxygen to the embryo (Buckingham et al., 2005). Formation of heart
is a complex process starting at early phase of embryogenesis prior to gastrulation.
Cardiac cells originate from the mesodermal germ layer with inductive signals
coming from the adjacent cell populations, especially from the endoderm (Verma et
al., 2013). The initial form of the heart is the heart tube that results from migration
and organization of precursor cells from the cardiac crescent (Figure 3) (Nemer,
2008). In addition to growth of cells within the heart tube, studies in chicken and
mouse have shown that further recruitment of heart progenitor cells occurs at the
poles of the heart tube referred as the heart fields. The first heart field gives rise to
differentiated myocardial cells of the cardiac crescent and early heart tube. The
second heart field, located in the heart tube at the outflow tract (ot, Figure 3), has
been identified as another source of cells with myocardial potential. (Buckingham et
al., 2005) Differentiation process from mesodermal cells into cardiac progenitor cells
in the cardiac crescent leads towards immature cardiomyocytes when the cells stop
proliferating (Verma et al., 2013). Primitive heart tube starts to beat at approximately
3 weeks of gestation in man (Brand, 2003).  Heart tube is composed of a contractile
myocardium that is essential for its action as a central pump. Heart tube, formed by
the fusion of cardiac crescent, subsequently undergoes looping that is followed by
expansion into primitive chambers. After multi-phased regionalization of the
myocardium, a four-chambered heart tissue is formed. (Buckingham et al., 2005)
Adult human heart has been shown to have some regenerative capacity. Cells isolated
from human atrial and ventricular biopsies possess characteristics typical to stem and
endothelial progenitor cells and appear to have properties of adult cardiac stem cells
(Messina et al., 2004).
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Figure 3. The major stages of human heart development after conception. a=atria; ao=aorta; la=left
atrium; lv=left ventricle; ot= outflow tract; pa= pulmonary aorta/trunk; ra= right atrium; rv= right ventricle;
sv= sinus venosus; v= ventricle. Image modified from Nemer (2008).
Heart has been shown to be particularly prone to toxic effects of both cardiac and
noncardiac drugs. Cardiotoxic substances can cause severe effects on heart functions
including decreased contractility, increased arrhythmia and ischemia. (Redfern et al.,
2003, Lasser et al., 2002, Lexchin, 2005) The toxicity is typically targeted to the
electrophysiological properties of the heart (Andersson et al., 2010).
2.2.1 Differentiation of human pluripotent stem cell derived cardiomyocytes
Human pluripotent stem cells (hPSC), namely embryonic stem cells (hESC) and
induced pluripotent stem cells (iPSC), are capable for indefinite self-renewal and
differentiation into all somatic cell types. Directed differentiation of hPSC towards
cardiomyocytes is commonly based on developmental principles detected in the
gastrulation when myocardial mesodermal progenitor cells are formed in the
embryo. (Braam et al., 2009) A global gene expression profile of early hPSC-CM is
more similar to fetal cardiac tissue than to adult cardiac tissue (Xu et al., 2009).
Differences are seen in the number of cardiac ion channel and calcium handling
genes highlighting the immature phenotype of hPSC-CM compared to adult heart
tissue (Synnergren et al., 2007).
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hESC differentiation is classically achieved through spontaneous differentiation as
embryoid bodies. Another method used is to co-culture hESC with a mouse visceral
endodermal cell line.  Differentiation into CM can be performed quite rapidly, in
approximately 20 days. However, the reported cardiac differentiation efficiencies of
the hESC lines show enormous differences between 8.1-70 %. (Pekkanen-Mattila et
al., 2009) Differentiated CM express markers typical for human cardiac cells with
properly functioning L-type Ca2+ channels and a β-adrenoreceptor system.
(Pekkanen-Mattila et al., 2009, Lian et al., 2013)
The use of human embryo derived cells may, however, face ethical concerns that
limit the applications of these cells. Moreover, the generation of patient- or disease-
specific cells is difficult from hESC. (Takahashi et al., 2007) Yamanaka´s group
introduced induction of pluripotent status in somatic cells by direct reprogramming.
iPSC can be generated from somatic cells by retroviral transduction with
transcription factors Oct3/4, Sox2, Klf4, and c-Myc. The established human iPSC
are similar to hESC in morphology, proliferation, surface markers, gene expression,
in vitro differentiation and teratoma formation. (Takahashi et al., 2007)
2.2.2 Cellular composition of the heart
Heart tissue is a complicated organ having multiple cell types and highly organized
structure and function. The major cell types present in the human heart are
cardiomyocytes (CM), smooth muscle cells, endothelial cells (EC) and fibroblasts
(Nag, 1980, Banerjee et al., 2007, Vidarsson et al., 2010). Cardiomyocytes in the adult
heart have highly limited proliferation capacity. Furthermore, they cannot be
propagated as a cell line.  After birth there is a transition from hyperplastic to
hypertrophic growth that increases myocardial mass without CM proliferation.
Although CM occupy 80-90 % of the total myocardium mass they constitute only
20-30% of the cells present in the adult heart tissue. The remaining two-thirds are
proliferating non-myocytes including EC and fibroblasts. (Soonpaa & Field, 1998,
Chien et al., 2008)
From the onset of cardiac development, endothelial cells are prerequisite for
myocardial maturation, physiological function and survival (Brutsaert, 2003).
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Vascular EC produce several compounds including angiopoietin 2 and nitric oxide
that may influence on myocardial growth. Angiopoetin-1 and VEGF are mainly
produced by the cardiomyocytes. (Brutsaert, 2003, Leucker et al., 2011). In mature
myocardial tissue every CM has a physical contact with at least one capillary.
Coronary vasculature is typically generated by angiogenesis in response to specific
local demands. (Garzoni et al., 2009) The interactions between vasculature and
myocardium are bidirectional (Bhattacharya et al., 2006, Balligand et al., 1997) and
active through the adult life affecting to cardiac growth, function and rhythmicity
(Brutsaert, 2003). Although cardiomyocytes in adult heart are considered mainly as
terminally differentiated cells, they may respond to hypertrophic growth including
hypoxia and growth factors. Many signaling factors affecting to myocardial growth
have been shown to be produced by adult endothelial cells. In vitro co-culture
experiments with endothelial cells and cardiomyocytes have shown that depending
on the origin of EC, adult cardiomyocytes either maintain their adult phenotype or
undergo dedifferentiation. (Brutsaert, 2003)
The myocardial microenvironment is composed of CM and non-myocytes
embedded in an aligned and structured ECM which is mainly produced by the
cardiac fibroblasts. In the healthy heart, the extracellular matrix guiding cellular
orientation facilitates also efficient cell contraction, force transduction and electrical
transmission of the cells. The importance of alignment of CM in coordinated
contraction is proven by the native cardiac structure, but also in in vitro studies. (van
Spreeuwel et al., 2014)
2.2.2.1 Morphology and maturation of human Pluripotent Stem Cell-derived
Cardiomyocytes
Human pluripotent stem cell-derived cardiomyocytes (hPSC-CM) differ from adult
cardiomyocytes with respect to structure, proliferation, metabolism and
electrophysiology. (Robertson et al., 2013). Human PSC-CM can be classified into
early stage with roughly 3-5 weeks after cardiac differentiation and late stage
corresponding to 12–15 weeks of culture after cardiac differentiation. Early stage
hPSC-CM have an immature phenotype, reflecting cardiomyocytes in the very early
fetal heart including contractility with some proliferative capacity and embryonic like
electrophysiology. However, hPSC-CM do show progressive maturation with
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duration in culture (Hartman et al., 2015) and adult characteristics, i.e. loss of
proliferative capacity and more adult-like electrophysiology, arise in late stages
(Robertson et al., 2013). Although the factors affecting maturity remain largely
unknown, cell line, time in culture, co-cultured cells and other culture conditions
appear to have an effect on the maturity suggesting that after initiation of
contraction, genetic and environmental factors interact leading to a more mature
phenotype (Robertson et al., 2013).
Differences are seen when the morphology of hPSC-CM is compared to adult CM
(Snir et al., 2003). In the adult human heart, ventricular cardiomyocytes are large
(~ 130 μm in length) with brick-shaped morphology and sarcomere structures that
are readily apparent by phase-contrast microscopy (Hartman et al., 2015) while early
hPSC-CM are small and round with approximately 5-10 μm in diameter. Late hPSC-
CM (>35 days) develop more oblong morphology (30 μm × 10 μm) but remain
small compared to adult. Additionally, most adult CM are bi- or multinucleated with
large numbers of mitochondria whereas hPSC-CM are mono-nuclear, have moderate
numbers of mitochondria and show smaller sarcomeric regions. Since the extensive
t-tubule network present in adult ventricular CM is absent in hPSC-CM, excitation-
contraction coupling is slower and calcium primarily enters the cell through the cell
membrane instead of releasing from the sarcoplasmic reticulum. However, with
increasing time in culture late hPSC-CM develop a more adult-like morphology but
do not appear to develop t-tubules or multinucleation. (Robertson et al., 2013)
The expression of mRNAs for cardiac structural proteins myosin light chain 2
ventricular isoform (MLC2v), α-actinin (ACTN2) and α-myosin heavy chain
(MYH6) is undetectable or very low in undifferentiated cells but is strongly
upregulated in CM at day 18 of differentiation. Immunocytochemical analyses
revealed that at day 18 human iPSC- and hESC-CM stain positively for cardiac
proteins α-actinin and troponin T and display typical pattern of cross-striations
indicative of sarcomeric organization in CM. The highly ordered striated pattern
recapitulates the normal architecture of the contractile apparatus in functional CM.
(Gupta et al., 2010)
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2.2.3 Functional properties of cardiomyocytes
Spontaneous and synchronous contraction is the hallmark of differentiated hPSC-
CM and is seen as early as 5 days after the initiation of differentiation. Spontaneous
contraction with basal rhythm around 40 beats per minute can be maintained for
more than 1 year in culture in strong contrast to adult CM. (Zhang et al., 2009)
Responses of α-, β1-, and β2 -adrenoceptors have all been demonstrated in hPSC-
CM. As in vivo, isoprenaline has been shown to increase the contraction rate and
the amplitude of the calcium transient and decrease the relaxation time. (Brito-
Martins et al., 2008)
Important differences in cardiac ion channels and calcium handling genes were seen
when hPSC-CM and adult heart tissue were compared. (Robertson et al., 2013) The
major ionic currents present in adult CM are expressed also in hPSC-CM although
frequently at abnormal levels. Intracellular calcium handling and sarcolemmal ion
channels that are necessary for contraction, play a critical role also in functional
maturation of hPSC-CM and contribute to their electrical properties (Louch et al.,
2015). Signals from neighboring non-cardiomyocytes enhance the electrical
maturation of hPSC-CM especially through sarcolemmal ion channel development
(Kim et al., 2010).
The cardiac action potential is a combination of different ion channel conductances
including Na+, Ca2+ or K+ currents. In the resting state of the cell, a negative
membrane potential exists. In typical action potential, the cell is polarized due to
high K+ conductance as within the cell K+ remains the main cation and outside it is
Na+. In the rapid depolarization, Na+ channels open and the membrane potential
changes to positive. The plateau phase of the action potential follows when the Ca2+
moves in and K+ out of the cell. As K+ efflux exceeds Ca2+ influx, the cell membrane
repolarizes. This rapid repolarization reduces the Ca2+ current resulting in
contraction (Finlayson et al., 2004)  as Ca2+ binds to troponin C. For relaxation, Ca2+
dissociates from troponin C and turns off the contractile machinery. (Bers, 2000). In
the final stage of the action potential, complete repolarization occurs where K+
channels reopen and flow out of the cell thereby restoring the negative resting
potential. Gap junctions enable the spontaneous depolarization and action potential
to be proceeded thus allowing coordinated contraction of the heart. (Finlayson et al.,
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2004) In early stage hPSC-CM, almost no Ca2+ is released from the sarcoplasmic
reticulum thus leading to slow, diffusion-limited Ca2+ influx. Late stage hPSC-CM
perform better but still show slow influx compared to adult CM. The K+ currents,
considered to be responsible for arrhythmias, are expressed in hPSC-CM.
(Robertson et al., 2013)
 Rate dependence of action potential is a fundamental property of cardiomyocytes.
QT interval, measured from the beginning of the QRS complex to the end of the T
wave in the electrocardiogram (Figure 4), must be corrected for the cardiac rhythm.
In electrocardiogram, the QT interval represents the time from the beginning of
ventricular depolarization to the end of ventricular repolarization. (Davila et al.,
2004) Thus, the QT interval in the electrocardiogram represents the duration of the
ventricular action potential and a prolongation of the QT interval corresponds to a
prolongation of the ventricular action potential. A prolonged QT interval, i.e. long
QT syndrome, induced by drugs or rare mutations, increases the possibility of
developing severe ventricular arrhythmias and sudden death. (Finlayson et al., 2004).
When drug responses of hPSC-CM were studied, multielectrode array (MEA) and
impedance measurements with 28 cardioactive drugs indicated a strong correlation
between in vitro and known in vivo arrhythmia and QT prolongation effects.
Interestingly, although hPSC-CM generally exhibit immature phenotype, hPSC-CM
for QT and arrhythmia detection show a strong correlation to adult responses. These
results demonstrate the robust utility of hPSC-CM in prediction QT prolongation
and arrhythmia thus making them a useful tool for drug discovery and safety
pharmacology. (Kolaja, 2014)
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Figure 4. Diagram of QT interval as measured from the beginning of the QRS complex to the end of
the T wave in the electrocardiogram. Image modified from https://en.wikipedia.org/wiki/QT_interval
2.2.4 Regulation of heart development
Cardiac development is a complex and highly regulated process controlled by genes
and cell–cell interactions. Inductive signals including bone morphogenetic proteins,
FGF-2 and Wnt proteins guide the cardiac development in early embryonic stages.
(Nemer, 2008) The Wnt signaling pathway is one of the key regulators of
cardiogenesis in vivo and in vitro. Canonical Wnt ligands direct cell proliferation and
cell fate determination during embryonic development. (Lian et al., 2012) In
addition, Nkx2.5 and the GATA family of zinc-finger transcription factors are
specifically expressed in the heart (Brand, 2003).  Also the Notch signaling pathway
has been shown to affect in cardiogenesis. Notch1 has a role in the differentiation
of cardiac cell types into ventricles. (Chau et al., 2006) Similarly to in vivo heart
development, in vitro cardiogenesis is a dynamic process that is tightly controlled by
the chronological expression of several signaling factors (Verma et al., 2013).
2.2.4.1 Vascular growth factors related to heart
VEGF has an important role in the function of heart since mice with cardiomyocyte
specific deletion of exon 3 in the VEGF-A results in the loss of all VEGF-A
isoforms. The hearts of these mice had fewer coronary microvessels, thinned
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ventricular walls, decreased contractile function and an abnormal response to β-
adrenergic stimulation. These findings suggest that cardiac myocytes have a critical
role as secretory cells and that cardiac muscle is the major source of VEGF in the
heart. (Giordano et al., 2001)
In the infarcted myocardium, PDGF-A and PDGF-D are significantly increased as
well as receptors PDGFR-α and -β. In an in vitro study using cultured cardiac
fibroblasts, PDGF-D was shown to promote cardiac fibroblast proliferation and
collagen synthesis. Furthermore, it is reported that pretreatment of PDGF-AB
promotes angiogenesis in the aging rat hearts after coronary ligation. (Liu et al., 2014)
Angiopoietins have a critical role in cardiovascular biology. Knockout of Ang-1 and
Tie-2 leads to embryonic lethal cardiac defects, including impairments in vascular
maturation with abnormal recruitment of smooth muscle cells and endocardial
formations.  (Nishishita & Lin, 2004, Dallabrida et al., 2005) Ang-1 has an
indispensable role in coronary vein formation in developing heart presumably by
promoting differentiation of immature EC (Arita et al., 2014). Ang-1 levels increase
as the cardiovascular development have reached the adult, mature state suggesting
that Ang-1 may serve a maintenance function for the vasculature in vivo. (Dallabrida
et al., 2005)  In the study of Dallabrida et al. 2005 Ang-1 was shown to markedly
increase cardiomyocyte survival and protect cardiomyocytes from apoptosis.
(Dallabrida et al., 2005)
In the cardiovascular system, FGFs are known to mediate various processes
including angiogenesis, embryonic heart development and cardioprotection.
However, the role of FGF signaling system in adult heart is poorly understood. FGF-
2 has been shown to have beneficial effects when overexpressed in myocardial
infarction or ischemia-reperfusion injury studies.  Gap junction protein connexin 43
has been proposed to be one of the effectors in FGF-2 mediated cardioprotection.
More precisely, FGFs is required for maintenance of cardiomyocyte cell-cell
junctions and myocardial integrity in vitro and in vivo. (Sakurai et al., 2013)
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2.3 Tools for development of in vitro models
In vitro cell culture was developed to enable observation and manipulation of cells to
study the basic biological mechanisms, development and diseases (Shamir & Ewald,
2014). Traditional in vitro models are mainly based on utilization of either primary
cells isolated from tissues or of transformed cell lines with genetic manipulations
(Laustriat et al., 2010). The main limitation of in vitro models is their inability to
mimic the complexity of the in vivo situation. Absorption, distribution, metabolism
and excretion processes controlling the exposure of the target tissue are absent in
the in vitro systems in addition to cross-talk between different organs. (Scanu et al.,
2011)
A new kind of innovation for development of in vitro models arose in 1998 when the
first stem cell lines were established (Laustriat et al., 2010). The enormous potential
benefits of stem cells results from their unique properties compared to primary
human cells including unlimited proliferation ability, plasticity to generate specific
cell types and also easily available sources of human cells (Davila et al., 2004). Human
mesenchymal stem cells could replace the currently used transformed cell lines and
primary cells and eliminate the limitations related to these test systems thus
improving the relevance of predictive in vitro assay (Scanu et al., 2011). In addition,
the in vitro production of differentiated cells, such as cardiomyocytes, from human
pluripotent stem cells provides a source of cells for applications in drug discovery,
disease modeling, regenerative medicine and toxicity screening (Mordwinkin et al.,
2013, Chow et al., 2013). With the iPSC technology it is possible to isolate somatic
cells, generate pluripotent iPS cells out of them and genetically engineer these cells
for different purposes. Since the pluripotent cells match the donors genetic
background, it is possible to generate a variety of somatic cells that are
immunological identical to the donor and therefore do not induce immune rejection
when transplanted. Furthermore, with reprogramming techniques, it has become
possible to generate patient specific iPSC lines from donors independent of sex or
age or to use patient specific iPSC to generate disease model-specific iPSC for in vitro
modeling. (Pfannkuche et al., 2010a, Musunuru et al., 2010)
Stem cell-based systems offer a very promising and innovative alternative to obtain
large numbers of cells for early efficacy and higher toxicity screening thus allowing
46
scientists to improve the selection of lead candidates and, further, the possibility to
decrease the adverse effects in clinical phase of drug development (Davila et al.,
2004, Lou & Liang, 2011). Since in vitro assays should improve the translation of
preclinical data into the clinical studies, a critical component is to use physiologically
relevant in vitro model that mimics the complexity of the clinical situation (Engle &
Puppala, 2013). The most relevant cell types used in in vitro models and in this study
are discussed in detail below.
2.3.1 Primary cells
Natural type of the cells used in in vitro models enables to maintain better the
structural and biochemical complexity found in vivo. Therefore, primary cells are
often a preferred choice for in vitro studies. However, after being isolated from
original tissue, primary cells begin to de-differentiate within hours to days when
cultured in vitro. Primary cells may also be sensitive to passaging, result in altered
phenotypes, possess slow proliferation rates and metabolic capacities, and,
additionally, develop early senescence after few expansions. (Astashkina et al., 2012)
Isolation of human primary cardiomyocytes from heart tissue is challenging and the
access to the tissue is problematic. At the same time, the process is uncontrolled with
respect to donor disease and treatment modalities. (Vidarsson et al., 2010)
Furthermore, cardiomyocytes from the adult heart have highly limited proliferation
capacity and they cannot be propagated as a cell line. Therefore, repeated isolation
of primary tissue is necessary for sustainable in vitro studies (Braam et al., 2009).
2.3.1.1 Endothelial cells
Among the most extensively used primary endothelial cells of human origin are
human umbilical vein endothelial cells (HUVEC) that can be easily isolated from the
umbilical cord and have been successfully cultured since 1973. HUVEC grow as a
monolayer with polygonal cell morphology in comparison to long, slender, spindle-
shaped and overlapping fibroblasts. (Jaffe et al., 1973). Although all vascular
endothelial cells share common functions, it has been shown that considerable
heterogeneity exists in the vascular network and between different organs. Evidence
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show that endothelial cell heterogeneity develops through interactions with the
microenvironment either through soluble factors or cell-cell contacts. Thus, blood
vessel type–specific and tissue-specific characteristics of EC are under the control of
their microenvironment. (Lacorre et al., 2004) See also chapter 2.1.2.1.
2.3.1.2 Fibroblasts
Fibroblasts are a heterogeneous population of cells with mesenchymal origin that are
present in various tissues. Although fibroblasts from different tissues have similar
morphology, DNA-microarray studies have demonstrated that they have unique
gene expression profiles and characteristic phenotypes. Fibroblasts secrete various
growth factors and cytokines with direct effect on cell proliferation, differentiation
and formation of extracellular matrix. In neovascularization, fibroblasts contribute
to basement membrane formation by producing collagen types IV and VII and have
an important paracrine role. (Wong et al., 2007) Human foreskin derived fibroblasts
have been widely used to study the basic mechanisms of cell function and signaling,
wound repair, topical pharmaceuticals and have been incorporated also into
bioengineered skin products (Nahm et al., 2002).
2.3.1.3 Primary cardiomyocytes of animal origin
Animal-derived, adult cardiomyocytes are routinely used in vitro models in
cardiovascular research. While freshly isolated cardiomyocytes remain functional for
10–12 hours, cultured cardiomyocytes can be used for longer term studies
(approximately 5 days). However, while long-term viability is an advantage, the long
culture time allows the cells also to adapt to the culture conditions and alter their
phenotype. Adult rat cardiomyocytes have shown to undergo critical morphological
and functional changes including internalization of intercalated disks, decreased
tubule density, altered calcium signaling and reduced contractility in addition to
decreased resting membrane potential and L-type calcium current density. (Banyasz
et al., 2008)
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2.3.2 Immortalized cells
Immortalized cells have their origin in primary cells that have been further genetically
modified. Immortalization is the result of oncogene transfection to enable rapid
proliferation in culture, resistance to dedifferentiation, improved passaging and
greater resilience. As a result of genetic transformations, these cells are no longer
primary cells, not phenotypically identical and often only marginally similar to their
original primary phenotype. Immortalized cells are typically easy to maintain, can be
expanded and stored and are stable for up to 25–50 passages. However, cell
behavioral changes upon immortalization are reported when compared to
homologous primary cells. Specifically, immortalized cell lines have been shown to
possess altered genomic content, abnormal expression of intracellular proteins, lack
or significant morphological features such as tight junctions, ligands, transporters,
cellular receptors as well as loss of cellular polarity. These changes have to be
considered while using immortalized cell lines in in vitro models.  (Astashkina et al.,
2012)
2.3.3 Stem cells
Stem cells can be roughly characterized as embryonic or adult stem cells. Embryonic
stem cells from the fertilized oocyte are called totipotent. These totipotent cells are
able to specialize and form the blastocyst from which the embryo will develop.
Embryonic stem cells from within blastocyst are called pluripotent sine these cells
form all three germ layers. In addition, adult tissues and organs contain niche of
multipotent adult stem cells that are able to differentiate into varying cell lineages.
The key properties for all stem cells are to exhibit unlimited self-renewal and
multilineage differentiation potential. (Salem & Thiemermann, 2010)
2.3.3.1 Adult stem cells
Mesenchymal stem cells (MSC) are adult stem cells with capacity for self-renewal
and differentiation with a large tissue distribution (Williams & Hare, 2011). MSC,
also called mesenchymal stromal cells, are non-hematopoietic cells that originate
from the mesoderm and exist in almost all tissues. MSC differentiate into mesoderm
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lineages, such as chondrocytes, osteocytes and adipocytes, but also ectodermic cells
and endodermic cells. MSC can be easily isolated from the bone marrow, adipose
tissue, the umbilical cord, fetal liver, muscle, and lung and further successfully
expanded in vitro. (Wei et al., 2013) The International Society for Cell Therapy
proposed a criteria for MSC identification that include (1) adherence to plastic in
standard in vitro culture conditions; (2) expression of the surface markers CD73,
CD90, CD105 and the absence of CD34, CD45, HLA-DR, CD14 or CD11b,
CD79a, or CD19 surface molecules and (3) the ability to differentiate into
osteoblasts, adipocytes and chondroblasts in vitro. (Williams & Hare, 2011)
The endogenous role for MSC is the maintenance of stem cell niche and contribution
to organ homeostasis, wound healing, and successful aging. In regenerative
medicine, MSC are emerging as an extremely promising therapeutic tools for tissue
regeneration. (Williams & Hare, 2011)
2.3.3.1.1 Adipose tissue derived stromal cells
Previously, research related to adult stem cells has focused on mesenchymal stem
cells found within the bone marrow stroma.  However, adipose tissue, like bone
marrow, is derived from the embryonic mesenchyme and contains a stroma that can
be easily isolated. (Zuk et al., 2002) Adipose tissue represents an ideal source of
autologous stem cells since it is easy to obtain with minimal patient discomfort, but
yet capable for extensive expansion in vitro. The stem cell population derived from
collagenase-digested human adipose tissue stated as stromal-vascular fraction has
been shown to differentiate into multiple cell types including adipocytes,
chondrocytes, osteoblasts, myocytes, neuronal cells, endothelial
cells, cardiomyocytes and smooth muscle cells.  Term human adipose tissue derived
stromal cells (hASC) refers to plastic-adherent cell population that includes vascular
cells (pericytes and endothelial progenitor cells); adipocyte progenitor cells and adult
multipotent mesenchymal stem cells in addition to blood cells, fibroblasts,
endothelial cells, smooth muscle cells and immune cells. (Madonna et al., 2009)
The high proliferation and differentiation capacity of hASC makes them an ideal
source for vascular modeleling (Madonna et al., 2009, Miranville et al., 2004, Hutton
et al., 2012). hASC monocultures have been shown to spontaneously generate
vascular structures through the coordination of its subpopulations in the absence of
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exogenous ECM proteins (Hutton et al., 2012). Moreover, hASC are shown to
exhibit significantly higher potential to stimulate vascular-like network formation
compared to smooth muscle cells or fibroblasts (Merfeld-Clauss et al., 2010). Due
to putative endothelial progenitor cell population, hASC might represent a tool for
vasculogenesis research (Miranville et al., 2004). This is supported by reports stating
that endothelial progenitor cells possess high plasticity with the ability to give rise to
smooth muscle cells (Moonen et al., 2010), enhance the differentiation of MSC
towards pericyte phenotype and increase the ability of MSC to attach to the tubule
structures in vitro (Goerke et al., 2012). Vasculogenic potential of hASC is suggested
to be dependent on direct and reciprocal interaction with EC resulting in secretion
of cytokines and ECM proteins (Merfeld-Clauss et al., 2010, Merfeld-Clauss et al.,
2015).
hASC are known to secrete several angiogenic and anti-apoptotic growth factors
such as VEGF, hepatocyte growth factor (HGF), FGF-2, PDGF-B and TGF-β and
matrix metalloproteinases that are known to act in a synergistic manner (Rehman et
al., 2004, Rubina et al., 2009, Verseijden et al., 2010b). In the formation of vascular
structures, cells originating from hASC contribute to vessel maturation by aligning
along the vascular structures thus stabilizing them in vitro and in vivo. Cell–cell
contacts appear to be important in the formation of stable vascular-like structures in
vitro (Rubina et al., 2009, Traktuev et al., 2008) as direct interaction between hASC
and EC shifts hASC paracrine activity from being pro-angiogenic to angiostatic
(Merfeld-Clauss et al., 2015, Merfeld-Clauss et al., 2014).
EC and ASC co-culture have been shown to produce vascular structures in vitro and
in vivo (Merfeld-Clauss et al., 2010, Verseijden et al., 2010a, Traktuev et al., 2009,
Verseijden et al., 2010b, Rohringer et al., 2014). Vascular-like network formation is
shown to be associated with extracellular accumulation of ECM proteins such as
fibronectin and collagen IV (Merfeld-Clauss et al., 2010). Preformed vascular
structures within in vitro constructs can also integrate with the host vascular system
and improve the vascularization upon implantation (Verseijden et al., 2010a,
Traktuev et al., 2009).
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2.3.3.2 Pluripotent stem cells
Human pluripotent stem cells (hPSC) can be isolated from the blastocyst resulting
in embryonic stem cells or reprogrammed from somatic cell sources (e.g. fibroblasts)
to pluripotent state resulting in induced pluripotent stem cells. Human PSC have
raised high degree of interest due to their potential use in applications from basic
research to novel cell based therapies and tissue engineering. (Hartman et al., 2015)
Although the development of human embryonic stem cells (hESC) and, more
recently, human induced pluripotent stem cells (hiPSC) has offered an alternative to
human primary cells (Engle & Puppala, 2013), improved methods to derive specific
cell subtypes and improvements in their maturation into a more adult-like phenotype
is needed (Hartman et al., 2015). Moreover, challenges typical for all in vitro systems
also apply to utilization of pluripotent stem cells including the phenotypic
characterization of the cells, the cell culture conditions, the composition and
architecture of the cell culture systems, the time of the experiments and the
measurement and interpretation of endpoint results to assess the potential human
risk. (Hartman et al., 2015)
Industrial utilization of pluripotent stem cells will require the control of the
expansion and differentiation processes as well as large scale expansion of the cells
with reasonable costs. The high-throughput production of iPSC have shown to be
time-consuming and troubled with batch-to-batch variability. Another specific
challenge for iPSC cells with the transcription factor based reprogramming, is the
epigenetic memory since their epigenetic profile is related to the tissue of origin and
may limit the directed differentiation. However, despite the current technical
limitations, the potential of pluripotent stem cells, particularly with iPSC, will
certainly contribute to in vitro safety assessment in the future. (Suter-Dick et al., 2015)
2.3.3.2.1 Human pluripotent stem cell derived cardiomyocytes
Human pluripotent stem cell derived cardiomyocytes may provide significant
advantages over previous cardiac models. Similar to currently available
cardiomyocyte models, hPSC-derived cardiomyocytes contract rhythmically and
respond appropriately to numerous cardioactive drugs. However, questions of their
immaturity complicate their adoption as a new in vitro model. (Robertson et al., 2013)
hPSC-derived cardiomyocytes can be used to study cellular responses including, but
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not limited to, contractile function, cardiac arrhythmia, resistance to apoptosis and
protection from ischemia. (Sartipy et al., 2007) See also chapters 2.2.2.1. and 2.2.3.
2.3.4 Cell culture conditions
2.3.4.1  Defined medium
Good cell culture practice guidance is developed to provide common standards for
development of in vitro methods and use of chemically defined media is part of it.
The defined composition of the media used in the study is essential to achieve high
experimental reproducibility. Although defined media are commercially available for
some cell types, information on the composition of the media provided by the
manufacturing companies is often limited.  (van der Valk et al., 2010) Cell culture
media used in in vitro models often do not reflect the in vivo situation. Serum
concentration in culture media often comprises of 5–10 % of the volume and
additional cell nutrients are commonly used. Arguments on the justification for use
of a specific cell culture media are rarely provided in published reports. (Astashkina
et al., 2012) Since serum is a complex mixture of components with unknown
chemical structure and protein binding affinities, serum-free medium is
recommended when studying the effects of different chemicals (Shen et al., 2013).
For example, serum heparin is needed for the attachment of some growth factors to
their cell surface receptors. VEGF121 does not bind to heparin and is freely
diffusible while the larger isoforms including VEGF165 contain heparin-binding
residues and are bound to the cell surface or sequestered in the ECM (Liekens et al.,
2001, Ashikari-Hada et al., 2005).
The concentration of serum in the medium plays an essential role in determining the
morphology, growth characteristics and differentiation of the CM. More mitogenic
medium stimulates cell proliferation whereas CM cultured in lower serum
concentrations (0-5 %) maintain the cell number, phenotype and contractile
properties. (Passier et al., 2005, Xu et al., 2006, Li, 2002)
Beside serum, other specific supplements in the medium are important. Adult rat
CM in primary culture re-express markers of hypertrophy that are normally
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expressed during fetal stage and are down-regulated during maturation. The growth
factors FGF-2 and IGF-1 have shown to guide this process into opposite directions.
FGF-2 increases the expression of dedifferentiation markers, such as atrial
natriuretic factor, α-smooth muscle-actin and myofibrillar organization, while IGF-
1 promotes more differentiated CM phenotype. (Montessuit et al., 2004) In in vitro
vascular models, several growth factors are added to medium to induce vascular-like
network formation. VEGF was added to induce vascular structure formation of EC
and hASC co-culture in spheroids (Verseijden et al., 2010b). In another study, EC
and hASC were co-cultured in the presence of 5 % FBS medium supplemented with
VEGF or HGF (Merfeld-Clauss et al., 2010).
2.3.4.2 2D vs 3D culture
Although in vitro models have shown to be powerful tools in drug screening and in
toxicity assessment, these models are only as good as their ability to recapitulate the
in vivo physiological processes and specific properties under study. Commonly
employed methods of in vitro testing include organ explants, organotypic cultures,
dissociated 2D cultures and 3D cultures (Figure 5). (Astashkina et al., 2012)
Traditional 2D in vitro cell culture does not include the complexities of the cellular
microenvironment nor the extracellular matrix within tissues in vivo (Shamir &
Ewald, 2014). Growth on 2D surfaces results in cell flattening and changes in cell
morphology and internal cytoskeleton (Knight & Przyborski, 2014, Pontes Soares et
al., 2012). These changes have been shown to alter gene expression, affect nuclear
shape, cell performance and consequently influence the results of biological assays.
(Knight & Przyborski, 2014) Growing evidence show that 3D cell arrangement, co-
culture of different cell types and physico-chemical properties lead to improved
predictive value of the test system (Shamir & Ewald, 2014, Song et al., 2014,
Tourovskaia et al., 2014).  Currently, there are a large variety of 3D constructs with
different degrees of complexity. Bioreactors, lab on a chips and microtissues
comprises the most commonly used 3D constructs. (Suter-Dick et al., 2015)
The 3D culture enables cell-cell and cell-matrix contacts resulting in increased
intercellular signaling, facilitating developmental processes and allowing cells to
differentiate into more complex and mature structures. The loss of extracellular
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matrix-cell interactions and cell-cell communication often results in rapid cell
dedifferentiation and poor passaging in in vitro cell culture systems. (Astashkina et al.,
2012) Tissue-like structures are able to form in 3D environment also through more
uniform expression of adhesion molecules. Receptors and adhesion molecules are
more naturally and evenly spread over the cell surface in 3D cell culture whereas in
2D culture cells are polarized with binding proteins concentrated on the side where
they attach to the cell culture plastic. (Knight & Przyborski, 2014)
Most 3D tissue-engineering strategies rely on the use of exogenous, biocompatible
scaffolds as alternatives for extracellular matrix in which cells are seeded and matured
(Shimizu et al., 2003, Norotte et al., 2009, Hussain et al., 2013). In myocardial tissue,
cell density is high to enable synchronous beating. The use of scaffolds in cardiac
constructs has been, however, associated with reduced cell-cell contacts, as well as
incorrect deposition and alignment of extracellular matrix thus affecting to the force
generation ability of the constructs. (Norotte et al., 2009)
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Figure 5. Different methods for in vitro modeling. 1) Organ explant cultures maintain whole or partial
histological architecture of an isolated organ; 2) In organotypic culture multiple different cell types are
used to recapitulate the in vivo situation; 3) Dissociated 2D cell cultures on plastic surfaces are the
traditional in vitro model used; 4) 3D cell culture models enables  cell-cell and cell-matrix contacts; 5)
Transwell culture system allows co-culture and paracrine activity of different cell types ; 6) In vitro
models can be optimized for high throughput screening systems to improve the efficiency of the method.
Image modified from Astashkina et al. (2012)
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2.4 In vitro and in vivo models of vasculature and heart
2.4.1 Safety and efficacy assessment in respect of 3R´s
In 1959 Russell and Burch introduced the conception of Replacement, Reduction
and Refinement (3R´s) of animal testing in the book “The principles of humane
experimental technique”. They stated that mammalian tissue cultures have become
one of the most important replacement techniques for animal experiments.
Although Russell and Burch demanded reduction of inhumane animal experiments,
they also acknowledge that animal experimentation has brought substantial benefit
for medicine and enhanced the development of science knowledge overall. Russell
and Burch also pointed out that similar species do not necessarily possess good
correlation between each other.   (Jennings, 2014, Russell & Burch, 1959)
Presently, animal models are still generally regarded as the most relevant model
systems and this is reflected in the regulatory guidelines for safety assessment
evaluation worldwide (Suter-Dick et al., 2015). In European Union, the total number
on animals used for experimental and other scientific purposes in 2011 was
approximately 11.5 million (European Commission, 2013). However, the poor
relevance of animal models to humans in addition to ethical, cost and time concerns
increases the need for physiologically relevant in vitro models for safety and efficacy
assessment. European Union has set the final goal to replace animal experiments
with non-animal approaches in the Directive 2010/63/EU. (Heinonen, 2015) At
2011-2012, the cause for drug attrition in clinical development phase was mostly due
to a lack of efficacy (56%) or to safety issues (28%) (Arrowsmith & Miller, 2013).
Hepatotoxicity and cardiotoxicity are the two leading causes of failure in preclinical
development of new drugs (Davila et al., 2004). Recently, numerous non-cardiac
drugs have had to be withdrawn from the market due to cardiotoxicity concerns.
This indicates that the current drug testing strategies have severe limitations. (Feric
& Radisic, 2015).  Beside drug development, the safety of industrial chemicals stated
in REACH (Registration, Evaluation, Authorization and Restriction of Chemical
substances) legislation on the evaluation of chemicals reinforce the need to develop
a new, robust and economical in vitro models (Laustriat et al., 2010).
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Food and Drug Adminstration (FDA) and European legislators have identified
prolongation of the QT interval as a critical drug safety issue. QT prolongation is
most commonly induced when component of a drug molecule binds to hERG ion
channel and affects the rapid potassium current (Braam et al., 2010). Block of hERG
K+ channels (IKr) is a predominant risk factor for drug-induced Torsade de Pointes
which is rare but life-threatening type of ventricular arrhythmia associated with the
prolongation of the QT interval in humans (Redfern et al., 2003). Several clinically
successful drugs in the market have revealed to inhibit hERG and create a
concomitant risk of sudden death as a side effect (Finlayson et al., 2004).
Consequently, the assessment of the risk for QT interval prolongation is part of the
standard preclinical evaluation of new compounds defined by the International
Conference of Harmonization (ICH) Expert Working Group in topic S7B (ICH
S7B) for all drugs in development (Braam et al., 2010).
Angiogenesis is studied extensively due to its broad importance in medicine. In vitro
models of blood vessel formation are needed for basic biomedical research as well
as for translational research including drug development that needs relevant test
systems for screening of pro- and anti-angiogenic compounds. (Ucuzian & Greisler,
2007, Folkman, 2007) In addition, detection of drug-induced vascular injury has been
a major challenge for the pharmaceutical industry for decades causing termination
of development of new drug candidates in nonclinical safety assessment. Drugs
associated with vascular injury include anti-bacterials, anti-malarials, anti-virals, anti-
inflammatory agents as well as drugs related to neurologic diseases, cardiovascular
diseases and diabetes mellitus (Mikaelian et al., 2014, Morton et al., 2014).
2.4.2 In vitro vascular models
An ideal in vitro vascular model would be robust, rapid and reproducible with reliable
readouts and should include automated computational analysis. In addition, it should
include multi-parameter assessment with positive and negative controls and should
relate directly to results seen in the clinical studies. Despite the increasing numbers
of in vitro and in vivo assays, a “gold-standard” vascular model does not exist. (Staton
et al., 2009) Commonly used in vitro vascular models are presented below and in
Table 1.
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Quantification of EC proliferation with thymidine incorporation is the simplest form
of in vitro angiogenesis screening. This assay has the advantage of being quantitative,
rapid and easy to perform although some steps in the assay protocol may be prone
to inter-observer variability. (Friis et al., 2003) Another method for detecting tubule
formation in vitro includes EC proliferation in a gel composed of collagen, fibronectin
or Matrigel (Nicosia & Ottinetti, 1990). However, tubule formation in Matrigel is
not specific to EC. Primary human fibroblasts, a metastatic breast cancer cell line, a
metastatic prostatic carcinoma cell line and glioblastoma cells are also able to form
tubule structures in Matrigel but not when co-cultured with fibroblasts in the absence
of Matrigel. (Donovan et al., 2001) Several co-culture models, comprising of EC and
stromal cells, mimicking angiogenesis have been developed (Donovan et al., 2001,
RW.ERROR - Unable to find reference:41, Merfeld-Clauss et al., 2010, Friis et al.,
2003). The advantage of these co-culture assays is the interactions between the EC
and stromal cells thus leading to more mature tubule structures (Merfeld-Clauss et
al., 2010).
Presently, one of the most specific angiogenesis assays are the ones establishing EC
to form 3D tubule structures in different matrices (Auerbach et al., 2003, Peterson
et al., 2014, Koh et al., 2008). First 3D in vitro angiogenesis assays were established
already at 1990´s. In the assay EC were seeded on gelatine coated microcarriers into
a 3D fibrin matrix. Each microcarrier gave rise to a limited number of capillaries and
the angiogenic response could be easily quantified by determining the average
number of capillary-like structures. (Nehls & Drenckhahn, 1995, Nakatsu et al.,
2003) Also another 3D angiogenesis assay in type I collagen gel suitable for EC
migration studies and to the evaluation of angiogenic compounds have been
reported (Vernon & Sage, 1999).
Improvements in iPSC technology, tissue engineering and microfabrication
techniques have enabled the development of 3D microphysiological systems that
more accurately reflect human biology compared to traditional 2D cell culture
systems or animal models (Moya et al., 2013). For modeling the human tissue
microenvironment, a microfluidic chip with connecting tubule structures was
developed. In the chip, EC are seeded on tubule channels and surrounded by
extracellular matrix. Consequently, a perfusable system with connected upstream and
downstream fluidic channels is formed. With these chips, models of angiogenesis,
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the blood–brain barrier and tumor-cell extravasation can be developed. (Tourovskaia
et al., 2014)
Moreover, microfluidic based platforms consisting of co-culture of EC and
fibroblasts, pericytes or cancer cells with perfusable microvessels have been
developed. An open delivery of nutrients, chemical compounds, biomolecules and
cell suspensions as well as flow-induced mechanical stimuli are the main benefits of
the perfused microvasculature. This platform provides applications in vascular
physiology studies as well as in developing vascularized organ-on-a-chip and human
disease models for pharmaceutical screening. (Kim et al., 2013) Also complex
combination of microcirculation, the cardiac muscle and a solid tumor integrated
into 3D microphysiological system simulating perfused cardiac muscle and solid
tumor on a single platform have been developed. This platform provides a new
paradigm for accurate drug and toxicity screening with the focus on anti-cancer
drugs with minimal cardiotoxicity. (Moya et al., 2013)
2.4.3 In vivo vascular models
Animal models mimicing blood vessel formation are considered essential in
development of anti- or pro-angiogenic therapeutic treatments (Norrby, 2006,
Auerbach et al., 2003). However, although the in vivo the complexity can be assessed,
these assays are limited with species-to-species differences, administration of the test
substances and lack of quantitative analysis (Staton et al., 2009). Among the most
commonly used in vivo vascular models are chicken chorioallantoic membrane assay
(CAM), corneal angiogenesis assay, mouse retinal angiogenesis assay, rat hindlimb
ischemia model, Matrigel assay and different tumor models (Table 1) (Auerbach et
al., 2003, Staton et al., 2009).
CAM (chicken chorioallantoic membrane) assay was developed by experimental
embryologists more than 50 years ago.  In the assay, the CAM of 7–9 day old chick
embryos is exposed by making a window in the eggshell and tissue grafts, with or
without test compounds, are placed directly on the CAM. After that, eggs are
reincubated and the grafts recovered after an appropriate length of time and later on
scored according to the growth and vascularization. (Auerbach et al., 2003) The
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CAM assay is useful in tumor-induced angiogenesis studies since the host immune
system is not completely developed. (Norrby, 2006) CAM assays are relative easy
and inexpensive to perform, semi high-throughput studies can be executed and
monitoring the reaction throughout the study is possible. (Auerbach et al., 2003)
Corneal angiogenesis assay is considered one of the best in vivo assays as the cornea
itself is avascular and transparent. Thus, blood vessel formation taking place in the
cornea is solely due to angiogenic stimulation by tissues or compounds. The method
was developed for rabbit eyes but has been adapted also to mice. Briefly, a pocket is
made in the cornea and test tumors or tissues with possible test substances are
introduced into this pocket. (Auerbach et al., 2003) The advantage of this assay is
the ability to monitor progress of angiogenesis as well as the absence of background
vasculature. Technical factors, including the surgical procedure, may, however, affect
the angiogenesis quantification. The assay is also relatively time consuming thus
limiting the application of the assay in high-throughput screening. (Staton et al.,
2009)
Widely used mouse retinal angiogenesis assay allows the study of developmental as
well as pathological vasculature formation since retinal vascular development occurs
postnatally in rodents. With this assay, different stages of formation and regression
of blood vessels can be studied in controlled settings.  Retinas are usually visualized
with whole-mount stainings and in-situ hybridization techniques. (Stahl et al., 2010)
In rat ischemic hindlimb model ischemia is created in the left hind limb with the
right leg serving as control. In the assay, all left side branches of the aorta distal to
the renal arteries and of the iliac artery are ligated. After 5 days, the femoral artery is
also ligated. After ligations, growth factors are injected and implanted into the
animal.  In addition to rat and rabbit ischemic hind-limb model, Cao et al. (2003)
used Matrigel assay. In Matrigel assay, growth factor loaded beads were mixed with
Matrigel and subcutaneously injected into mice. After 2 weeks, Matrigel pellets were
collected and fixed in paraffin. Paraffin sections were stained and quantified to assess
the blood vessel formation. (Cao et al., 2003) Matrigel assay is considered one of the
best methods for rapid assessment of pro- anti-angiogenic potential of compounds.
However, Matrigel assays suffers of high variability between different experiments.
(Norrby, 2006)
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Several animal models have been established to mimic complex tumor angiogenesis.
In experimental tumor models, tumor cells, either genetically identical or of human
origin, are implanted into the animal. Tumor angiogenesis is influenced by the organ
site or microenvironment and also animal strain of choice or tumor cell line used,
thus displaying large heterogeneity in terms of angiogenesis and chemosensitivity. In
cancer research, tumor models have an essential role in the assessment of efficacy of
novel compounds in preclinical studies. (Staton et al., 2009)
Standard assessment of embryogenesis disruption involves testing of pregnant
laboratory animals, typically rats and rabbits, with at least two generations involved
in standard test system (Piersma, 2006, Knudsen & Kleinstreuer, 2011). Animals are
exposed during the critical organogenesis and evaluated just before term. In the
animal models, intrauterine death, fetal growth retardation, structural variations and
abnormalities are the main endpoints in the assessment of developmental toxicity.
Although the current animal models are used in the assessment of developmental
toxicity, they are also low-throughput, slow, costly and ethically questionable.
Consequently, the use of animal models in the assessment of developmental toxicity
results in a relatively low number of compounds with sufficient in vivo data
concerning the potential adverse effects on human development. (Knudsen &
Kleinstreuer, 2011)
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Table 1. Typical characteristics of commonly used in vitro and in vivo vascular models.
In vitro vascular models Cells used End points Applications
Endothelial cell
proliferation assay
endothelial cells of different
origin
3H-thymidine
incorporation during
cell proliferation
studies on cell migration and
proliferation
2D and 3D tubule formation
assay in biomaterials
rings of rat aorta, human
endothelial cells
tubule formation vascular physiology studies,
evaluation of angiogenic
compounds
Angiogenesis co-culture
assays
human endothelial
cells+fibroblasts/pericytes/hu
man adipose stromal cells
tubule formation vascular physiology studies,
evaluation of angiogenic
compounds
Microfluidic chips human endothelial cell
monocultures, human
endothelial
cells+fibroblasts/pericytes/can
cer cells
tubule formation, cell
migration, permeability
vascular physiology studies,
disease model development,
evaluation of angiogenic
compounds
In vivo vascular models Animals used End points Applications
Chorioallantoic membrane
assay
chicken embryo tubule formation tumor-induced angiogenesis
studies
Corneal angiogenesis
assay,
Mouse retinal angiogenesis
assay
rabbit, mouse tubule formation,
structure, morphology
evaluation of angiogenic
compounds, developmental,
physiological and pathological
vascular studies
Rat ischemic hindlimb
model
rat, rabbit, mice tubule formation,
histopathology
evaluation of angiogenic
compounds, ischemic studies
Tumor angiogenesis
models
several species tubule formation,
chemosensitivity,
histopathology
cancer research, evaluation of
angiogenic compounds
Embryogenesis disruption
model
rat, rabbit, other species intrauterine death, fetal
growth retardation,
abnormalities
developmental toxicity studies
2.4.4 In vitro cardiac models
Currently, in vitro screening utilizes mainly cell lines that express human cardiac ion
channels, cardiac cell cultures, isolated tissues preparations such as Purkinje fibres
and perfused heart preparations. Electrophysiology remains the “gold standard”
method to characterize ion channel properties and drug discovery will undoubtedly
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benefit from the development of more high-throughput electrophysiological
systems. However, despite of the new technology, there is no clear guidelines stating
which protocols should be used to study hERG channels in vitro. (Finlayson et al.,
2004) The most relevant in vitro cardiac models are discussed below and presented
in Table 2.
Presently, two functional in vitro assays are routinely used in the assessment of drug's
potential to delay cardiac repolarization. Repolarization assay performed with canine
Purkinje fibers characterizes drug-induced changes in the action potential duration
of cardiac tissues and ionic current assay evaluates drug-induced block of the hERG
current or native IKr current. In an evaluation of the functionality of these assays
with pharmaceuticals, results showed a poor correlation between hERG and
repolarization assays suggesting that the hERG assay oversimplifies drug effects on
the repolarization process and that neither assay alone adequately predicts pro-
arrhythmic risk. (Martin et al., 2004)  Another study using human hERG transfected
embryonic kidney cells (HEK293) also showed that the hERG assay alone does not
adequately identify drugs inducing QT prolongation (Lu et al., 2008).
Rat ventricle myoblasts (H9c2) and mouse atrial HL-1 cells are available for the
analysis of compound interaction with cardiac ion channels. (Vidarsson et al., 2010)
Rodent cells are widely used in drug-related studies although they exhibit several
distinctions from human cells: a shorter action potential, different calcium handling,
a higher percentage of alfa-myosin heavy chain isoform, a higher resting heart rate
and an inverse force-frequency relationship. In particular, the differences in ion
channels and currents complicate the transferability of the data from drug screening
and toxicity studies from murine to humans. (Polini et al., 2014)
The voltage-dependent contractile properties of hPSC-CM are necessary to mimic
the primary in vivo role of cardiomyocytes. For mechanistic toxicological studies,
rhythmic perturbations must be assessed as well as the consequences of energy
production as they relate to drug-induced cardiotoxicity simultaneously. Using a
variety of molecular markers, including mitochondrial membrane potential,
endoplasmic reticulum integrity, Ca2+ metabolism and membrane permeability
beside the assessment of cell viability, hPSC-CM were shown to be more predictive
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than primary dog cardiomyocytes and H9c2 cell line when tested with therapeutic
concentrations. (Kolaja, 2014)
Presently, there are several cardiac in vitro models with scaffolds and cardiomyocytes
of animal origin. Garzoni et al (2009) created a 3D tissue-like spheroid model where
cardiomyocytes are co-cultured either with EC or mesenchymal stromal cells. In the
model, murine fetal cardiomyocytes form 3D contractile structures, couple through
gap junctions and form vascular structures in co-culture with HUVEC. Furthermore,
human mesenchymal cells were seen to form vascular structures by vasculogenesis.
The presence of vascular structures led to long-term survival and contractile capacity
of cardiac microtissues. (Garzoni et al., 2009)
Moreover, a 3D in vitro cardiac model composed of rat embryonic cardiomyocytes
and adult rat bone marrow stromal cells to study myocardial regeneration has been
developed. In the system, cells were seeded on 3D tubular scaffold engineered from
type I collagen fibers. The 3D co-culture system was shown to maintain the
embryonic cardiomyocytes differentiation process and, at the same time, induce the
differentiation and maturation of rat bone marrow stromal cells into cardiomyocyte-
like cells. (Valarmathi et al., 2010) Another 3D in vitro cardiac model was developed
to mimic healthy aligned and diseased disorganized cardiac matrix. In the system,
neonatal mouse cardiomyocytes and cardiac fibroblasts were suspended in a
collagen–matrigel hydrogel and seeded to form microtissues. Cardiomyocytes in
aligned matrix were shown to be more elongated and possess aligned sarcomeres.
Furthermore, proliferation of the cardiac fibroblasts had an effect on the microtissue
contraction rate. (van Spreeuwel et al., 2014)
Simple and robust systems with human embryonic stem cell (hESC) have been
created for basic research and preclinical safety assessment. Fibrin based human
engineered heart tissue in a 24-well format with cardiomyocytes was developed.
Cardiomyocytes formed a dense network of longitudinally oriented, interconnected
and cross-striated cells. Furthermore, chronotropic responses to calcium and the β-
adrenergic agonist were detected. Well known pro-arrhythmic compounds induced
concentration-dependent and reversible decreases in relaxation velocity and, further,
an asynchronous beating at concentrations similar to those used in hERG assays.
(Schaaf et al., 2011)
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Vascularized, implantable tissue constructs are one of the main goals of regenerative
medicine. In cell sheet tissue technology, neonatal rat cardiomyocytes were co-
cultured with EC of rat origin on temperature sensitive culture dishes. Co-cultured
EC formed networks within the cardiomyocyte sheets. Cardiac cell sheets were
layered into 3D myocardial tissues and the tissue grafts were transplanted into
infarcted rat hearts. As a result, cardiac function could be significantly improved.
Moreover, vascular structures from the cardiac tissues were shown to integrate into
the infarcted myocardium and to connect with capillaries of the host heart. (Sekine
et al., 2008, Sekine et al., 2013)
In the study by Caspi et al (2007) the aim was to form a multicellular tissue construct
that enables the generation of highly vascularized human engineered cardiac tissue.
In the protocol, hESC-CM were seeded on 3D biodegradable, polymeric scaffolds
and co-cultured with EC with or without embryonic fibroblasts. The presence of
fibroblasts was shown to decrease EC death and increase EC proliferation.
Moreover, the presence of EC derived vascular structures increased cardiomyocyte
proliferation without limiting the cardiomyocyte orientation and alignment. This 3D
vascularized human cardiac construct is proposed for utilization in studies related to
cardiac development, function and tissue replacement therapy. (Caspi et al., 2007)
2.4.5 In vivo cardiac models
To assess the potential of a drug to delay ventricular repolarization in safety
pharmacology, dogs, monkeys, swine, rabbits, ferrets and guinea pigs are considered
as suitable animal models according to ICH guideline S7B. Smaller rodents (adult rat
and mice) are excluded due to their markedly different mechanism of repolarization
compared to humans.(Food and Drug Administration, 2005) The advantages of in
vivo experiments is that the effects of anti-arrhytmic compounds, If blockers and also
effects of non-cardiovascular chemicals can be identified.  Moreover, all routes for
drug administration can be applied. The disadvantage of animal models include high
doses of compounds that may induce side effects on other organs thus increasing
the complexity of assessing cardiac toxicity. Moreover, in vivo tests are time-
consuming, allow only low-throughput and faces ethical problems. (Kettenhofen &
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Bohlen, 2008) The most relevant in vivo cardiac models and the benefits and
disadvantages related to them are discussed below and presented in Table 2.
Explanted hearts of guinea pigs and rabbits, as well as Purkinje fibres of guinea pig
or dog origin, are common models in cardiac safety pharmacology studies
(Kettenhofen & Bohlen, 2008). Action potential duration and arrhythmogenic
effects can be measured using isolated Purkinje fibres and perfused hearts from
rabbits. (Lu et al., 2008) These tests belong to the “Gold Standard” of test batteries
for the investigation of new chemical entities prior to clinical trials. (Kettenhofen &
Bohlen, 2008) However, standardization of these models is difficult due to inter-
operator differences and inter-animal variations. Furthermore, the short
experimental times severely limit the ability to assess long-term exposure of toxic
compounds. (Kettenhofen & Bohlen, 2008)
To study safety pharmacological effects of new chemical entities, the whole animal
models with different species are preferred. In vivo cardiac safety studies are most
commonly performed using dogs. However, none of the animal models used appears
to produce Torsade de Pointes with complete reliability.  Studies in dogs, whether
conscious or anaesthetised, appear to be invaluable in assessing the arrhythmic
potential of new chemical entities. Since the dog studies are laborious and costly,
alternative models such as the anaesthetised guinea pigs have been used. However,
guinea pigs have, at molecular level, heterogeneity in cardiac ion channels that is not
detected in rabbits, swine or dogs. (Finlayson et al., 2004)
Although rodent studies are considered inappropriate for assessment of cardiac
repolarization, transgenic mouse models with appropriate cardiac ion channel
mutations may be useful in identifying of novel arrhythmic mechanisms. (Finlayson
et al., 2004)
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Table 2. Typical characteristics of commonly used in vitro and in vivo cardiac models.
In vitro cardiac models Cells used End points Applications
Repolarization assay dog Purkinje fibers, human
pluripotent stem cell-derived
cardiomyocytes
action potential duration,
arrhythmia
drug development, safety
assessment of chemicals,
basic research
Ion current assay transfected cell lines of different
origin, rat ventricle myoblasts,
mouse atrial cells, human
pluripotent stem cell-derived
cardiomyocytes
hERG current, IKrcurrent drug development, safety
assessment of chemicals,
basic research
3D spheroid models
with/without
biomaterials
human pluripotent stem cell-
derived cardiomyocytes, rodent
fetal cardiomyocytes+endothelial
cells/stromal cells
electrophysiology,
morphology, tubule
formation
cardiovascular development
studies, disease modeling,
drug development
Vascularized cardiac
constructs with/without
perfusion
human pluripotent stem cell-
derived cardiomyocytes/neonatal
rat cardiomyocytes+endothelial
cells+fibroblasts of different
origin
electrophysiology,
viability, structure, tubule
formation
tissue engineering,
regenerative medicine,
embryonic heart
development, drug
development
In vivo cardiac models Animal used End points Applications
Explanted heart guinea pig, rabbit action potential duration,
arrhythmia
drug development, safety
assessment of chemicals,
basic research
Whole animal models dog, guinea pig, swine,
transgenic mouse, rabbit
electrophysiology,
arrhythmia,
histopathology
drug development, safety
assessment of chemicals,
disease modeling
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3 Aims of the study
The aim of this thesis was to develop advanced, human cell based tissue models to
supplement or replace animal tests and to be used for biomedical research. First
objective was to establish and characterize human vascular models for testing of pro-
and anti-angiogenic substances. Second aim was to combine vascular model with
cardiomyocytes in order to develop cardiovascular model for cardiac safety and
efficacy assessment. The specific aims of this thesis were as follows:
1. To develop and optimize human cell based stromal-vascular and
vasculogenesis-angiogenesis models (I)
2. To characterize the human vasculogenesis-angiogenesis model for chemical
testing as well as for tissue engineering platform (II)
3. To develop cardiovascular model composed of two different vascular
platforms, vasculogenesis-angiogenesis model and angiogenesis model, and
neonatal rat cardiomyocytes for a proof-of-concept level (III)
4. To develop functional human cell based cardiovascular model composed of
angiogenesis model and human cardiomyocytes (IV)
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4 Materials and methods
4.1 Origin of cells and ethical approvals
This study conforms to the principles outlined in the Declaration of Helsinki.
Human adipose stromal cells (hASC) used in studies I, II and III were isolated in
FICAM from adipose tissue samples that were received as a leftover material from
surgeries at Tampere University Hospital, Tampere, Finland with individual written
informed consents. Utilization of hASC has received an approval of Joint Municipal
Authority of the Pirkanmaa Hospital District with ETL-code R03058.
Human umbilical vein endothelial cells (HUVEC) used in all four studies were
isolated in FICAM from human umbilical cords that were received from caesarean
sections at Tampere University Hospital, Tampere, Finland with individual written
informed consent. Utilization of HUVEC has received an approval of Joint
Municipal Authority of the Pirkanmaa Hospital District with ETL-code R08028.
Human foreskin fibroblasts used in studies III and IV were purchased from
American Type Culture Collection (CRL-2522; ATCC, Manassas, VA, USA).
Neonatal rat cardiomyocytes (NRC) used in the study III were isolated from one to
four-day-old Sprague Dawley rat pups. Rats were obtained from Animal Facilities of
University of Tampere and cells were isolated in accordance with the Finnish animal
protection laws and accepted by the Department for Social Welfare and Health
Services of State Provincial Office of Western Finland. Euthanasia was performed
by decapitation, a method approved in Directive 2010/63/EU. The use of NRC
does not require permission for animal testing since the animals are being euthanized
immediately (animal test level K0).
Human embryonic stem cell derived cardiomyosytes (hESC-CM, cell line H7) used
in study III and IV were purchased from WiCell Research Institute (Madison, WI,
USA). The induced pluripotent stem cells (iPSCC) used in study IV were derived
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from human foreskin fibroblasts. Patient-specific iPSC cell line UTA.04602.WT was
established in University of Tampere from healthy control individual as described
earlier (Lahti et al., 2012, Takahashi et al., 2007). Results of the characterization of
iPSC-derived cardiomyocyte cell line UTA.04602.WT used in study IV has been
described earlier (Lahti et al., 2012). The Ethical Committee of Pirkanmaa Hospital
District has granted approval for iPSC cells study with ETL-code R08070.
4.2 Development of media (I-IV)
In order to replace the commercial HUVEC medium (Table 3) and to create a
completely defined medium, a vascular stimulation medium (VSM, Table 3) was
developed to induce optimal vascular-like network formation in vasculogenesis-
angiogenesis model (II). For cardiovascular models (III,IV), a universal medium was
developed to primarily support CM functionality and maturation and secondarily to
induce adequate vascular-like network formation. Development and optimization of
media for different in vitro models was performed throughout the studies. The cell
culture media used in all fours studies are presented in Table 3.
Medium was changed every two to three days to fibroblasts, HUVEC and hASC that
were quality-controlled and tested for mycoplasma contamination (MycoAlert®
Mycoplasma Detection Kit, Lonza) before experimental use.
In study I, the different test media were: 1) HUVEC medium; 2) HUVEC
medium/HS where 2 % FBS was replaced with 2 % HS; 3) HUVEC medium/-
serum where serum was excluded and 4) HUVEC medium/-gf where growth factors
were excluded and 0,1 % gentamicin, 2 % FBS and 1 mM L-glutamine added to the
medium. Detailed description of the media components is presented in Table 3.
In study II, the different test media were: 1) HUVEC medium; 2) HUVEC
medium/HS, where 2 % FBS was replaced with 2 % HS; 3) serum free basal medium
(SFBM) and 4) vascular stimulation medium (VSM).  Detailed description of the
media components can be seen in Table 3. In the first, above mentioned media
comparison study, the ascorbic acid (AA), hydrocortisone (HY) and heparin (HE) in
VSM were received from EGM-2 kit Single Quots -supplements (Lonza) and used
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according to manufacturer´s protocol (concentrations of these supplements are not
publicly available). After first media comparison study, concentrations of AA, HE
(Heparin sodium salt from bovine intestinal mucosa) and HY, all purchased from
Sigma, were optimized for VSM. In the concentration optimization study, the tested
concentrations of AA were 0, 50, 100, 200, 500, 1000 and 2000 µg/ml; of HY 0, 20
ng/ml, 200 ng/ml, 1 µg/ml and 2µg/ml and of HE 0, 50 ng/ml, 500 ng/ml, 10µg/ml
and 50 µg/ml. The concentrations of 10 ng/ml VEGF and 1 ng/ml FGF-2 used for
VSM were optimized previously by us (Sarkanen et al., 2011).
In study III, altogether six different media were tested to find out the most optimal
medium for rat cardiovascular model. The media were chosen to represent optimal
culture media for either NRC (NRC medium 1 and 2, Table 3), angiogenesis model
(angiogenic medium 3 and 4, Table 3) or vasculogenesis-angiogenesis model
(vasculogenic-angiogenic medium 5 and 6, Table 3). The media 3-6 were chosen
according to study II and according to our previous results (Sarkanen et al., 2011).
Detailed description of the all test media components can be seen in Table 3.
Hydrocortison, ascorbic acid and heparin used in NRC medium 2 were received
from Single Quots -supplements (Lonza) with unknown concentrations.  All media
were tested with NRC monoculture and with rat cardiovascular model.
In study IV, due to our objective to have a low-serum or serum-free culture
conditions in human cardiovascular model the minimum serum concentration for
human CM monoculture was tested. Altogether five different serum concentrations
including 0, 2, 5, 10 and 20 % FBS (Table 3) in EB medium were tested for
dissociated human CM. All media were tested with CM monoculture and with
human cardiovascular model.
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Table 3. List of the cell culture, differentiation and stimulation media used for cell culture studies
Medium Basal medium Serum Supplements Study
Angiogenic medium 1 EBM-2 (Lonza) 2% FBS 10 ng/ml VEGF, 1 ng/ml FGF-2,
1 % l-glutamine
III
Angiogenic medium 2 EBM-2 (Lonza) 2% HS
(Lonza)
10 ng/ml VEGF, 1 ng/ml FGF-2,
1 % l-glutamine
III
Angiogenesis
stimulation medium
EBM-2 (Lonza) 2% FBS 1 % l-glutamin, 10 ng/ml VEGF,
1 ng/ml FGF-2
III,IV
EB medium DMEM/
F-12
(Invitrogen)
0, 2, 5, 10,
20% FBS
1% NEAA (Lonza), glutamax
(Invitrogen), 50 U/ml
penicillin/streptomycin (Lonza)
IV
Fibroblast medium MEM 10% FBS 1 % NEAA, 1 % l-glutamin III, IV
hASC medium DMEM/
F-12
10% HS
(Lonza)
1 % l-glutamin I-III
HUVEC medium EBM-2 (Lonza) 2% FBS Single Quots –supplements
(Lonza): VEGF, FGF-2, IGF-I,
EGF, hydrocortisone, ascorbic
acid, heparin
I-IV
HUVEC medium/HS EBM-2 (Lonza) 2% HS
(Lonza)
Single Quots -supplements
(Lonza): VEGF, FGF-2, IGF-I,
EGF, hydrocortisone, ascorbic
acid, heparin
I
HUVEC medium/-
serum
EBM-2 (Lonza) - Single Quots -supplements
(Lonza): VEGF, FGF-2, IGF-I,
EGF, hydrocortisone, ascorbic
acid, heparin
I
HUVEC medium/- gf EBM-2 (Lonza) 2% FBS 0,1 % gentamicin, 1 mM l-
glutamine
I
KSR medium DMEM/
F-12
(Invitrogen)
20% KnockOut
serum
replacement
(Invitrogen)
1% NEAA (Lonza), 2 mM
Glutamax (Invitrogen), 50 U/ml
penicillin/streptomycin (Lonza),
0.1 mM β-mercaptoethanol
(Invitrogen), 7.8 ng/ml FGF-2
(R&D Systems)
IV
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Table 3-continued. List of the cell culture, differentiation and stimulation media used for cell culture
studies
Medium Basal medium Serum Supplements Study
NRC medium 1 DMEM/
F-12
- 10 ng/ml VEGF, 1 ng/ml FGF-2,
10 % BSA, 2.8 mM Sodium
Pyruvate (Lonza), 2.56 mM L-
glutamine, ITS and T3
III
NRC medium 2 DMEM/
F-12
- 10 ng/ml VEGF, 1 ng/ml FGF-2,
hydrocortisone, heparin, ascorbic
acid, 10 % BSA, 2.8 mM Sodium
Pyruvate (Lonza), 2.56 mM L-
glutamine, ITS and T3
III
NRC Seeding Medium
(NRC-SM)
DMEM/F-12 10% FBS 100 IU/ml Penicillin/0.1 mg/ml
Streptomycin, 2.56 mM L-
glutamine
III
NRC Serum Free
Medium
(NRC-SFM)
DMEM/F-12 - 10 % BSA, 2.8 mM Sodium
Pyruvate (Lonza), 2.56 mM L-
glutamine, ITS and T3
III
Serum free basal
medium (SFBM)
DMEM/
F-12
- 10 % BSA, 2.8 mM Sodium
Pyruvate (Lonza), 2.56 mM L-
glutamine, ITS and T3
II
Vascular stimulation
medium (VSM)
DMEM/
F-12
- 10 ng/ml VEGF, 1 ng/ml FGF-2,
hydrocortisone, ascorbic acid,
heparin, 10 % BSA, 2.8 mM
Sodium Pyruvate (Lonza), 2.56
mM L-glutamine, ITS and T3
II
Vasculogenic-
angiogenic medium 1
EBM-2 (Lonza) 2% HS
(Lonza)
Single Quots -supplements
(Lonza): VEGF, FGF-2, IGF,
EGF, gentamycin,
hydrocortisone, ascorbic acid,
heparin
III
Vasculogenic-
angiogenic medium 2
EBM-2 (Lonza) - Single Quots -supplements
(Lonza): VEGF, FGF-2, IGF,
hEGF, gentamycin,
hydrocortisone, ascorbic acid,
heparin
III
Detailed description of the hPSC-derived cardiomyocyte differentiation media is presented in chapter 4.3.8.
All media components without supplier information were purchased from Gibco.
NEAA= non-essential amino acids
BSA= Bovine Serum Albumin (Sigma)
ITS= Insulin– transferrin–sodium selenite media supplement composed of 1 μM insulin, 5.64 μg/ml transferrin and 32 nM selenium
(Lonza)
T3= 100 IU/ml P/0.1 mg/ml S 0.1 nM 3,3’,5-Triiodo-L-thyronine sodium salt (Sigma)
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4.3 Cell isolation, differentiation and culture
All cell culture was performed in incubators at 37 °C, under 5 % CO2 atmosphere
and at constant humidity.
4.3.1 Culture of human foreskin fibroblasts (I,III,IV)
Human foreskin fibroblasts were cultured in fibroblast medium (Table 3). After
thawing cells were grown to confluency 2-3 days and used for further experiments.
4.3.2 Isolation and culture of human adipose stromal cells (I-III)
Human adipose tissue specimens were cut into small pieces, enzymatically digested
with 0,05% collagenase I (Invitrogen, Paisley, Scotland, UK) in plain DMEM/F12
(Gibco, Invitrogen, Carlsbad, CA, USA) for 60 min at 37↓C in a gyratory water bath.
The digested tissue was centrifuged at 600 x g for 10 min in room temperature. The
digested tissue was filtered through a 100 µm filter (Sarstedt, Nümbrecht, Germany),
centrifuged and filtered through a 40 µm filter (Sarstedt). Cells were seeded into 75
cm2 flasks (Nunc EasyFlask™, Nunc, Roskilde, Denmark) in hASC medium (Table
3). Cells were cultured to confluency and used for further experiments or
cryopreserved in liquid nitrogen at passage 0-2 before experimental use.
4.3.3 Isolation and culture of human umbilical vein endothelial cells (I-IV)
HUVEC were isolated from human umbilical cord vein by using enzymatic
procedure according to Jaffe et al. (Jaffe et al., 1973) but the process was further
optimized by us (Sarkanen et al., 2011). The umbilical cord was separated from the
placenta and the umbilical vein was cannulated with a 20G needle. The needle was
secured by clamping the cord over the needle with a surgical clamp. The vein was
perfused with Umbilical cord Buffer Solution (UBS; 0,1 M phosphate buffer solution
containing 0,14 M NaCl , 0,004 M KCl and 0,011 M glucose) to wash out blood.
After that the opposing end of the umbilical vein was clamped with a surgical clamp.
The vein was infused with 0.05% collagenase I in a water bath at 37 °C up to 20 min.
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After incubation, the collagenase I solution containing HUVEC was flushed from
the cord by infusing the vein with UBS into 50 ml polypropylene tube. The cells
were centrifuged at 250 x g for 10 min, resuspend to HUVEC medium (Table 3) and
seeded into 75 cm2 flasks. Cells were cultured to confluency and cryopreserved in
liquid nitrogen at passage 2 before experimental use.
4.3.4 GFP-infection to human umbilical vein endothelial cells
Lentiviral construct pLKO-MISSION-Bright-GFP was purchased from
Biomedicum Genomics (BMGen, Biomedicum Helsinki, Helsinki, Finland). The
infection was carried out with HUVEC at low passages with 300 µl of pLKO-
MISSION-Bright-GFP in 1 ml HUVEC medium (1 U/ml). Virus infection was
accelerated with 8 µg/ml hexadimethrine bromide (Sigma). After 24 hours of
incubation, medium was replaced with fresh HUVEC medium. Highly fluorescent
clones were selected with cloning rings and further selected with dilution cloning to
obtain pure GFP-HUVEC-culture.  GFP-infected HUVEC were cultured to
confluency and used for vasculogenesis-angiogenesis model to assess the origin and
ratio of the cells responsible for vascular-like network formation in hASC and
HUVEC co-culture.
4.3.5 Isolation and culture of neonatal rat cardiomyocytes (III)
Neonatal rat cardiomyocytes were harvested from one to four-day-old Sprague
Dawley rat pups hearts as described by Uusimaa et al. (Uusimaa et al., 1992). Briefly,
the hearts were perfused with collagenase solution and cut into 1-2 mm pieces. The
heart pieces were incubated at 37 °C for 5 min and the supernatant was discarded.
Fresh 5 ml of collagenase solution was added and this step was repeated five times.
The supernatants were collected and filtered (100µm) into 20 ml of NRC seeding
medium (NRC-SM, Table 3). The cells were preplated for 45 minutes to reduce the
number of non-muscle cells and to achieve more pure NRC population. After the
preplating, the NRC were collected and seeded in NRC-SM into 48-well plates
(Nunc, Thermo Fisher Scientific, USA) at a density of 0,1 – 0,4 x 106 cells/cm2.
Serum free medium (NRC-SFM, Table 3) was changed day after plating and
thereafter every second or third day.
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4.3.6 Establishment of neonatal rat cardiomyocyte monoculture (III)
After preplating, the NRC were collected and seeded in NRC-CM seeding medium
at a density of 0,1 – 0,4 x 106 cells/cm2. Serum free medium was changed the day
after cell seeding and thereafter every second or third day. NRC monoculture was
used as a control to cardiovascular constructs in study III and cultured 7-14 days
prior to end point analysis.
4.3.7 Establishment of human iPSC line (IV)
Patient-specific iPSC line UTA.04602.WT (from a 55-year-old female) was
established using lentivirus infection followed by retrovirus infection into the
primary fibroblasts from adult skin. Primary fibroblasts from a skin biopsy were
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (Lonza) containing 10%
fetal bovine serum (Lonza), 2 mmol/l L-glutamine and 50 U/ml
penicillin/streptomycin. The cells, plasmids and reagents used in the iPSC line
establishment included 293FT cells (Invitrogen, Carlsbad, CA), PlatE cells (Cell
Biolabs, San Diego, CA), pLenti6/UbC/mSlc7a1 vector (Addgene, Cambridge,
MA), ViraPower Packaging Mix (Invitrogen), Lipofectamine 2000 (Invitrogen),
pMX retroviral vector (hOCT3/4, hSOX2, hKLF4 or hc-MYC; Addgene) and
Fugene 6 (Roche Diagnostics). The protocol for iPSC line establishment has been
described previously (Takahashi et al., 2007). 293FT cells were maintained in
Dulbecco’s Modified Eagle’s Medium (DMEM) (Lonza) containing 10% fetal
bovine serum (Lonza), 2 mmol/l L-glutamine, 50 U/ml penicillin/streptomycin and
1% non-essential amino acids (Cambrex, East Rutherford, NJ). Plat-E cells,
irradiated SNL-76/7 cells and mouse embryonic fibroblasts (MEF; Millipore,
Billerica, MA) were cultured without antibiotics.
4.3.8 Differentiation and culture of human cardiomyocytes (IV)
Patient-specific iPSC or hESC differentiation into cardiomyocytes (CM) was carried
out with either by co-culturing iPSC/hESC with murine visceral endoderm-like
(END-2) cells (Humbrecht Institute, Utrecht, The Netherlands) as described earlier
(Mummery et al., 2003) or with small molecule differentiation method via temporal
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modulation of canonical Wnt signaling (Lian et al., 2013). In small molecule method
pluripotent stem cells were cultured on Geltrex (Life Technologies) coated plates in
mTeSR1 (StemCell Tehcnologies) medium for at least 3 passages before initiating
the cardiac differentiation. After fully confluent, cells were passaged with Versene
(Life Technologies). For differentiation, cells were treated with Accutase (Merck
Millipore) at 37 °C for 5 min and single cells were seeded onto Geltrex coated plates
at 0,17-0,25 x 106 cell/cm2 in mTeSR1 supplemented with 5 μM ROCK inhibitor
(RD Systems) for 4 days. The medium was changed to RPMI/B27 (Life
Technologies) without insulin containing a Gsk3 inhibitor CHIR99021 (Miltenyi
Biotech) to start differentiation (day 0) and it was changed to RPMI+B27 without
insulin on next day (day 1). RPMI/B27 without insulin containing 5 μM IWP-4 was
added to cells on day 3.  The RPMI/B27 without insulin was changed to cells on day
5 and 7 after which the cells were maintained in the RPMI/B27 starting from day
10, with the medium changed every 3 days. Both differentiation methods resulted in
beating cardiomyocyte aggregates. Aggregates were mechanically excised and treated
with collagenase A (Roche Diagnostics) to dissociate aggregates to single cell level
for further experimental use.
Patient-specific iPSC (UTA.04602.WT) and hESC (H7) were cultured on mitomycin
C inactivated mouse embryonic fibroblasts (MEF) in KSR medium (Table 3). The
medium was refreshed daily, and the stem cell colonies were passaged onto a new
MEF layer once a week using 1 mg/ml collagenase IV (Invitrogen).
4.3.9 Establishment of human cardiomyocyte monoculture (IV)
After dissociation human CM were seeded in EB medium with 5 % FBS (Table 3)
at density of 0,01-0,04 x 106 cells/cm2. EB medium with 5 % FBS was changed 1-2
days after cell seeding and thereafter every second or third day. CM monoculture
was used as a control to cardiovascular construct in study IV and cultured 6-13 days
prior to end point analysis.
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4.3.10 Development of tissue models
In this thesis two different vascular models, a stromal-vascular model (study I) and
vasculogenesis-angiogenesis model (studies I, II) were developed to mimic
embryonic vasculogenesis and adult angiogenesis. In parallel, cardiovascular model
based on rat cardiomyocytes mimicking adult heart was develop for a proof-of-
concept level (study III).  In rat cardiovascular model, neonatal rat cardiomyocytes
were combined with vasculogenesis-angiogenesis model and with angiogenesis
model that was previously developed and validated in FICAM (Sarkanen et al., 2011).
These two different vascular models were tested for their ability to support the
viability and contractility of cardiomyocytes. Finally, completely human cell based
cardiovascular model with human cardiomyocytes and angiogenesis model (study
IV) mimicking adult human heart was developed.
4.3.11 Stromal-vascular model (I)
hASC (six different cell lines from different donors, passages 1-7 were used) were
seeded in HUVEC medium at a density of 20 000 cells/cm2. Cells were cultured for
either 3 or 6 days in HUVEC medium to assess vascular-like network formation.
HUVEC medium and other test media inducing vascular-like network formation
was changed once to cells cultured for 3 days and twice to cells cultured for 6 days.
4.3.12 Vasculogenesis-angiogenesis model (I, II)
hASC were seeded (p1-7) in HUVEC medium (Table 3) into 48-well plates at a
density of 20 000 cells/cm2. After 1-3 hours HUVEC (p4) were seeded on top of
hASC at a density of 4000 cells/cm2 in HUVEC medium. The seeding densities of
hASC and HUVEC were chosen in study I. Vasculogenesis-angiogenesis model was
cultured 3 or 6 days prior to end point analysis in study I, and 6 days prior to end
point analysis in study II. Vasculogenesis-angiogenesis model was cultured for
approximately 24 hours prior to utilization in cardiovascular construct used in study
III. HUVEC medium and other test media inducing vascular-like network formation
was changed once to 3 day culture and twice to 6 day culture.
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4.3.13 Rat cardiovascular model (III)
Two different vascular platforms were cultured with neonatal rat cardiomyocytes
(NRC) in order to develop an optimal cardiovascular model. NRC were seeded on
top of the (1) vasculogenesis-angiogenesis model and (2) angiogenesis model
approximately after 24 hours at a density of 0,1-0,4 x 106 cells/cm2 in NRC-SM
(Table 3).  Angiogenesis model was constructed as described previously by us
(Sarkanen et al., 2011). Briefly, fibroblasts (p6-7) were seeded at a density of 20 000
cells/cm2 in fibroblast medium (Table 3) and grown for 2-3 days to confluency.
HUVEC medium was changed and HUVEC were seeded on top of the fibroblast
culture at a density of 4000 cells/cm2 in HUVEC medium (Table 3). Rat
cardiovascular models consisted of HUVEC+hASC+NRC and
HUVEC+fibroblast+NRC. After approximately 24 hours after NRC seeding serum
free medium (NRC-SFM, Table 3) and other test media was changed and thereafter
three times in a week. Rat cardiovascular models were cultured 7-14 days prior to
end point analysis.
4.3.14 Human cardiovascular model (IV)
EB medium with 5 % FBS (Table 3) was changed to angiogenesis model before
seeding of CM. Angiogenesis model was constructed as described previously by us
(Sarkanen et al., 2011). Briefly, fibroblasts (p6-7) were seeded at a density of 20 000
cells/cm2 in fibroblast medium (Table 3) and grown for 2-3 days to confluency.
HUVEC medium was changed and HUVEC were seeded on top of the fibroblast
culture at a density of 4000 cells/cm2 in HUVEC medium (Table 3).  Angiogenic
stimulation medium (ASM, Table 3) inducing vascular-like network formation was
changed the day after cell seeding and thereafter twice. Dissociated human iPSC- or
hESC-derived CM were seeded on top of the angiogenesis model at day 6, when the
vascular-like network was already formed, at a density of 0,01-0,04 x 106 cells/cm2
in EB medium with 5 % FBS. 1-2 days after CM seeding first EB medium with 5 %
FBS change was performed and thereafter three times in a week. Human
cardiovascular model was cultured 6-12 days prior to end point analysis.
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4.4 Flow cytometric analysis (I,II)
Characterization of individual cells was performed to the building blocks, i.e. hASC
and HUVEC, of vasculogenesis-angiogenesis model. hASC (p1) and HUVEC (p3)
were analysed for surface and intracellular marker expression using a BD
FACSCanto II and FACSAria flow cytometers (both BD Biosciences,
Erembodegem, Belgium). The markers used in the analysis are listed in Table 4. The
analysis was performed using 5 000-10 000 cells per sample. Isotype controls and
unstained cell samples were used to eliminate background fluorescence.
Compensation was performed using compensation particles (BDTM CompBeads,
BD Biosciences). The results were analyzed using BD FACSDivaTM Software (BD
Biosciences).
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Table 4. Surface and intracellular* markers used in flow cytometric analysis
Cell                     Marker                          Target
hASC vWf*-APC von Willebrand factor
CD144-FITC vascular endothelial cadherin
eNOS*-PE endothelial nitric oxide synthase
CD140b-PE platelet derived growth factor receptor beta
CD45-PE leukocyte common antigen
CD14-FITC surface antigen expressed on monocytes/macrophages
CD68-FITC glycoprotein expressed on monocytes/macrophages
CD309-PE vascular endothelial growth factor receptor 2
CD31-V450 platelet endothelial cell adhesion molecule
NG2-PE chondroitin proteoglycan expressed on pericytes
CD90-FITC mesenchymal stem cells, T cells
CD105-V450 endoglin expressed on mesenchymal stem cells
CD73-PE-CY7 ecto-5'-nucleotidase
CD34-APC sialomucin-like adhesion molecule expressed  on hematopoietic progenitor cells
HUVEC vWf*-APC/PE von Willebrand Factor
CD144-FITC/PE vascular endothelial cadherin
CD309-PE vascular endothelial growth factor receptor 2
CD73-PE-CY7 ecto-5'-nucleotidase
CD68-FITC glycoprotein expressed on monocytes/macrophages
eNOS*-PE endothelial nitric oxide synthase
CD105-V450 endoglin expressed on mesenchymal stem cells
CD34-APC sialomucin-like adhesion molecule expressed  on hematopoietic progenitor cells
CD31-V450/FITC platelet endothelial cell adhesion molecule
CD140b-PE platelet derived growth factor receptor beta
NG2-PE chondroitin proteoglycan expressed on pericytes
CD13-PE aminopeptidase N
CD44-FITC hyaluronate, homing cell adhesion molecule (HCAM)
CD117-APC receptor tyrosine kinase protein, mast/stem cell growth factor receptor
CD 133-PE glycoprotein prominin-1 expressed in endothelial progenitor cells
CD202b angiopoietin receptor Tie-2
CD63-PE tetraspanin expressed in basophils
VEGFR2 vascular endothelial growth factor receptor 2
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4.5 Immunocytochemical analysis (I-IV)
For immunocytochemical stainings, cells were  washed two to three times with PBS,
fixed with ice-cold 70 % ethanol or 4 % paraformaldehyde for 20 minutes,
permeabilized with 0,5 % Triton X-100 (JT Baker, Phillipsburg, NJ, USA) for 15
minutes and blocked for unspecific staining with 10 % bovine serum albumin (BSA,
Sigma) for 30 minutes. After blocking, the cells were incubated with the primary
antibodies at 1 hour at RT or in + 4 °C o/n. After primary antibody incubation, cells
were washed three times with PBS and incubated 30 min with secondary antibody.
Fluorescence was visualized with Nikon Eclipse Ti-S microscope (Nikon, Tokyo,
Japan) or with confocal laser scanning microscope Zeiss LSM 700 (Zeiss LSM 700
on the Axio Observer, Carl Zeiss Microimaging GmbH, Jena, Germany) and the
images were processed with Zen2009 (confocal images, Carl Zeiss) and with Adobe
Photoshop software 7.0 (Adobe Systems, San Jose, CA, USA) and Corel Draw
software 10.0 (Corel Corporation, Ottawa, ON, Canada).  A complete list of primary
and secondary antibodies used in immunocytochemical stainings is shown in Table
5.
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Table 5. List of antibodies used in studies (I-IV)
Primary antibody Target Dilution Origin Secondary
antibody
Supplier of
prim. ab
von Willebrand factor endothelial cells 1:100 rabbit IgG-TRITC, IgG
A568
Sigma-Aldrich
collagen IV basement membrane 1:500 mouse IgG-FITC Sigma-Aldrich
calponin contractile smooth muscle
cells
1:800 mouse IgG-FITC Sigma-Aldrich
α-smooth muscle
actin
smooth muscle actin
pericytes
1:200 mouse IgG-FITC DAKO
smooth muscle
myosin heavy chain
vascular smooth muscle
cells
1:800 mouse IgG-FITC Sigma-Aldrich
platelet derived
growth factor
receptor β
pericytes, smooth muscle
cell progenitors
1:800 mouse IgG-FITC Sigma-Aldrich
vascular endothelial
cadherin
endothelial cell junctions 1:50 mouse IgG-FITC BD Biosciences
occludin endothelial cell junctions 1:300 mouse IgG-FITC Sigma-Aldrich
troponin t cardiomyocytes 1:1500
1:500
goat
mouse
IgG Alexa Fluor
488
IgG Alexa Fluor
568
IgG-FITC
Abcam
Abcam
α-actin cardiomyocytes 1:1500 mouse IgG-FITC Sigma-Aldrich
connexin-43 cardiomyocyte gap
junctions
1:1000 mouse
rabbit
IgG-FITC
IgG-TRITC
Sigma-Aldrich
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4.6 Microscopical analysis (I-IV)
4.6.1 Analysis of cardiomyocyte contractility (III, IV)
NRC contractility was estimated visually as weak (10-30 % beating cardiomyocytes
per cm2), moderate (30-50 % of the cardiomyocytes beating per cm2) or strong (50-
70 % synchronously beating cardiomyocytes per cm2).
Human CM viability and functionality was microscopically observed three to five
times in a week under phase contrast microscope. In the assessment of human CM
contractility, the size of the areas of beating CM, beating frequency and
synchronization were visually observed.
4.6.2 Analysis of vascular-like network formation
In studies I and II, the vascular-like network formation, i.e. vWf-positive tubule
structures,  were analysed with Nikon Eclipse TS100 microscope (Nikon, Tokyo,
Japan) from with 40x magnification (study I, II) or using Cell-IQ (Chipman tech.,
Tampere, Finland) with 10x objective and 5x5 grid (study II). The analysis and
grading was based on the length and the branches of the tubules.  After Cell-iQ
imaging, the quantitation of the area of the vascular-like network was performed
using ImageJ software (National institutes of health, NIH, Maryland, USA). The total
vascular-like network area was calculated as the total number of pixels in images.
In study III, the vascular-like network formation in rat  cardiovascular model in
different media were analysed visually using Nikon Eclipse TS100 microscope and
compared to a control medium that gave value of 100 % vascular-like network
formation. In rat cardiovascular model composed of hASC+HUVEC+NRC, the
control media was HUVEC medium and in rat cardiovascular model composed of
fibroblast+HUVEC+NRC the control medium was angiogenesis stimulation
medium (Table 5).  The analysis was based on vascular-like network formation, i.e.
the length and the branches of tubules.
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4.7 Electron microscopical analysis (II)
To study the microstructure of vascular-like network, the vasculogenesis-
angiogenesis model was cultured in 24 well UpCell plate (ThermoFisher) for
transmission electron microscopy (TEM) and on glass cover slip coated with 0,1 %
Gelatin for scanning electron microscopy (SEM). Culture was maintained for 6 days
and washed twice with PBS prior to fixation.
SEM specimens were fixed in 2 % glutaraldehyde in 0.1 M phosphate buffer after
which the SEM samples were dehydrated in alcohol and dried in Baltec critical point
dryer (Baltec, CPD030, Balzers, Liechtenstein). A layer of platinum was sputtered
on the specimens with a sputter coater (Agar Scientific, Stansted, England).
Specimens were examined in a Zeiss Ultra Plus scanning electron microscope, (Carl
Zeiss MT- Nanotechnology System Division, Carl Zeiss NTS Gmbtt, Oberkochen,
Germany) using 5 kV as an accelerating voltage.
TEM specimens were detached from temperature sensitive 24 well UpCell plate and
transferred to fixative with 1 % glutaraldehyde 4 % formaldehyde mixture in 0.1 M
phosphate buffer for 10 minutes. The cell sheet was immersed in 2% Agarose in
distilled water and postfixed in 1% osmiumtetroxide, dehydrated in acetone and
embedded in Epon LX 112 (Ladd Research Industries, Vermont, USA). Thin
sections were cut with Leica Ultracut UCT ultramicrotome, stained in uranyl acetate
and lead citrate and examined in Cm 100 transmission electron microscope.  Images
were captured by Morada CCD camera (Olympus Soft Imaging Solutions GMBH,
Munster Germany).
4.8 Gene expression studies (I,II,IV)
Quantitative reverse-transcriptase polymerase chain- reaction (qRT-PCR) was
performed to stromal-vascular model (d3 and d6, study I), vasculogenesis-
angiogenesis model (d3 and d6, studies I and II), angiogenesis model (d1, d6 and
d18, study IV), human cardiomyocyte monoculture (d7 and d18, study IV) and
human cardiovascular model (d7 and d18, study IV).  The total RNA was extracted
using TRIzol® (Invitrogen, study I), RNAeasy minikit (Qiagen, studies II and IV)
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or PureLink RNA Mini Kit (Life Technologies, study IV) following the
manufacturer’s protocol. The concentration and purity of RNA was assessed using
spectrophotometry (GeneQuant II RNA/DNA calculator, Pharmacia Biotech GE
Healthcare UK Ltd and microplate reader in Varioskan Flash Spectrophotometer,
ThermoScientific) before further use. Reverse transcription of the total RNA to
cDNA was performed using High-Capacity cDNA Reverse Transcriptase Kit (Life
Technologies, study I), RT2 First Strand Kit (Qiagen, study II) or iScript cDNA
synthesis kit (Bio-Rad, study IV) following manufacturer’s instructions. qRT-PCR
was performed according to standard protocols on Abi Prism 7000 sequence
detector (Applied Biosystems, study I) or on Bio-rad CFX96 Real Time System
(BioRad Laboratories, USA, studies II and IV).
Human Angiogenesis RT² Profiler™ PCR Array (Qiagen) was used to profile the
expression of 84 key human angiogenesis-related genes (study II). A comprehensive
list of genes included in the array can be found in http://www.sabiosciences.com.
Additionally, the expression of human angiogenesis related genes including VEFG-
A, FGF-2, PDGF-β, TGF-β1, angiopoietin-1, angiopoietin-2, caldesmon, PECAM
and human cardiac related genes including CACNA1C, TNNT2, KCNJ2, CX-43,
MYH-6, MYH-7, ADRB1 and SCN5a were studied (Table 6). Reference genes for
human RPLP0 and GAPDH were used for data normalization. 1-50 ng of total
cDNA and 300 nM primer pairs were used in each PCR reaction, except for human
angiogenesis RT² Profiler™ PCR Array (study II) 980 ng of total cDNA was used.
Relative RNA expression was calculated in comparison to reference gene RNA
expression using the Pfaffl method (Pfaffl, 2001). Ratio of relative expression=
(Etarget) ΔCP target (control-sample)  / (Ereference) ΔCP reference (control-sample)
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Table 6. The list of human SYBR-green primers and Taqman primer-probe sets* used in qRT-PCR
Gene                                 Forward primer Reverse primer                                   Study
VEFG-A AGGGCAGAATCATCACGAAGT AGGGTCTCGATTGGATGGCA IV
FGF-2 AGAAGAGCGACCCTCACATCA CGGTTAGCACACACTCCTTTG IV
PDGFβ CTCGATCCGCTCCTTTGATGA CGTTGGTGCGGTCTATGAG IV
TGFβ1 CAATTCCTGGCGATACCTCAG GCACAACTCCGGTGACATCAA IV
Angiopoietin1 AGCGCCGAAGTCCAGAAAAC
AGCTACCACCAACAACAGTG
TACTCTCACGACAGTTGCCAT
CAAAGATTGACAAGGTTGTGG
IV
I
Angiopoietin2 ACCCCACTGTTGCTAAAGAAGA CCATCCTCACGTCGCTGAATA IV
CACNA 1C TGACATCGAGGGAGAAAACT ACATTAGACTTGACTGCGGC IV
TNNT2 TTCACCAAAGATCTGCTCCTCGCT TTATTACTGGTGTGGAGTGGGTGTGG IV
KCNJ2 GAGCACAGCTCCTCAAATCC TTCCACTGTCAAACCCAACA IV
CX-43 GGTCTGAGTGCCTGAACTTGCCT TGCCTGGGCACCACTCTTTTGC IV
MYH6 AGGGATAACCAGGGGAAGCACC TGCGAATGTCAAAGGGCCGGG IV
MYH7 GGCAAGACAGTGACCGTGAAG CGTAGCGATCCTTGAGGTTGTA IV
PECAM TCATTTCTGGGATCC ATATG A TGGGTGTAGAGAAGGATTCCGT I
caldesmon AAGAATCCTTGGGACAGGTGAC GTGGTGGTTGTCTTGGCCTC I
RPLP0 AATCTCCAGGGGCACCATT CGCTGGCTCCCACTTTGT I
ADRB1* Hs02330048_s1 IV
SCN5A* Hs00165693_m1 IV
RPLP0* Hs04189669_g1 IV
GAPDH* Hs02758991_g1 IV
4.9 Functional studies
4.9.1 Microelectrode array (MEA) measurements
The electrophysiological properties, especially field potentials, and conductance of
cardiovascular constructs were analyzed using the MEA system (Multi Channel
Systems MCS GmbH, Reutlingen, Germany). Cells were grown on top of the
electrodes on MEA well with which the field potential can be measured (Reppel et
al., 2004). The MEA wells (8x8 standard MEAs or 6-well MEAs) were first
hydrophilized with FBS for 30 min at RT and then coated with 0.1 % gelatin type A
(Sigma-Aldrich) for 1 hour at RT.
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In rat cardiovascular model (study III), the MEA measurements were performed as
described in Kujala et al. (Kujala et al., 2011). Briefly, an MEA1060-Inv-BC
amplifier, a 20 kHz sampling rate and MC_Rack software (all from Multi Channel
Systems MCS GmbH) was used. The recordings were performed at room
atmosphere keeping the temperature at +37 °C with MEA amplifier’s heating
element. To maintain the sterility of the cultures the MEAs were covered with a gas-
permeable membrane (ALA Scientific). The field potential signals were recorded
twice during each culture and for three minutes at a time. The measurements were
performed with MC_Rack, files converted with MC_DataTool and signals analyzed
with AxoScope.
In human cardiovascular model (study IV), field potentials were recorded at + 37°C
and signals were recorded for 2 min. The sampling frequency was 20 kHz. Field
potentials were recorded during spontaneous baseline beating, and with 1µM
adrenaline (Sigma-Aldrich) or 300nM E-4031 (Sigma-Aldrich). Drugs were diluted
and measurements performed in EB medium with 5 % FBS. A wash-in time of two
to five minutes was allowed for the drugs before measurement. The field potentials
were recorded with MC_Rack v.4.5.7 software (Multi Channel Systems MCS
GmbH). Signals were analyzed with Cardiomyocyte MEA Data Analysis
(CardioMDA) software (Pradhapan et al., 2013).
4.9.2 Analysis of Ca2+ cycling
Human cardiovascular model (study IV) was loaded with 4 µmol/L Fura-2 AM
(Invitrogen, Molecular Probes) for 30 minutes in HEPES based medium.
Measurements were performed in 37°C and the extracellular solution and consisted
of (in mmol/L): 137 NaCl, 5 KCl, 0.44 KH2PO4, 20 HEPES, 4.2 NaHCO3, 5 D-
glucose, 2 CaCl2, 1.2 MgCl2 and 1 Na-pyruvate (pH was adjusted to 7.4 with NaOH).
Ca2+ measurements were conducted on an inverted IX70 microscope (Olympus
Corporation, Hamburg, Germany) where spontaneously beating CM were visualized
with a UApo/340 x 20 air objective (Olympus). Images were acquired with an
ANDOR iXon 885 CCD camera (Andor Technology, Belfast, Northern Ireland)
synchronized with a Polychrome V light source by a real time DSP control unit and
TILLvisION software (TILL Photonics, Munich, Germany). Fura-2 in CM was
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excited at 340 nm and 380 nm light and the emission was recorded at 505 nm. For
Ca2+ analysis, areas of interests were selected for spontaneously beating cells and
background noise was subtracted before further processing. The Ca2+ levels are
presented as ratiometric values of F340/F380. The changes in Ca2+ were recorded
during spontaneous baseline beating and spontaneous beating during 1µM
adrenaline (Sigma-Aldrich) perfusion.
4.10 Statistical analysis (I-IV)
In study I, statistical analyses were performed and graphs processed with
GraphPadPrism 5.0 (GraphPad Software, Inc., San Diego, CA, USA). Analysis of
vascular-like network formation and qRT-PCR results were subjected to One-way
ANOVA followed by Dunnett’s and Bonferroni’s post-tests. The results were
reported as mean ± SD and differences were considered significant when p<0.05*,
p<0.01** and p<0.001***.
In study II, PCR results were analyzed using the PCR Array Data Analysis Web
Portal (http://www.SABiosciences.com/pcrarraydataanalysis.php). Two fold
change compared to housekeeping gene GAPDH was considered significant.
Statistical analyses were performed and graphs processed with GraphPad Prism 5.0
(GraphPad Software, Inc., San Diego, CA, USA). The results concerning vascular-
like network formation were subjected to One-way ANOVA followed by Dunnett’s
and Bonferroni’s post-tests. The results were reported as mean ± SD and differences
were considered significant when p<0.05*, p<0.01** and p<0.001***.
In study III, a linear mixed-effect model was used to assess differences in vascular-
like network formation in control versus other media. A linear mixed-effect model
with estimation as a dependent variable was fitted separately for angiogenesis model
and vasculogenesis-angiogenesis model using function lme in R (Software
environment for statistical computing and graphics, version 2.13.0, The R
Foundation for Statistical Computing). Experiments and media were used as
independent variables. Random intercept for parallel wells was used together with
independent random errors.
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In study IV, comparative ΔΔCt method (Livak & Schmittgen, 2001) was used in
gene expression studies to analyze the relative expression levels of angiogenesis and
cardiac related genes. qPCR data is expressed as mean values +/- SD. Statistical
analysis for the qPCR data was performed by IBM SPPS Statistics 22-software and
by using Mann-Whitney U-test for independent samples. Bon ferroni -correction
was included when more than two groups were analyzed. A p-value less than 0.05
was considered statistically significant.
In MEA and Ca2+ imaging data, the significance of differences between the two
groups (CM monoculture and cardiovascular construct) was evaluated with the
unpaired Student’s t-test. The significance of changes within a group was evaluated
with the paired Student’s t-test. MEA and Ca2+ imaging data are expressed as average
± S.E.M. In Ca2+ imaging data n refers to the number of cells and in MEA data n
refers to number of MEA chips. A p-value less than 0.05 was considered statistically
significant.
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5 Results
5.1 Development of in vitro vascular models (I,II)
Two different human cell based in vitro vascular models, a stromal-vascular model
and a vasculogenesis-angiogenesis model, were developed. Stromal-vascular model
consisted of hASC monoculture and vasculogenesis-angiogenesis model consisted
of hASC and HUVEC co-culture (Figure 6). In vasculogenesis-angiogenesis model
simultaneous seeding of hASC and HUVEC was shown to produce an optimal
vascular-like network.
Figure 6. The in vitro (A) stromal-vascular model and (B) vasculogenesis-angiogenesis model
developed in this study at day 6. Anti-von Willebrand factor staining, scale bars 500 µm.
5.1.1 Vascular-like network formation in in vitro vascular models (I)
The vascular-like network formation capacity of the stromal-vascular model and
vasculogenesis-angiogenesis model was compared in two different time points (day
3 and day 6). The results showed that vasculogenesis-angiogenesis model produced
more extensive vascular-like network with high reproducibility compared to stromal-
vascular model (Figure 6). Vascular-like network formation in vasculogenesis-
angiogenesis model was independent of the cell line or passage number (p1-7 were
tested) whereas in stromal-vascular model induction to vascular-like network
formation was not seen repeatedly. With passage dependent manner, less than 50 %
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of the tested hASC lines (six lines, p1-7) produced a vascular-like network in some
degree. Although vascular-like network was produced in vasculogenesis-
angiogenesis model already at day 3, a significantly higher (p<0.001) vascular-like
network formation with multilayered tubules was seen at day 6.
Immunocytochemical staining with anti-collagen IV, a marker of the basement
membrane, was widely used in this study to assess the stability and maturity of
vascular-like network. Basement membrane covering the tubules was intact in
vasculogenesis-angiogenesis model at day 6 whereas in stromal-vascular model the
development of basement membrane was incomplete. As a conclusion, further
characterization including medium development was performed to vasculogenesis-
angiogenesis with 6 day culture.
5.1.2 Optimal medium for vasculogenesis-angiogenesis model (II)
First, commercial HUVEC medium (Table 3) was used to induce vascular-like
network formation for vasculogenesis-angiogenesis model. In order to replace the
commercial HUVEC medium and to create a completely defined medium, a vascular
stimulation medium (VSM) was developed for vasculogenesis-angiogenesis model.
VSM was shown to produce evenly distributed vascular-like network with connected
branches and less cell aggregates compared to vascular-like network formed in
HUVEC medium.  Moderate differences in the expression of angiogenesis-related
genes were detected between HUVEC medium and VSM. In VSM, nine genes were
upregulated (Angpt1, F3, FIGF, IGF-1, LEP, MDK, MMP2, MMP9, PGF) and nine
genes (CCL11, CXCL9, FN1, IL6, IL8, SERPINE1, TGFB2, THBS2, TIMP1) were
down-regulated compared to gene expression in HUVEC medium.
5.1.2.1 Impact of serum (II)
In the HUVEC medium, the effect of human serum (HUVEC medium/HS, Table
3), fetal bovine serum (HUVEC medium, Table 3) and the absence of serum
(HUVEC medium/-serum, Table 3) on vascular-like network formation capacity of
vasculogenesis-angiogenesis model was studied. The results showed that FBS could
be replaced with HS without significant effect on the vascular-like network
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formation as tested with one-way ANOVA. Also in the absence of serum an
extensive vascular-like network formation similar to HS induction was detected.
In the development of VSM, a low serum (2 %) and serum-free medium enabled
stable cell attachment and induced a dense, connected vascular-like network with
intact tubule walls.  The presence of HS in the medium was found to induce denser
and more connected vascular-like network than presence of FBS (see Figure 1 in the
original publication II).
5.1.2.2 Growth factor optimization (II)
Before developing VSM, vascular-like network formation in the vasculogenesis-
angiogenesis model and in the stromal-vascular model was induced in the HUVEC
medium in the presence of angiogenic growth factors and substances including
vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF-2),
epidermal growth factor (EGF), insulin-like growth factor (IGF), heparin (HE),
hydrocortisone (HY) and ascorbic acid (AA). In the absence of growth factors
(HUVEC medium/-gf, Table 3), the vascular-like network formation was markedly
decreased in vasculogenesis-angiogenesis model.
In the development of VSM for vasculogenesis-angiogenesis model, concentrations
of 10 ng/ml VEGF and 1 ng/ml FGF-2 were used according to our previous study
(Sarkanen et al., 2011). Concentrations of heparin, hydrocortisone and ascorbic acid
were optimized by comparing the vascular-like network formed in HUVEC medium.
An optimal vascular-like network formation was received with ascorbic acid
concentration 100 µg/ml and heparin concentration 0-500 ng/ml.  The results
showed that vascular-like network was formed in the absence of heparin supplement
with minor morphological differences. However, low concentration of heparin (50
ng/ml) increased the total area of vascular-like network significantly compared to
HUVEC medium. An optimal hydrocortison concentration was shown to be 0.2
µg/ml.
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5.1.3 Maturation of vasculogenesis-angiogenesis model (I-IV)
An intact basement membrane was detected in tubule structures formed in VSM as
detected in collagen IV immunocytochemical staining. Additionally, smooth muscle
actin (SMA), smooth muscle myosin heavy chain (SMM) and contractile smooth
muscle calponin positive cells were seen to surround the tubule structures (Figure
7.A-C). The presence of platelet derived growth factor receptor-β (PDGFR-β)
positive cells were also detected (Figure 7.D).
Figure 7. Vascular-like network formed in VSM showed properties of vascular maturation. Anti- von
Willebrand factor -staining shown in red in all figures. (A) Calponin -; (B) SMA - and (C) SMM -positive
cells surrounding the vascular-like network. (D) α-PDGFR-β stained pericytes are located along the
tubules. Scale bars 100 μm.
Analysis of 84 angiogenesis-related genes was performed to study the maturation of
vasculogenesis-angiogenesis model in VSM compared to HUVEC medium that was
used as a control (study II). The expression of angiopoietin 1, a marker for maturated
tubules, was significantly high (p<0.05) in vasculogenesis-angiogenesis model in
VSM at day 6. VEGF-A and FGF-2, indicators of the early stage of angiogenesis,
were moderately down-regulated in VSM  but not in statistically significant manner.
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TGF-β1, a marker for tubule maturation, was slightly down-regulated. An up-
regulation of MMP-2 and MMP-9, enzymes that are involved in degradation of the
ECM in the early stages of angiogenesis, were detected.
5.1.4 Morphology and microstructure of vasculogenesis-angiogenesis
model (I,II)
Confocal laser scanning microscopical analysis showed approximately 196 µm
thickness and three-dimensional structure with overlaying tubules in the
vasculogenesis-angiogenesis model cultured in HUVEC medium (Figure 8.A-B).
Basement membrane marker collagen IV was widely expressed and covered the
tubule structures (Figure 8.B). With electron microscopy, the microstructure of the
tubules formed in VSM was studied. The analysis showed the presence of lumen,
basement membrane and adherence junctions.  Moreover, the electron microscopic
as well as immunocytochemical analysis showed that vasculogenesis-angiogenesis
model actively produces extracellular matrix components including basement
membrane, fibrillins and collagens (Figure 8.C). Immunocytochemical staining with
VE-Cadherin and occludin confirmed the presence of adherence junctions between
endothelial cells (Figure 8.C). The 3D structure of the vascular-like network and
shape of the tubules can be seen in the close-up image (Figure 8.D).
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Figure 8. Structure of vascular-like network in vasculogenesis-angiogenesis model. (A) 3D projection of
the vascular-like network; (B) multilayered tubule formation with intact basement membrane, some of
the crossing points of the tubules are indicated with arrows. Anti-von Willebrand factor antibody (red)
and anti-collagen IV (green); (C)Transmission electron microscopy image of tubule in earlier stage of
vascular development showing endothelial cell with large nucleus (white arrow), lumen (L), adherence
junctions (AJ) and ECM. Scale bar 2 µm; (D) scanning electron microscopy image shows the 3D
structure and the tubule shape of the vascular-like network. Scale bar 2µm.
5.1.5 Vasculogenic properties of vasculogenesis-angiogenesis model (I,II)
Stromal-vascular model (hASC monoculture) had a passage and donor dependent
differentiation capacity towards endothelial cells. hASC monoculture typically forms
short cords with less than 50 % of the tested hASC lines (six lines, p1-7) producing
a vascular-like network  in some degree (study I).
hASC and GFP-infected HUVEC co-culture model was created to evaluate the
origin of the cells responsible for the tubule formation in vasculogenesis-
angiogenesis model. The results showed that co-culture stained with anti-vWf was
mostly mosaic and consisted of two different populations of vWf-positive cells.
Approximately half of the vWf-positive cells was GFP-infected and the other half
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of was GFP-negative cells (see Figure 2 in the original publication I). In addition, the
expression of endothelial cell marker PECAM-1 was significantly increased in hASC
monoculture from day 3 to day 6 (p<0.05).
We analyzed whether population of endothelial progenitor cells capable for
vasculogenesis resides inside hASC population. In FACS analysis, high expression
of CD90 and a moderate expression of CD34 was seen. The expression levels of
mature endothelial cell markers CD31 and CD144 in hASC population were very
low. However, another endothelial progenitor cell marker CD309 (VEGFR2)
showed very low expression in all six hASC lines that were analyzed (study II).
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5.2 Development of in vitro cardiovascular models (III,IV)
In this thesis, two different in vitro cardiovascular models were developed. Rat
cardiovascular model consisted of human angiogenesis model and human
vasculogenesis-angiogenesis model combined with neonatal rat cardiomyocytes
(fibroblast+HUVEC+NRC and hASC+HUVEC+NRC, respectively) (Figure 9.A-
B). Human cardiovascular model composed of human angiogenesis model and
human pluripotent stem cell derived cardiomyocytes
(fibroblast+HUVEC+hESC/iPS-CM) (Figure 9.C).
Figure 9. In vitro cardiovascular models developed in this study. Rat cardiovascular model with (A)
fibroblast+HUVEC+NRC and with (B) hASC+HUVEC+NRC stained with anti-troponin T (green,
cardiomyocytes) and anti-vWf (red, vascular-like network). Human cardiovascular model with (C)
fibroblast+HUVEC+human pluripotent stem cell derived cardiomyocytes stained with anti-troponin t
(red, cardiomyocytes) and anti-collagen IV (green, vascular-like network). Scale bars 300μm.
5.2.1 Optimal media for cardiovascular models (III,IV)
For cardiovascular models, a universal medium was developed to primarily support
cardiomyocyte functionality and maturation and secondarily to induce adequate
vascular-like network formation. Of the six different medium, serum free medium
supplemented with 10 ng/ml VEGF and 1 ng/ml FGF (NRC medium 1, Table 3)
supported most efficiently the viability and contractility of rat cardiovascular models
as an entity. NRC medium 1 provided 50-70% contractility of NRC and the vascular-
like network formation was 34.7 % in hASC+HUVEC+NRC co-culture and 68.9
% in fibroblast+HUVEC+NRC co-culture. Although additional supplements in
NRC medium 2 (AA, HE and HY, Table 3) were seen to increase vascular-like
network formation, cardiomyocyte contractility was decreased to 30–70 %. Due to
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stronger and more repeatable cardiac contractility, NRC medium 1 was chosen for
further experiments.
The optimal medium for human cardiovascular model was EB medium without
addition of exogenous growth factors (Table 3). VEGF and FGF-2 were used to
induce vascular-like network formation in angiogenesis model until day 6 and
removed before seeding of human CM. An optimal serum concentration for human
cardiovascular model was assessed by studying the effect of different serum
concentrations on the morphology of human CM. In low serum (2%) and serum-
free medium the size of the human CM was small compared to CM cultured in
control medium supplemented with 20 % FBS. In concentrations of 5, 10 or 20 %
FBS there were no differences between human CM in size or growth of the cells.
Therefore, EB medium with 5 % FBS was chosen for further studies with human
cardiovascular model.
5.2.2 Vascular-like network formation in cardiovascular models (III,IV)
In rat and human cardiovascular models, the vascular-like network formation was
shown to be dependent on the culture media, serum concentration and growth factor
composition (see chapter 5.2.1.). The vascular-like network formation capacity of
vasculogenesis-angiogenesis model and angiogenesis model in rat cardiovascular
model was evaluated. Differences in the formation of vascular-like structures were
seen with more dense and branching network in co-culture of
HUVEC+hASC+NRC (Figure 9.B) whereas orientation of vascular-like structures
was more parallel in co-culture of HUVEC+fibroblast+NRC (Figure 9.A).
Importantly, both vascular platforms supported cardiomyocyte viability and
functionality.
Although mature vascular structures are formed in angiogenesis model in the
presence of VEGF and FGF-2 prior to seeding of human CM at day 6 (Figure 9.C),
the vascular-like network starts to regress after CM seeding. Basement membrane in
tubules becomes less intact and tubules becomes shorter due to absence of
supporting growth factors in EB medium (Table 3).
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Expression levels of angiogenesis related genes including VEGF, FGF-2, TGF-β,
PDGF-β, angiopoietin-1 and angiopoietin-2 in time points 0, 6 and 18 days were
analysed in human cardiovascular model and in angiogenesis model that was
considered as a control. The expression levels of the FGF-2, TGF-β, angiopoietin-1
were at the similar level in cardiovascular model and in angiogenesis model.
However, the expression levels for VEGF and PDGF-β were significantly higher in
the cardiovascular model (p<0.05). On the contrary, the expression level of
Angiopoietin-2 was significantly lower in the cardiovascular model compared to
angiogenesis model (p<0.05).
5.2.3 Morphology, orientation and maturation of cardiomyocytes (III,IV)
Human CM morphology and orientation in the absence and presence of vascular-
like network was studied to assess the maturation state and structure of the human
cardiovascular model. As a result, structural maturation of the CM was detected with
oblong, brick-shaped phenotype of mature CM in the presence of vascular-like
structures (Figure 10.C-D). Moreover, 2D (Figure 10.F) as well as 3D projection
(Figure 10.E) showed that CM co-localized mostly longitudinally and parallel around
the tubule structures. On the contrary, CM in the monoculture remained rounded,
less organized and orientation of the cells could not be detected (Figure 10.A-B).
Similar results were seen in rat cardiovascular model. NRC were distributed
throughout the dense, branching vascular-like network without organization into any
major direction in hASC+HUVEC+NRC co-culture (see Figure 9.B) whereas a
parallel organization of vascular-like and co-localization of cardiomyocytes was seen
in fibroblast+HUVEC+NRC co-culture (see Figure 9.A).
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Figure 10. (A-B) Human pluripotent stem cell derived cardiomyocytes in monoculture show round
morphology whereas (C-D) cardiomyocytes cultured with vascular-like network in human cardiovascular
model possess oblong phenotype.  Stained with anti-troponin t (green). (E) 3D and (F) 2D projections
show the alignment of human stem cell derived cardiomyocytes (anti-troponin t, red) with vascular-like
network (anti-collagen IV, green) in human cardiovascular model.  Scale bars 50 µm.
Human CM maturation was detectable also in gene expression level. Expression
levels of cardiac structure related genes in time points 0, 6 and 18 days were analysed
in human cardiovascular model and in human CM monoculture that was considered
as a control. As a result, levels of cardiac muscle myosin transcripts MYH6, MYH7
and troponin t were seen to increase markedly throughout the culture in
cardiovascular model whereas they remained constant in CM monoculture. Also
expression level of gap junction marker connexin 43 was shown to increase
significantly in cardiovascular model while remaining low in CM monoculture
(Figure 11).
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Figure 11. Expression of levels of cardiac related genes troponin t (TNNT2), cardiac muscle myosins
(MYH6, MYH7), connexin 43 (Cx43), calcium channel (CACNA1C), potassium channel (KCNJ2),
sodium channel (SCN5A) and beta-1-adrenergic receptor (ADBR1) at day 7 and day 18 in human
cardiomyocyte monoculture and in human cardiovascular model.* p<0.05 indicates statistically
significant difference between the groups.
5.2.4 Electrophysiological properties of the cardiovascular models (III,IV)
Microelectrode array (MEA) was used to analyse the electrophysiological properties
and conductivity of the both cardiovascular models. The results showed that rat as
well as human cardiovascular model conducted the electrical signal of
cardiomyocytes and the electrical activity was detectable in MEA despite of the thick
cell layer. Microscopical analysis and MEA measurements showed that the
contractility of cardiomyocytes in rat as well as in human cardiovascular model was
synchronous. Furthermore, there were no differences detected in the baseline
beating frequency of cardiomyocytes in monoculture compared to cardiomyocytes
in either cardiovascular model.
The capability of two different vascular-like networks to support the functionality of
NRC was compared to NRC monoculture. In NRC monoculture, the
cardiomyocytes were contractile approximately for seven days in any of the tested
media (Table 3) whereas in the presence of vascular-like network the NRC
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maintained their contractile capacity for at least 14 days. Differences in duration of
contractility were not detected between hASC+HUVEC+NRC and
fibroblast+HUVEC+NRC cultures and a synchronized contractility was visually
observed in both models. In addition, the number of NRC was less critical when
they were cultured with the vascular-like network compared to NRC monoculture
as the contractility was stronger even with a fewer number of NRC (study III).
Functionality of human cardiovascular model was analyzed with adrenalin and
potassium channel-blocker E-4031 exposure. Adrenaline increased the beating
frequency of human CM thus decreasing the field potential duration (FPD) in
cardiovascular model as well as in CM monoculture. The increase in beating
frequency and decrease in FPD was statistically significant (p<0.05) between baseline
and adrenaline perfusion only in cardiovascular model (Figure 12.A-B).
E-4031, a hERG blocker, was shown to significantly prolong (p<0.05) the FPD in
human cardiovascular model and in CM monoculture compared to the baseline
(Figure 12.B-C). However, there was no statistically significant difference between
CM monoculture and cardiovascular model (Figure 12.D). Prolongation of FPD due
to E-4031 exposure resulted in additional adverse effects including pausing beating
and/or arrhythmias. These adverse effects were seen in CM monoculture as well as
in cardiovascular model.
Expression levels of transcripts related to cardiac ion channels in time points the day
after CM seeding (day 6) and at the end of co-culture (day 18) were analysed to assess
the electrophysiological properties of human cardiovascular model. An increase in
the expression level of sodium channel SCN5A and in calcium channel CACNA1C
was detected while potassium channel KCNJ2 remained constant in the
cardiovascular model (Figure 11). Moreover, the expression of beta-1 adrenergic
receptor, ADRB1, was shown to increase markedly from day 1 to day 13 in
cardiovascular model (Figure 11). In human CM monoculture, used as a control,
expression levels of SCN5A, CACNA1C, KCNJ2 and ADRB1 remained constant
(Figure 11).
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5.2.5 Calcium metabolism in human cardiovascular model (IV)
Ca2+ transients of the human cardiovascular model was detectable with Ca2+ imaging
method. Human cardiovascular model and human CM monoculture were shown to
respond similarly to adrenaline exposure. In cardiovascular model, adrenaline caused
significant increase in the frequency of calcium cycling and significant decrease in
amplitude compared to CM monoculture (Figure 12.E).
Figure 12. Electrophysiological and calcium cycling analysis of human cardiovascular model (black
columns) and human cardiomyocyte monoculture (white columns). Statistical analysis of (A) beating
frequencies and (B) field potential durations (FPD) in MEA measurements show significant difference
between baseline and adrenaline exposure in human cardiovascular model, * p<0.05. (C) Overlay plot
show the effect of 300nM E-4031 on field potential duration; (D) significant difference between baseline
and E-4031 responses of 300nM E-4031 in human CM monoculture (n=6) and in human cardiovascular
model (n=7) were detected. Difference was calculated as relative change from the baseline, * p<0.05;
(E) significant difference between human cardiomyocyte monoculture and human cardiovascular model
was detected in amplitude and frequency of calcium cycling.  Analysis was performed separately for
each cell as the ratio of adrenaline response divided by baseline response. CM monoculture n=16,
cardiovascular model n=26, * p<0.05.
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6 Discussion
Presently, the main test systems for the assessment of safety of chemicals for
regulatory purposes as well as for efficacy testing in drug development are based on
animal biology.  However, it has been widely shown that animals are poor predictors
of human situation resulting in false negative and false positive predictions. The use
of animal models has been recognized as a contributing factor to low success rate in
drug development. (Heinonen, 2015) Furthermore, it has been hypothesized that a
major obstacle in the identification of adverse effects in safety assessment is the lack
of relevant in vitro test systems (Suter-Dick et al., 2015).
Commonly used in vitro assays consist of primary cells and transformed cell lines that
often fail to predict the in vivo situation (Suter-Dick et al., 2015). However, specific
cell types differentiated from human mesenchymal and pluripotent stem cells could
replace the currently used assays and improve the relevance by recapitulating more
closely the essential physiological structure and function of the target tissue (Scanu
et al., 2011, Pfannkuche et al., 2010a). In addition, appropriately engineered cell
culture environment could improve the predictive value of a test system (Knight &
Przyborski, 2014). The main benefit of implementing advanced in vitro methods will
be the reduction and/or replacement of animal testing, enhanced prediction of
specific adverse effects and the reduction of costs and time required for the toxicity
assessment. However, careful characterization, thorough validation and in vitro–in
vivo comparison is needed before stem cell based test systems can provide a valid
alternative to the current toxicity test systems. (Suter-Dick et al., 2015, O'Connor,
2013) Growing evidence show that three-dimensional cell arrangement and co-
culture of different cell types leads to improved predictive value of the test system.
Moreover, a key element in all tissue microenvironments is the presence of
vasculature. (Tourovskaia et al., 2014)
In vitro models of both vasculogenesis and angiogenesis are needed for basic
biomedical research as well as for translational research including pharmaceutical
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development that needs relevant test systems for screening of pro- and anti-
angiogenic compounds. (Ucuzian & Greisler, 2007, Folkman, 2007) In addition,
drug-induced vascular injury has been a difficult problem for the pharmaceutical
industry causing termination of development of new drug candidates in nonclinical
assessment of safety (Mikaelian et al., 2014, Morton et al., 2014). Presently, there are
no relevant in vitro models available for screening applications to study drug-induced
vascular injury (Mikaelian et al., 2014) or embryonic vascular development as part of
developmental toxicity assessment (Heinonen, 2015).
Heart has been shown to be particularly prone to toxic effects of drugs that can cause
severe adverse effects including decreased cardiac contractility, increased arrhythmia,
ischemia and sudden death. (Redfern et al., 2003, Lasser et al., 2002, Lexchin, 2005)
Hence, assessment of the risk of a drug to cause cardiac electrophysiological
disturbances, mainly ventricular arrhythmia detected as QT interval prolongation in
electrocardiogram, is regulated as part of the standard preclinical evaluation of new
compounds (Braam et al., 2010). Since adverse cardiac effects are the main cause for
drug withdrawal from the market and delays in regulatory approval, heart is one of
the major target for pharmaceutical industry. For these reasons, relevant test systems
for cardiac toxicity assessment are urgently needed.(Kettenhofen & Bohlen, 2008)
In this thesis in vitro vascular models (studies I, II) and cardiovascular models (studies
III, IV) were developed. Artificial scaffolds were not used in the development of
these in vitro test systems. Instead, vascular-like network formed in vascular models
served as a natural, supporting and interactive scaffold in cardiovascular models. In
addition, throughout this thesis, development of an optimal media was part of the
process of establishing defined in vitro models.
6.1 Development of in vitro vascular models (I,II)
In this thesis, two different vascular models, a stromal-vascular model and
vasculogenesis-angiogenesis model, were developed for safety and efficacy
assessment of pro- and anti-angiogenic compounds, for biomedical research and for
utilization in tissue constructs as a vascular platform.
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hASC were used as building blocks in vascular models due to their human origin,
availability, ability to differentiate into several vascular cell types (Madonna et al.,
2009, Miranville et al., 2004) and due to the ability to secrete several angiogenic and
anti-apoptotic compounds (Rehman et al., 2004, Rubina et al., 2009, Verseijden et
al., 2010b). HUVEC, on their behalf, are among the most extensively used primary
endothelial cells of human origin and can also be easily isolated from the umbilical
cord (Jaffe et al., 1973). As hASC, HUVEC can be easily expanded in vitro and freezed
for further experimental use as a cell banks.
Marked differences between the stromal-vascular model (hASC monoculture) and
vasculogenesis-angiogenesis model (hASC and HUVEC co-culture) were detected.
The vascular-like network formation capacity of the vasculogenesis-angiogenesis
model was shown to be more reproducible, more extensive and independent of the
cell line or passage number compared to stromal-vascular model. Immature tubule
structures were formed in stromal-vascular model detected as incomplete formation
of the basement membrane. In addition, in stromal-vascular model, less than 50 %
of the tested hASC lines were shown to form short cords and produce a vascular-
like network in some degree. Although donor-to-donor variability is a well known
characteristic related to hASC, the ability of four different donors of hASC to give
rise to similar vascular structures has been reported (Hutton et al., 2012).
Our findings suggest that hASC monoculture may not provide a relevant vascular
model for screening of angiogenic compounds due its low reproducibility but it
might, however, provide an inductive platform for tissue constructs. Due to high
proliferation and differentiation capacity (Madonna et al., 2009, Miranville et al.,
2004) and the ability to secrete several angiogenic and anti-apoptotic factors
(Rehman et al., 2004, Rubina et al., 2009, Verseijden et al., 2010b), hASC could
provide promising source for development of stromal-vascular platform for
complex tissue constructs. In the present study, further characterization towards
routine test system was performed to vasculogenesis-angiogenesis model due to its
higher reproducibility, more mature structure and indepence of donor-to-donor
variability.
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6.1.1 Development of optimal medium for in vitro vascular models
Mammalian cells are generally cultured under controlled conditions in humidified
incubators typically at 37 °C and in gas mixture consisting of 5 % CO2 and 95% O2.
For longer cell cultivations, the basal medium must be supplemented with various
factors including serum. (van der Valk et al., 2010) The concentration of serum in
the medium plays an essential role in determining the morphology and
differentiation of the cardiomyocytes as mitogenic medium stimulates cell
proliferation whereas CM cultured in lower serum concentrations (0-5 %) maintain
the cell number, phenotype and contractile properties. (Passier et al., 2005, Xu et al.,
2006) In order to achieve high reproducibility within an in vitro test system, the
defined composition of the medium is essential. However, commercial media
producing companies do not necessarily publish the specific compositions of their
media.  (van der Valk et al., 2010) Our objective was to create low-serum or serum-
free culture conditions for in vitro models in order to provide physiologically relevant
environment and improve the predictive capacity of the test systems.
We developed a defined vascular stimulation medium (VSM) for vasculogenesis-
angiogenesis model. This was important for thorough characterization of the model
and, additionally, critical for utilization in chemical testing since medium
components may interact with test compounds. Serum was excluded from the VSM
as we detected that network formation increased and tubule walls remained intact in
serum-free environment. This was beneficial for the model compared to similar
study from Merfeld-Clauss et al. where they reported use of 5 % FBS in the culture
medium (Merfeld-Clauss et al., 2010).
Our results showed that with specific concentrations of VEGF, FGF-2, ascorbic
acid, hydrocortisone and heparin in VSM, an extensive vascular-like network was
created with high reproducibility.  Moreover, genetic analysis of 84 angiogenesis-
related genes between VSM and commercial HUVEC medium (Table 3) confirmed
an improved maturation of the vasculogenesis-angiogenesis model in VSM. We
conclude that VSM provides a valid, inductive medium for in vitro vascular models
with the benefits of being serum-free and completely defined by its composition
compared to commercial HUVEC medium with unknown growth factors
concentrations. Hence, our results suggest that VSM could be used also
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commercially in the development of different in vitro vascular models. Furthermore,
defined medium was an important developmental advantage for future intra-
laboratory validation of the vasculogenesis-angiogenesis model.
6.1.2 Characterization of vasculogenesis-angiogenesis model (I,II)
6.1.2.1 Vasculogenic properties of vasculogenesis-angiogenesis model (I,II)
In addition to model adult angiogenesis (Sarkanen et al., 2011), our objective was to
develop a relevant vascular model mimicking vasculogenesis, i.e. embryonic de novo
production of vasculature. First, we wanted to find out whether population of
endothelial progenitor cells capable for vasculogenesis resides in human adipose
stromal cell (hASC) population. As a result, high expression of two known
progenitor markers, CD90 and CD34, was detected. In addition, we saw very low
expression levels of mature endothelial cell markers CD31 and CD144 indicating
that mature endothelial cells were removed during the hASC isolation process.
Similar results were reported by Miranville et al (2004) showing the presence of the
endothelial progenitor cell phenotype in the stromal-vascular fraction of isolated
human adipose tissue characterized as CD34+/CD31− cells (Miranville et al., 2004).
Our results suggest that endothelial progenitor cells capable for vasculogenesis does
exist in hASC population indicating that our vasculogenesis-angiogenesis model
have the potential to be used also as a test system to mimic vasculogenesis.
To further study the vasculogenic properties of vasculogenesis-angiogenesis model,
GFP-infection was performed to human umbilical vein endothelial cells (HUVEC)
in order to track the cells responsible for tubule formation. The results showed that
hASC and HUVEC co-culture was mostly mosaic and consisted of two different
populations indicating that hASC as well as HUVEC contribute to tubule formation.
Hence, our results suggest that vasculogenesis-angiogenesis model is a suitable test
system to study both vasculogenesis and angiogenesis. However, further studies are
needed to confirm the predictive capacity of the model by testing a set on known
chemicals that interfere the process of vasculogenesis and angiogenesis.
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6.1.2.2 Maturation and structure of vascular-like network (I,II)
In order to mimic adult blood vessel formation, the vascular-like network must
mature. Maturation involves formation of adherence junctions and branching of the
vascular network to meet the tissue-spesific requirements (Jain, 2003, Stratman et al.,
2009, Risau, 1997). In addition, an essential feature of the maturation is the
recruitment of mural cells including pericytes and vascular smooth muscle cells
(Aguilera & Brekken, 2014). Our results showed that vascular-like network
formation in vasculogenesis-angiogenesis was significantly increased from day 3 to
day 6. Pericyte receptors were detected in cells surrounding the tubules as well as
cells expressing several smooth muscle markers showing the presence of supporting
mural cells around the tubules. In addition, vascular endothelial cadherin and
occludin stainings confirmed the presence of adherence junctions. In mature
vasculature, endothelial cells and pericytes form a common basement membrane
(Hall, 2006). In our vasculogenesis-angiogenesis model, an intact basement
membrane was repeatedly seen in the vascular structures formed in vasculogenesis-
angiogenesis model. These markers indicated the maturated state of vasculogenesis-
angiogenesis model can be received in 6 day culture. Maturation was confirmed by
genetic studies showing an up—regulation of angiopoietin-1 and contractile smooth
muscle caldesmon at day 6.
The structure of the vascular-like network was shown to be thick and three-
dimensional with overlapping tubules and lumen thus resembling the morphology
of native vessels. However, tubules in different stages of development were detected
in electronmicroscopical as well as in genetic analysis indicating the ongoing process
of network formation. It has been reported that timing of maturation processes may
overlap thus allowing the sustained development of vasculature towards maturation
(Jain, 2003, Stratman et al., 2009, Risau, 1997).
Production of extracellular matrix (ECM) is part of the maturation process (Stratman
& Davis, 2012). ECM components including basement membrane, fibrillins and
collagens were shown to be produced in vasculogenesis-angiogenesis model thus
providing a natural, in vivo-like microenvironment. ECM has a mechanical role in
supporting the tissue architecture and stabilizing blood vessel structures (Sottile,
2004) with accumulation of ECM proteins such as collagen IV (Merfeld-Clauss et
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al., 2010). Thus, with the production of extracellular matrix components and
inductive growth factors (Rehman et al., 2004, Rubina et al., 2009, Verseijden et al.,
2010b), vasculogenesis-angiogenesis model can be used as a supporting and
interactive platform in different tissue constructs. Presently, several angiogenesis
assays are based on the utilization of different scaffolds (Auerbach et al., 2003,
Peterson et al., 2014, Koh et al., 2008) such as fibrin matrix (Nehls & Drenckhahn,
1995, Nakatsu et al., 2003) or collagen gel (Vernon & Sage, 1999) as alternatives to
in vivo ECM. However, the use of scaffolds has been shown to interfere cell-cell
contacts and affecting to the force generation ability in cardiac constructs (Norotte
et al., 2009). In the third study of this thesis, we published, for the first time, the
utilization of vasculogenesis-angiogenesis model in tissue construct with
cardiomyocytes. Our study showed that beside mechanical support and production
of angiogenic and anti-apoptotic growth factors, another advantage of the vascular
platform is the absence of artificial scaffold.
The utilization of vasculogenesis-angiogenesis model with human pluripotent stem
cell derived cardiomyocytes is presently under study. Although high proliferation and
differentiation capacity of hASC makes them an ideal source for vascular models
(Madonna et al., 2009, Miranville et al., 2004, Hutton et al., 2012), it also increases
the detachment of the thick cell layer especially when contractile cells are included
into the co-culture as detected in our ongoing studies. Although not tested yet, the
use of additional scaffold is one possibility to prevent the detachment. Nonetheless,
this is an issue that needs to be solved before vasculogenesis-angiogenesis model can
be utilized in tissue construct for long term studies.
6.2 Development of in vitro cardiovascular models (III, IV)
In this thesis two different in vitro cardiovascular models were developed. Rat
cardiovascular model consisted of neonatal rat cardiomyocytes combined with
angiogenesis model (fibroblast+HUVEC+NRC) and with vasculogenesis-
angiogenesis model (NRC+hASC+HUVEC). Human cardiovascular model
consisted of human pluripotent stem cell derived cardiomyocytes and angiogenesis
model (fibroblast+HUVEC+hPSC-CM). Intra-laboratory validated angiogenesis
model consisting of co-culture of HUVEC and fibroblast, previously developed by
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us, was used as a platform in development of cardiovascular models due to its stable
structure and ability to mimic adult vasculature.  Furthermore, since fibroblasts are
known to give mechanical support by producing ECM components and enhance
alignment of cardiomyocytes (Pfannkuche et al., 2010b) the use of fibroblasts might
improve functional properties of the cardiovascular models.
First objective was to test the ability of two different vascular platforms to support
the viability and contractility of NRC and to establish a proof-on-concept for the in
vitro cardiovascular model. NRC were used due to their availability, ability for
spontaneous contraction for several days and also since rodent cardiomyocytes are
a routinely used in vitro models in cardiovascular research (Banyasz et al., 2008). As
a final goal, we developed a completely human cell based cardiovascular model for
cardiotoxicity and efficacy assessment that is urgently needed especially for drug
development and testing of new chemical entities. hPSC-CM provide number of
advantages over previous cardiac models with the benefit of being human origin, the
ability to contract rhythmically and respond appropriately to numerous cardioactive
drugs (Robertson et al., 2013). Cardiomyocytes in monoculture were used in parallel
with cardiovascular models throughout these studies as a control to provide a
baseline for analyzed parameters.
6.2.1 Development of optimal media for cardiovascular models
The concentration of serum in the medium had a significant impact on the
functionality and structure of cardiovascular models. In both cardiovascular models,
a universal medium was developed to primarily support CM functionality and
maturation and secondarily to induce adequate vascular-like network formation. CM
cultured in medium with low serum concentrations (0-5 %) have been shown to
maintain the cell number, phenotype and contractile properties (Li, 2002). Our
results showed that optimal medium for rat cardiovascular model was serum-free
medium with angiogenic growth factors VEGF and FGF-2. Since serum was not
needed to support NRC contractility, our results suggest that in vitro models with
different primary cell types can be maintained in serum-free conditions that supports
the functionality of the cells. This might be due to beneficial microenvironment
similar to native tissue. Moreover, although FGF-2 have been shown to increase the
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expression of dedifferentiation markers, such as atrial natriuretic factor, α-smooth
muscle-actin and myofibrillar organization, in adult rat cardiomyocytes (Montessuit
et al., 2004) we detected more mature phenotype of NRC in the presence of vascular-
like network compared to NCR in monoculture.
In human cardiovascular model, VEGF and FGF-2 were excluded from the medium
due to unknown effects on hPSC-CM differentiation and maturation. In addition, 5
% concentration of FBS was needed to maintain physiologically relevant phenotype
and growth of the human CM. hPSC-CM have been, however, successfully cultured
in serum-free medium at least in monoculture (Stancescu et al., 2015). Hence, further
optimization of the medium components might be needed for human cardiovascular
model especially when combining vasculogenesis-angiogenesis model with hPSC-
CM.
6.2.2 Rat cardiovascular model
The importance of endothelial cells and hASC to the viability of primary CM has
been reported earlier (Sadat et al., 2007, Narmoneva et al., 2004).  However, the
effects of vascular-like network on CM viability and contractility without artificial
scaffold was studied here for the first time. Our results showed that the contractility
of NRC could be maintained twice as long in culture with vascular-like network
compared to NRC monoculture.  The increased functionality provides a significant
advantage for the model and enables long term use or repeated dose toxicity studies.
We detected that vascular-like network provides mechanical support and inductive
growth factors for cardiovascular model thus acting as a natural scaffold. Hence, our
results highlight the importance of relevant microenvironment and supportive,
essential cell types for the viability and functionality of in vitro models as suggested
also by others (Suter-Dick et al., 2015, Knight & Przyborski, 2014). This should be
taken into consideration in the development of all in vitro cell- and tissue models
including tissue constructs aimed for regenerative medicine. Since the angiogenesis
model possessed more stable platform with parallel co-localization of NRC, it was
chosen for further development of completely human cell based cardiovascular
model.
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The microelectrode array (MEA) is a robust, widely used method to analyse the
electrophysiological properties of CM. Our results showed that rat cardiovascular
model conducted the electrical signal and electrophysiology of the construct was
detectable with MEA. This is essential if the model is to be used for screening of
cardiotoxic compounds that often affect on the electrophysiological properties of
CM. In addition, vascular-like structures in cardiovascular model might assist in the
formation of cell-cell contacts and gap junctions between the cardiomyocytes thus
enhancing the conduction of electrical signals.  Due to critical differences in
electrophysiological properties of human and rat cardiomyocytes, especially in the
response to rapid delayed rectifier potassium current (Hirt et al., 2014), chemical
tests were not performed to rat cardiovascular model. However, proof-of-concept
on the cardiovascular model was received.
6.2.3 Human cardiovascular model
Myocardium is composed of cardiomyocytes and non-myocytes embedded in ECM
guiding cellular organization and facilitating efficient cell contraction and electrical
transmission of the cells (van Spreeuwel et al., 2014). Previous in vitro studies have
shown that cell alignment improves CM calcium handling and contractile properties
when compared to randomly oriented CM monocultures (Pong et al., 2011, Feinberg
et al., 2012). However, since the use of scaffolds in cardiac constructs has been
associated with reduced cell-cell contacts as well as incorrect deposition and
alignment of extracellular matrix (Norotte et al., 2009), we used vascular-like network
to support and orientate CM. Genetic analysis showed that stable tubule structures
were formed before seeding of CM thus providing a supportive platform for CM
orientation and maturation in human cardiovascular model. In addition, our result
demonstrated that seeding of CM to stable vascular-like network orientates the cells
mostly parallel but also surrounding the vascular structures thus resembling the
architecture of in vivo myocardium.
Although regression of vascular structures after seeding of CM was seen in the
absence of VEGF and FGF-2, it did not seem to have effect on the human CM
viability or contractility as detected in the MEA and calcium metabolism
measurements. These results suggests that cell-cell as well as cell-matrix interactions,
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instead of completely developed vascular structures, are critical for CM viability and
contractility.
Although immature rodent cardiomyocytes have been used as model systems for
decades, mature human cardiomyocytes are likely to reflect the physiology of the
adult heart more closely and present more relevant in vitro model system for humans.
In addition, electrical and mechanical properties of hPSC-CM should resemble
native myocardium. (Yang et al., 2014) One of the main objective of this thesis was
to develop cardiovascular model using hPSC-CM to mimic adult human heart.
However, it is widely acknowledged that hPSC-CM possess fetal-like characteristics
that may limit their use as a relevant test systems (Robertson et al., 2013). Long-term
culture, 3D tissue engineering, electric stimulation and modulation of substrate
stiffness are suggested to contribute to the maturation of hPSC-CM (Yang et al.,
2014). Therefore, we were interested to know whether vascular-like network with
3D properties enhances the maturation of hPSC-CM and improves the utilization of
hPSC-CM as a models of adult human heart.
We detected that in culture with vascular-like structures hPSC-CM obtained more
mature phenotype compared to CM monoculture. Cardiac gene expression analysis
confirmed the structural maturation in cardiovascular model. These results suggest
a significant improvement in the structural maturation of fetal-like hPSC-CM
towards more adult phenotype in co-culture with vascular-like structures. With the
orientating and maturating benefits, the present cardiovascular construct provides
more advanced in vitro model for adult human cardiotoxicity assessment compared
to CM monoculture.
6.2.3.1 Electrophysiological properties of human cardiovascular model (IV)
The measurement of electrophysiological parameters is essential in characterizing
critical ion channel properties of cardiomyocytes (Finlayson et al., 2004). In this
study, Ca2+ imaging and MEA, two critical methods to assess functionality of
cardiomyocytes, were used to study the electrophysiological properties and calcium
metabolism of human cardiovascular model.
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Since several clinically successful drugs may inhibit hERG channel and lead to
potentially fatal long QT syndrome (Finlayson et al., 2004), our especial interest was
in detecting drug-induced QT prolongation in human cardiovascular model. hERG
blocker E-4031 exposure was performed to cardiovascular model to analyze the
effects of an antiarrhythmic drug to field potential duration including the QT
interval. The MEA measurements showed that E-4031 increased significantly the
field potential duration and arrhythmogenicity of the cardiovascular model. Similar
effect was detected in CM monoculture as has already been reported (Caspi et al.,
2009, Braam et al., 2008). These results indicate that the in vitro cardiovascular model
is a responsive test system and that drugs affecting to field potential duration and
rhythmicity can be tested with this system.
Although the major ionic currents normally present in adult CM are expressed also
in hPSC-CM (Robertson et al., 2013), differences are seen in the number of cardiac
ion channel and calcium handling genes (Synnergren et al., 2007). Our genetic
analysis showed that in the presence of vascular-like network the expression of
transcripts of sodium and calcium channels were increased in the cardiovascular
model. This in an important finding since intracellular calcium handling and
sarcolemmal ion channels have been shown to play critical role in functional
maturation of CM and contribute to their electrical properties (Kim et al., 2010).
These results support the earlier findings and confirm the maturation of CM in
human cardiovascular model thus bringing the model one step closer towards adult
characteristics.
Since intracellular Ca2+ is the key regulator of cardiac contractility, alterations in
cardiomyocyte Ca2+ regulation may be critical in mechanical dysfunction and in
arrhythmia (Bers, 2000). Calcium imaging analysis showed that Ca2+ transients were
detectable and adrenaline responses evident in the cardiovascular model. As in native
heart, adrenaline was shown to increase the diastolic Ca2+ level in cardiovascular
construct. Interestingly, we detected that adrenaline increased significantly the
beating frequency of cardiovascular model when compared to CM monoculture as
detected both in MEA and Ca2+ cycling measurements. Neighboring non-myocytes
could enhance the electrical maturation of CM in cardiovascular construct, especially
through sarcolemmal ion channel development, as also suggested by Kim et al.
(2010) (Kim et al., 2010).
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These result showing more sensitive response to adrenaline in cardiovascular model
compared to CM monoculture was confirmed by genetic analysis. In CM, adrenaline
binds to β1-adrenoreceptors and mediates the catecholamine-induced activation of
the cells.  We detected a higher expression of the transcripts of β1-adrenoreceptors
in cardiovascular model suggesting that due to higher number of β1-
adrenoreceptors, adrenaline increases the beating frequency more in the model
compared to CM monoculture. Since it is crucial to provide the CM the
microenvironment that supports their viability, adhesion and structural maturation
(Pfannkuche et al., 2010b), the present cardiovascular construct could serve as a
more mature and responsive test systems in cardiac safety and efficacy assessment.
However, more extensive characterization with cardiotoxic and antiarrhythmic drugs
is needed before entering into validation.
6.3 Future perspectives
Ever since establishment of modern cell culture techniques, in vitro models have been
used in basic biomedical research, and, more recently, in drug development,
regenerative medicine and in safety assessment. Traditionally, animal models have
been considered as the most relevant surrogates for humans for their apparent
similarity. However, most animals do not naturally develop human disorders, such
as Alzheimer’s disease, and genetically modified animals have been shown to poorly
mimic human situation (Engle & Puppala, 2013, Seok et al., 2013). In the drug
development, predictive capacity of animal models to assess human toxicity ranges
between 43-71 % (Olson et al., 2000, Heinonen, 2015).  The lack of human relevance
in addition to ethical concerns and high costs have raised the need for more relevant
model systems. Although drug screening requires miniaturized and automated test
systems with high throughput, the major argument to use human 3D tissue assays is
their human relevance. (Hirt et al., 2014)
Beside regenerative medicine and other fields that directly benefit human health,
human mesenchymal stem cell and pluripotent stem cell derived model systems have
an emerging potential in implicating the 3R principles of Refinement, Reduction and
Replacement of animals. Moreover, with reprogramming technology, patient-
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specific cells differentiated into tissues of interest may, in the future, assess chemical
safety and efficacy prior to exposing a human.
Although a lot of emphasis has been put in the development of elegant in vitro models
by numerous research groups worldwide, the development of valid in vitro test
systems to supplement or replace corresponding animal tests is challenging.
Replacement of an animal test reclaims several surrogate in vitro and/or in silico tests
for different parameters of interest. In addition, a paradigm change in toxicity
assessment is needed towards the identification of human adverse outcome pathways
instead of traditional histopathological findings of an animal tissue.
In the present thesis, in vitro models of human vasculature and heart were developed.
Unlike similar in vitro models described in chapters 2.4.2.-2.4.5., the main purpose
for the development of the models in this thesis was to use them in reducing or
replacing corresponding animal tests. To come closer to this objective, careful
characterization was performed to these models beyond the previously published
ones. In contrast to similar studies, a defined procedure for development,
characterization and, finally, validation of the model was applied in order to establish
an in vitro vascular model that could be used as a test system for regulatory purposes.
Hence, after development and characterization of vasculogenesis-angiogenesis
model, an intra-laboratory validation was performed.  As a result, the model is
presently used in the safety and efficacy assessment of pro- and anti-angiogenic
compounds. Similar method development process was applied to human
cardiovascular model.
The result of this thesis suggest that the vasculogenesis-angiogenesis model as well
as human cardiovascular model could serve as a relevant test systems in biomedical
research as well as in safety and efficacy assessment of compounds. This thesis also
provides understanding on the method development procedure that is essential for
the establishment of alternative in vitro methods to animal testing. In the thesis, more
advanced model systems compared to previously used cell monocultures were
developed in order to produce relevant data that is applicable to humans. However,
more detailed characterization with chemical tests and in vitro-in vivo comparison is
needed before human cardiovascular model may enter into validation.
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7 Conclusions
The aim of this study was to develop relevant in vitro models of human vasculature
and heart.
Based on the four studies the main findings and conclusions are as follows:
∂ Co-culture of human umbilical vein endothelial cells (HUVEC) and human
adipose stromal cells (hASC) forms extensive and reproducible vascular-like
network in six day culture.
∂ In further characterization of HUVEC and hASC co-culture model
properties of mature, 3D vascular structures were detected. Serum-free
vascular stimulation medium with specific growth factor concentrations was
developed to produce completely defined vascular model for further intra-
laboratory validation.
∂ In the HUVEC and hASC co-culture model, vasculogenic properties in
addition to angiogenic network formation were detected suggesting that
vasculogenesis-angiogenesis model can be used to study both vasculogenesis
and angiogenesis. Thus, the model has the potential to be used as a test
system for toxicity and efficacy assessment of angiogenic compounds and,
additionally, platform for tissue models.
∂ Two different vascular models were combined with neonatal rat
cardiomyocytes (NRC) to study the ability of these vascular-like networks to
support cardiomyocyte viability and contractility. We detected twofold
increase in the time of viability of NRC in rat cardiovascular model
compared to NRC monoculture. Consequently, proof-of-concept was
established with the ability to measure electrophysiological properties of the
cardiovascular construct.
∂ A completely human cell based cardiovascular model consisting of
HUVEC+fibroblast+human pluripotent stem cell derived cardiomyocytes
(hPSC-CM) aimed for cardiac safety and efficacy assessment of chemicals
was developed. In the human cardiovascular model, hPSC-CM were seen to
align with vascular-like network and show more mature morphology
compared to hPSC-CM monoculture.
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∂ Electrophysiological and calcium handling properties of the hPSC-CM in
human cardiovascular model were seen to resemble adult human heart. In
addition, responses to chronotropic and arrhythmic compounds were
physiologically normal including the prolongation of QT interval. It can be
concluded that the present cardiovascular model provides an advanced test
system for cardiotoxicity assessment with human relevance.
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both cell populations – hASC and HUVEC. hASC monocul-
ture had passage- and donor-dependent ability to form tu-
bular networks, with half of the cultures presenting tubule 
structures and basement membrane formation. Pericytic 
and smooth muscle cell markers were expressed in hASC 
monoculture even when tubules were absent. By combining 
the potential properties of hASC and features from the pres-
ent angiogenesis assays, we generated a natural-like, xeno-
free, prevascular-like network in vitro model with excellent 
reproducibility and minimal limitations in technical perfor-
mance. This tubular network model is an excellent tool for 
studying cell interactions during vascular development, for 
chemical and drug testing and for developing natural-like, 
multilayered, vascularized, scaffold-free tissue models. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 The current major limitation in designing three-di-
mensional vascularized tissue models and implantable 
tissue constructs is the lack of adequate vascularization in 
the construct and especially the maturation and stabiliza-
tion of the vasculature [Moon and West, 2008; Rivron et 
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 Abstract 
 The current limitation in designing three-dimensional tissue 
models is the lack of adequate vascularization with mature 
and stable vessels. Adipose tissue is known to secrete sev-
eral angiogenic factors, and human adipose stromal cells 
(hASC) are known to promote vessel growth, maturation and 
stabilization. In this study, hASC were induced to angiogen-
esis with growth factor-enriched medium either in monocul-
ture or in coculture with human umbilical vein endothelial 
cells (HUVEC) and analyzed for vascular, pericytic and smooth 
muscle cell markers. hASC and HUVEC cocultures showed an 
accelerated proliferation rate and the cells self-assembled, 
independent of the cell passage number, into multilayered 
three-dimensional tubular networks. The networks of hASC 
and HUVEC expressed endothelial markers, a complete base-
ment membrane and vessel-supporting cells with contrac-
tile properties. A hASC and green fluorescence protein-HU-
VEC-infection model revealed that cocultures consisted of a 
mosaic of von Willebrand factor-positive cells derived from 
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al., 2008]. The vascular network with stable and function-
al vessels [Abramsson et al., 2002] is essentially needed to 
meet the nutritional and functional demands of the organ 
[Gerhardt and Betsholtz, 2003]. The vessel engineering 
should optimally produce natural-like and xeno-free vas-
cular constructs. Preferably, no animal components or 
unnatural scaffold materials should be allowed in the tis-
sue culture, the cultures should contain only growth fac-
tors and proteins that occur in tissue naturally, and vessels 
forming in culture should have features of maturing ves-
sels, i.e. in addition to tubule structures, the pericyte re-
cruitment, basement membrane formation and vessel-
supporting layer of smooth muscle cells should appear. 
 Adipose tissue, an active endocrine organ, is known to 
secrete several angiogenic and adipogenic cytokines and 
growth factors such as vascular endothelial growth factor 
(VEGF), basic fibroblast growth factor (bFGF) and insu-
lin-like growth factor-I (IGF-I) [Gimeno and Klaman, 
2005; Rehman et al., 2004; Rubina et al., 2009; Sadat et al., 
2007; Verseijden et al., 2009]. Moreover, human adipose 
stromal cells (hASC), isolated as a stromal-vascular frac-
tion from the adipose tissue specimens, are known to 
have developmental plasticity both in vitro and in vivo 
[Planat-Benard et al., 2004; Rehman et al., 2004] and have 
the capacity to differentiate into multiple cell phenotypes 
such as adipose [Gimble and Guilak, 2003b; Zuk et al., 
2001], smooth muscle [Traktuev et al., 2008] and endo-
thelial cells [Miranville et al., 2004; Oswald et al., 2004; 
Pittenger et al., 1999; Planat-Benard et al., 2004; Wosnit-
za et al., 2007; Wu et al., 2007]. hASC are known to pro-
mote vessel growth, maturation and stabilization in vivo 
[Amos et al., 2008; Cai et al., 2009; Covas et al., 2008; 
Traktuev et al., 2008; Zannettino et al., 2007] by secreting 
angiogenic factors and by differentiating into vessel lin-
ing supporting cells with pericytic properties [Amos et 
al., 2008; Kilroy et al., 2007; Traktuev et al., 2008]. The 
high proliferation and differentiation capacity of hASC 
makes them an ideal component for angiogenesis model-
ing, and the use of abundant adipose tissue as a source of 
endothelial cells would also be attractive for vessel engi-
neering [Merfeld-Clauss et al., 2010; Miranville et al., 
2004; Planat-Benard et al., 2004; Wu et al., 2007]. More-
over, understanding the role of angiogenesis in adipose 
tissue is important, as vasculature regulates both the ad-
ipose tissue mass development and adipose tissue reduc-
tion, and is also suggested to have an impact on regulat-
ing the mass of other adult tissues [Rupnick et al., 2002]. 
 The angiogenic potential of hASC has widely been 
studied [Cao et al., 2005; Planat-Benard et al., 2004; Trak-
tuev et al., 2008; Verseijden et al., 2009], alone or in co-
culture with endothelial cells, in the presence of a sup-
porting scaffold, e.g. collagen I, Matrigel or fibrin [Diet-
rich and Lelkes, 2006; Lai et al., 2009; Miranville et al., 
2004; Oswald et al., 2004; Pittenger et al., 1999; Planat-
Benard et al., 2004; Rubina et al., 2009; Verseijden et al., 
2010; Wosnitza et al., 2007]. However, in general, in the 
previous methods, the capillary tubule formation has 
been quite modest or the test has contained animal-de-
rived components. Moreover, several previous methods 
have focused only on the role of endothelial cell migra-
tion and proliferation during angiogenesis, i.e. tubule for-
mation. However, as pericytes have a crucial role in the 
regulation of the microvessel growth, maturation and 
stabilization during angiogenesis [Amos et al., 2008; Ben-
jamin et al., 1998], the endothelial tubule formation alone 
is not a sufficient measure of vascular growth and differ-
entiation. The recruitment of pericytes along vascular tu-
bules is an essential step in vessel maturation, needed to 
induce basement membrane formation and to prevent 
vessel regression [Gerhardt and Betsholtz, 2003]. The fail-
ure of the endothelial cells to establish mature structures 
in vitro is often due to an absence of stabilizing mural 
cells [Merfeld-Clauss et al., 2010]. Coculture models that 
have been used in several studies [Bishop et al., 1999; 
Donovan et al., 2001; Friis et al., 2003, 2005; Merfeld-
Clauss et al., 2010; Montesano et al., 1993; Nicosia and 
Ottinetti, 1990] provide a useful method for studying an-
giogenesis in controlled conditions in vitro, with the ad-
vantage of being able to replicate some tissue-derived sig-
naling [Rubina et al., 2009]. However, only a few studies 
[Merfeld-Clauss et al., 2010; Traktuev et al., 2008] have 
Abbreviations used in this paper
bFGF basic fibroblast growth factor
COLIV collagen IV
EGM-2 endothelial cell growth medium-2
GFP green fluorescence protein
hASC human adipose stromal cells
HS human serum
HUVEC human umbilical vein endothelial cells
IGF-I insulin-like growth factor-I
PDGFR platelet-derived growth factor receptor-
PECAM-1 platelet/endothelial cell adhesion molecule-1
RPLP0 ribosomal protein large P0
SMA -smooth muscle actin
SMMHC smooth muscle myosin heavy chain
VEGF vascular endothelial growth factor
vWf von Willebrand factor
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characterized hASC and human umbilical vein endothe-
lial cells (HUVEC) scaffold-free cocultures and their an-
giogenic properties or hASC monoculture angiogenic 
properties [Miranville et al., 2004].
 Our specific aim was to develop a completely human-
based, simplified and improved angiogenesis model, a 
prevascular-like network with properties of maturing 
vessels, that could be used for studying angiogenesis in 
vitro, and that would aid in the development of tissue 
models by improving target cell proliferation, survival 
and differentiation. In this prevascular-like network 
model, cells are induced with natural growth factors and 
allowed to self-assemble into tubular network and vascu-
lar supporting structures. We studied the hASC+HUVEC 
coculture model by combining some properties and anal-
yses from previous studies [Friis et al., 2003; Merfeld-
Clauss et al., 2010] and the fibroblast-HUVEC coculture 
angiogenesis assay previously validated in our laboratory 
[Sarkanen et al., 2011]. We induced the hASC+HUVEC 
coculture or hASC monoculture with naturally occur-
ring angiogenic growth factors; epidermal growth factor, 
VEGF, bFGF and IGF-I [Mehta and Besner, 2007]. We 
evaluated the cultures for expression of vascular, peri-
cytic and smooth muscle cell markers by immunocy-
tochemistry and quantitative RT-PCR. We also studied 
the endothelial differentiation capacity of hASC in both 
hASC monoculture and a hASC and green fluorescence 
protein (GFP)-HUVEC-infection model. We produced 
an improved assay that, due to growth factor addition, 
induces a multilayered prevascular-like network with 
properties of maturing vessels that do not regress over 
time. We also showed that hASC, at low passages, are able 
to differentiate into endothelial-like cells alone and in 
hASC+HUVEC coculture. This improved and easy tubu-
lar network model is an excellent tool for studying cell 
interactions during vascular development, in drug and 
chemical screening, and most significantly, in designing 
vascularized tissue models in vitro or, as it is xeno-free, 
for creating vascularized tissue constructs for implanta-
tion. 
 Materials and Methods 
 The study was conducted in accordance with the Ethics Com-
mittee of the Pirkanmaa Hospital District, Tampere, Finland 
(R03058, R08028). The adipose tissue samples were obtained from 
surgical operations and the human umbilical cords from sched-
uled cesarean sections with informed consents at the Tampere 
University Hospital, Tampere, Finland. The experiments com-
plied with the current laws of Finland. 
 Isolation and Culture of hASCs 
 Stem cell isolation procedure was performed as described pre-
viously [Gimble and Guilak, 2003a; Hong et al., 2005; Niemela et 
al., 2007]. Briefly, human adipose tissue specimens were cut into 
small pieces, enzymatically digested with 0.05% collagenase I (In-
vitrogen, Paisley, UK) in Dulbecco’s Modified Eagle’s Medium 
Nutrient Mixture F-12 (Gibco, Invitrogen, Carlsbad, Calif., USA) 
for 60 min at 37   °   C in a gyratory water bath. The digested tissue 
was centrifuged at 600  g for 10 min at room temperature. The di-
gested tissue was filtered through a 100-  m filter (Sarstedt, Nüm-
brecht, Germany), centrifuged and filtered again through a 40-
  m filter (Sarstedt). Cells were seeded into 75-cm 2 flasks (Nunc 
EasyFlask TM , Nunc, Roskilde, Denmark) in Dulbecco’s Modified 
Eagle’s Medium Nutrient Mixture F-12 supplemented with 1%  L -
glutamine (Gibco), 1% antibiotic-antimycotic mixture (Gibco) 
and 15% human serum (HS; Cambrex, East Rutherford, N.J., 
USA). The next day, cells were washed several times with PBS. The 
cells were maintained at 37  °  C under a 5% CO 2 air atmosphere at 
a constant humidity and medium was changed every 2–3 days. 
After having grown to confluency, cells were divided in a ratio of 
1: 2 to 1: 3, or further used for cell culture studies. 
 Isolation and Culture of HUVEC 
 The HUVEC were isolated from human umbilical cord veins 
as described previously [Jaffe et al., 1973; Sarkanen et al., 2011]. 
 Briefly, the cord was separated from the placenta and the umbili-
cal vein was cannulated with a 20G needle and the needle was 
secured by clamping the cord over the needle with a surgical 
clamp. The vein was perfused with PBS to wash out blood and 
then the opposing end of the umbilical vein was clamped with a 
surgical clamp. Subsequently, the vein was infused with 0.05% 
collagenase I. The umbilical cord was incubated in a water bath at 
37  °  C for 15 min. After incubation, the collagenase I solution con-
taining HUVEC was flushed from the cord by perfusion with PBS 
into a 50 ml polypropylene tube (Sarstedt). The cells were centri-
fuged at 200  g for 10 min, washed once with medium, centrifuged 
again and resuspended in endothelial growth cell medium-2 
(EGM-2), BulletKit medium (Lonza Group Ltd., Basel, Switzer-
land) and seeded into 75 cm 2 flasks. Medium was changed every 
2–3 days and cells were divided when confluent. For assay con-
trols, HUVEC were plated at 4,000 cells/cm 2 and cultured in 
EGM-2 BulletKit medium.
 Flow Cytometric Surface Marker Expression Analysis of 
HUVEC 
 The HUVEC were harvested at passage 3 and analyzed with a 
fluorescence-activated cell sorter (FACSAria, BD Biosciences, 
 Erembodegem, Belgium). Monoclonal antibodies against CD13-
PE (BD Biosciences), CD31-FITC, CD34-APC and CD44-FITC 
(Immunotools GmbH Friesoythe, Germany), CD117-APC and 
CD133-PE (Miltenyi Biotech, Bergisch Gladbach, Germany), 
CD144-PE, CD202b and VEGFR2 (R&D Systems Inc., Minn., 
USA) and CD63-PE (Abcam, Cambridge, UK) were used. Mono-
clonal antibodies against von Willebrand factor (vWF, Abcam) 
were conjugated with IgG-PE (CalTag Laboratories, Calif., USA). 
Ten thousand cells were analyzed per sample and the positive ex-
pression was defined as the level of fluorescence greater than 99% 
of the corresponding unstained cell sample.
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 Lentivirus Infection  
 Lentiviral construct pLKO-MISSION-Bright-GFP was pur-
chased from Biomedicum Genomics (BMGen, Biomedicum Hel-
sinki, Helsinki, Finland). The infection was carried out with HU-
VEC at low passages with 300   l of pLKO-MISSION-Bright-GFP 
in 1 ml EGM-2 BulletKit medium (1 U/ml). Virus infection was 
accelerated with 8   g/ml hexadimethrine bromide (Sigma). After 
24 h of incubation, medium was replaced with fresh EGM-2 me-
dium. Highly fluorescent clones were selected with cloning rings 
and further selected with dilution cloning to obtain pure GFP-
HUVEC culture. After expanding the infected HUVEC, they were 
used for hASC and HUVEC coculture assay as described below.
 hASC Monoculture Assay 
 hASC (six different cell lines derived from different donors, 
passages 1–7 used) were seeded in EGM-2 BulletKit medium into 
48-well plates (Nunclon TM Multidishes, Nunc, Roskilde, Den-
mark) at a density of 20,000 cells/cm 2 . Cells were induced for 
either 3 or 6 days in EGM-2 BulletKit medium, a commercially 
available growth factor-enriched medium containing epidermal 
growth factor, VEGF, bFGF, IGF-I, ascorbic acid, heparin, 0.1% 
gentamicin/amphotericin-B and 2% FBS, or in DMEM/F-12 
 medium supplemented with 15% HS, 1 m M  L -glutamine and 1% 
antibiotic-antimycotic mixture. Medium was changed and the 
treatments applied once to cells cultured for 3 days and twice to 
cells cultured for 6 days. 
 hASC and HUVEC Coculture Assay 
 hASC (21 different cell lines derived from different donors, 
passages 1–7 used) were seeded in EGM-2 BulletKit (Lonza) cul-
ture medium into 48-well plates (Nunclon TM Multidishes, Nunc, 
Roskilde, Denmark) or for confocal imaging into 8-well slides 
(IbiTreat, Ibidi Gmbh, Martinsried, Germany) at a density of 
20,000 cells/cm 2 . HUVEC, cultured as above (24 different cell 
lines derived from different donors, passages 1–6 used), were im-
mediately carefully seeded on top of hASC at a density of 4,000 
cells/cm 2 . The seeding densities of hASC and HUVEC were cho-
sen according to previous studies by us and others [Donovan 
et al., 2001; Friis et al., 2003; Sarkanen et al., 2011]. The day 
after plating, the differentiation treatments were applied to 
hASC+HUVEC coculture. Treatments were (all in duplicate 
wells): (1) EGM-2 BulletKit medium (composition as described 
above in hASC monoculture assay); (2) EGM-2 BulletKit – me-
dium in which 2% FBS was replaced with 2% HS; (3) EGM-2 Bul-
letKit – medium without serum, and (4) endothelial cell basal me-
dium-2 (Lonza) containing no growth factors, supplemented with 
0.1% gentamicin, 2% FBS and 1 m M  L -glutamine. Cells were cul-
tured for either 3 or 6 days prior to immunocytochemistry or 
quantitative RT-PCR. Medium was changed and the treatments 
applied once to cells cultured for 3 days and twice to cells cultured 
for 6 days. 
 Quantitative RT-PCR  
 The primers used for angiogenesis and blood vessel matu-
ration genes – platelet/endothelial cell adhesion molecule-1 
( PECAM-1 , also referred to as CD31); the blood vessel stabilizing 
signal molecule angiopoietin 1  (Angiopoietin 1) ; the smooth mus-
cle cell microfilament protein regulating cell contraction, caldes-
mon  (Caldesmon) ; and reference gene ribosomal protein large P0 
( RPLP0 ; all oligonucleotides from Oligomer Oy, Helsinki, Fin-
land) – are shown in  table  1 . The total RNA from hASC or 
hASC+HUVEC was extracted from 3 or 6 days differentiated 
confluent cultures using TRIzol  (Invitrogen, Carlsbad, Calif., 
USA) following the manufacturer’s protocol. cDNA was synthe-
tized using High Capacity cDNA Reverse Transcriptase Kit (Ap-
plied Biosystems, Foster City, Calif., USA) according to manufac-
turer’s instructions. Quantitative RT-PCR analysis was performed 
in a 96-well optical reaction plate using an ABI Prism 7000 se-
quence detector (Applied Biosystems). As the expression of RPLP0 
gene was stable between experimental conditions, we used this 
gene as the reference for data normalization. hASC grown in 
hASC culture medium were used as controls for gene expression 
for  Angiopoietin 1 and  Caldesmon and HUVEC grown in EGM-2 
for  PECAM-1.  Reactions were performed using SYBR Green PCR 
Master Mix kit (Applied Biosystems), 50 ng cDNA sample and 10 
  M primers. The PCR conditions were as follows: 10 min at 95  °  C, 
followed by 40 cycles of 15 s at 95  °  C and 60 s at 60  °  C. The target 
and reference genes were amplified in separate wells. All reactions 
were performed in duplicate. Relative RNA expression was calcu-
lated in comparison to RPLP0 RNA expression for cell culture 
experiments using the Pfaffl method [Pfaffl, 2001]: 
 ratio of relative expression = (E target )  CP target (control-sample)/
(E ref )  CP ref (control-sample)
Table 1.  Oligonucleotide sequences used for RT-PCR experiments
Gene Primer
Human RPLP0 Forward 5-AATCTCCAGGGGCACCATT-3
Reverse 5-CGCTGGCTCCCACTTTGT-3
Human PECAM-1 (CD31) Forward 5-TCATTTCTGGGATCCATATGCA-3
Reverse 5-TGGGTGTAGAGAAGGATTCCGT-3
Human Angiopoietin 1 Forward 5-AGCTACCACCAACAACAGTG-3
Reverse 5-CAAAGATTGACAAGGTTGTGG-3
Human Caldesmon Forward 5-AAGAATCCTTGGGACAGGTGAC-3
Reverse 5-GTGGTGGTTGTCTTGGCCTC-3
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 Immunocytochemistry 
 The tubule formation was visualized with endothelial cell-
specific antibody to vWf (anti-vWf primary antibody produced in 
rabbit, 1: 500, Sigma). To evaluate human adipose stromal cell dif-
ferentiation, parallel double immunofluorescence staining with 
  -vWf was performed. Primary antibody against either common 
pericytic marker   -smooth muscle actin (monoclonal anti-  SMA 
clone 1A4, 1: 200, Sigma), vascular smooth muscle cell marker 
smooth muscle myosin heavy chain (anti-SMMHC,  1: 800, Sig-
ma), contractile smooth muscle cell marker calponin (anti-cal-
ponin, 1: 800, Sigma), pericytic and smooth muscle cell progenitor 
marker platelet-derived growth factor receptor-  (anti-PDGFR  
1: 800) or basement membrane marker collagen IV (anti-COLIV, 
1: 500, Sigma) was combined with anti-vWf. Cells were washed 
three times with PBS, fixed with ice-cold 70% ethanol for 20 min, 
permeabilized with 0.5% Triton X-100 (JT Baker, Phillipsburg, 
N.J., USA) for 15 min and blocked for unspecific staining with 
10% bovine serum albumin (Sigma) for 30 min. After blocking, 
cells were incubated with the primary antibody pairs for 1 h at 
room temperature. Cells were washed three times with PBS, in-
cubated for 30 min with secondary antibody polyclonal anti-rab-
bit IgG TRITC (1: 100, Sigma) for anti-vWf and polyclonal anti-
mouse IgG FITC (1: 100, Sigma) for anti-  SMA, anti-COLIV, an-
ti-PDGFR  and anti-SMMHC. Cell nuclei were stained with 
Hoechst 33258 (1   g/ml, Sigma) for 5 min and washed 5 times 
with PBS. For anti-GFP staining, the primary antibody pair was 
mouse monoclonal antibody to GFP (1: 100, Abcam, Cambridge, 
UK) and anti-vWf, secondary antibodies being anti-mouse IgG 
TRITC (1: 100, Sigma) and polyclonal antibody to rabbit IgG FITC 
(1: 500, Acris Antibodies GmbH, Hiddenhausen, Germany), re-
spectively. Fluorescence was visualized with a Nikon Eclipse Ti-S 
microscope (Nikon, Tokyo, Japan) or with a confocal laser scan-
ning microscope Zeiss LSM 700 (Zeiss LSM 700 on the Axio Ob-
server, Carl Zeiss Microimaging GmbH, Jena, Germany) and the 
images were processed with Zen2009 (confocal images, Carl 
Zeiss), with Adobe Photoshop software 7.0 (Adobe Systems, San 
Jose, Calif., USA) and Corel Draw software 10.0 (Corel Corpora-
tion, Ottawa, Ont., Canada). 
 Microscopic Analysis of Tubule Formation 
 After immunocytochemical staining, the tubules were ana-
lyzed with Nikon Eclipse TS100 microscope (Nikon, Tokyo, Ja-
pan) from 48-well plate wells with 40 ! magnification. The extent 
of tubules in different cultures was quantified visually by using a 
semiquantitative grading scale from 0 to 10. The grading was 
based on tubule formation, the length and the branches of tubules, 
as described in our previous study [Sarkanen et al., 2011].
 Statistical Analysis 
 Statistical analyses were performed and graphs processed with 
GraphPadPrism 5.0 (GraphPad Software Inc., San Diego, Calif., 
USA). Tubule formation and RT-PCR results were subjected to 
one-way ANOVA followed by Dunnett’s and Bonferroni’s post-
hoc tests when applicable. The results were reported as mean  8 
 SD and differences were considered significant with p  ! 0.05, p  ! 
0.01 and p  ! 0.001.
 Results 
 The Tubule Network Formation Is Induced in hASC 
Monoculture and in hASC+HUVEC Coculture in the 
Presence of Inductive Growth Factors  
 The tubule formation capacity and anti-vWf-positive 
endothelial tubule structures of hASC monoculture or 
hASC+HUVEC coculture were evaluated and compared 
at two different time points (day 3 and day 6) when grown 
in the growth factor-enriched EGM-2 BulletKit medium 
( fig. 1 a). hASC+HUVEC coculture showed an extremely 
accelerated proliferation rate that was shown at day 6 as 
a massive, dense, multilayered prevascular-like network 
formation. hASC+HUVEC coculture tubular network 
formation was very extensive early (day 3) in vitro, always 
reproducible and not dependent on the cell line or pas-
sage number of cells. In hASC monoculture, the induc-
tion towards angiogenesis was not seen repeatedly be-
tween different experiments, only approximately half of 
the cultures showed tubule formation in some degree and 
dense tubular network formation, as seen in  figure 1 a, 
was seen less often. When the tubule formation was 
 semiquantitatively evaluated ( fig. 1 b, tubule formation), 
hASC+HUVEC had significantly more tubules at day 6 
than at day 3 (p  ! 0.001) and significantly more tubules 
than hASC monoculture at day 3 (p  ! 0.01) and at day 6 
(p  ! 0.01). The two controls, hASC+HUVEC grown with-
out growth factors and HUVEC alone, both grown in 
growth factor-enriched EGM-2 medium, showed only 
mild tubule formation or no tubule formation, respec-
tively ( fig.  1 c). The surface marker characterization of 
control HUVEC is shown in  table 2 . We also studied the 
hASC+HUVEC tubule formation in EGM-2 when FBS 
was replaced with 2% human serum (hASC+HUVEC 
EGM-2, 2% HS,  fig.  1 d) or when FBS was completely 
 removed (hASC+HUVEC, without serum,  fig.  1 d). We 
were able to replace FBS without significant effect on the 
tubule formation capacity of hASC+HUVEC coculture 
as tested with one-way ANOVA.
 In order to further evaluate which cells were re-
sponsible for the massive tubule network formation in 
hASC+HUVEC coculture and to see whether hASC in-
duce the proliferation and tubule formation of HUVEC 
or also differentiate into endothelial-like cells, as seemed 
to be the case according to hASC monoculture studies, 
we created a hASC and GFP-infected HUVEC coculture 
(hASC+GFP-HUVEC,  fig. 2 ). The anti-vWf-stained co-
cultures ( fig. 2 , vWf) were mostly mosaic and consisted 
of two different populations of vWf-positive cells, ap-
proximately half of the cells being GFP infected ( fig. 2 , 
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GFP), and the other half of the anti-vWf-positive cells be-
ing GFP negative. Moreover, several GFP-negative and 
vWf-negative cells were surrounding the tubules as seen 
with Hoechst staining ( fig. 2 , merged). 
 Genes That Indicate Differentiation of Cells and 
Maturation of Tubule Structures Are Upregulated in 
hASC Monoculture and in hASC+HUVEC Coculture 
 hASC and hASC+HUVEC, both cultured in EGM-2 
BulletKit medium, were further tested for their matura-
tion stage with several pericytic and smooth muscle 
markers. The relative mRNA expression of  PECAM - 1 , 
 Angiopoietin 1 and Caldesmon were studied both in 
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 Fig. 1. The tubule formation of hASC monoculture and 
hASC+HUVEC coculture. Cells were stained with vWf antibody 
(anti-vWf, 1: 500, Sigma; red fluorescence shown with TRITC-
conjugated secondary antibody, 1: 100, Sigma).  a Comparison of 
tubule formation of hASC monoculture and hASC+HUVEC co-
culture. Cells were cultured and induced to angiogenesis for 3 or 
6 days in growth factor-enriched EGM-2 BulletKit medium.
 b Semi-quantitative analysis of the tubule formation between dif-
ferent treatments. hASC monoculture and hASC+HUVEC cocul-
ture were compared to each other at 3 and 6 days. Semiquantita-
tive scale according to Sarkanen et al. [2011]. The results are re-
ported as mean  8 SD and differences considered significant 
when  * *  p  ! 0.01 and  * * *  p  ! 0.001.  c The controls shown at day 6 
in vitro. HUVEC were plated at 4,000 cells/cm 2 and grown in 
growth factor-enriched EGM-2 and hASC+HUVEC cocultured 
without exogenous addition of growth factors.  d hASC+HUVEC 
were cultured in the growth factor-enriched EGM-2 with human 
serum (EGM-2, 2% HS) or without serum (EGM-2 w/o serum).  
Table 2. S urface protein expression of HUVEC
Antigen Surface protein HUVEC
CD 13 Aminopeptidase N 99.4
CD 31 PECAM 94.5
CD 34 Glycoprotein 3.9
CD 44 Hyaluronate, HCAM 44.5
CD 63 Tetraspanin 8.5
CD 117 c-kit, SCFR 8.4
CD 133 AC133 1.1
CD 144 VE-Cadherin 0.9
CD 202b Tie-2/TEK 31.9
VEGFR2 0.4
vWF/factor VIII 14.5
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hASC monoculture and in hASC+HUVEC coculture at 
days 3 and 6 ( fig. 3 ). As a control, hASC, grown in their 
normal culture media, were used. By day 3, only  Caldes-
mon showed significant activity, when compared to the 
control.  Angiopoietin 1 and Caldesmon expressions were 
significantly increased by day 6 with hASC and with 
hASC+HUVEC by days 3 and 6 (p  ! 0.05 and p  ! 0.001, 
respectively) when compared to the control hASC. The 
 PECAM-1 expression was significantly increased with 
hASC grown in growth factor-enriched medium by day 
6 (p  ! 0.05) when compared to the control hASC, and 
moreover, also between days 3 and 6 (p  ! 0.05).  PECAM-1 
expression was also seen to increase with hASC+HU-
VEC, but due to high variation, the result was not
sta tistically significant.  Caldesmon expression was in-
creased between days 3 and 6 with hASC and with 
hASC+HUVEC (p  ! 0.01 and p  ! 0.001, respectively). It 
seemed that the  PECAM-1 expression was lower with 
hASC+HUVEC than with the control hASC monocul-
ture. However, the  PECAM-1 expression was very low at 
day 3 in all treatments, which has probably caused an er-
ror in the normalization of the data.
 Induced Extracellular Matrix Production in Culture 
and Differentiation of hASC into Vessel Lining Cells 
 hASC monoculture and hASC+HUVEC coculture 
were also subjected to immunocytochemical staining. 
The results from day 6 are shown in  figure 4 , except for 
PDGFR  expression in hASC+HUVEC which is shown 
from day 3. PDGFR  expression was most intense in 
hASC+HUVEC at day 3, seen as dot-like structures 
 evenly surrounding the developing tubules. At day 6, 
PDGFR  was seen in some extent in both hASC and 
hASC+HUVEC, but the expression was not changed 
with hASC+HUVEC between days. COLIV, showing the 
development of a basement membrane, was remarkably 
widely expressed in hASC+HUVEC. The expression was 
colocalized with the developing tubules covering the tu-
bules.   SMA- and SMMHC-positive cells were expressed 
quite often in hASC and widely in hASC+HUVEC at day 
6, often localized in the branching points of tubular 
structures and between the tubules. SMMHC expression 
was increased between days 3 and 6, especially in 
hASC+HUVEC. In hASC monoculture, vessel-support-
ing pericytic and smooth muscle cell markers were ex-
pressed, even despite the lack of capillary formation at the 
area. COLIV was also expressed in hASC monoculture at 
the sites of tubule formation, but not elsewhere. The con-
focal laser scanning microscopy of basement membrane 
(COLIV) and tubule network (vWf) staining showed the 
multilayered nature of the tubule network ( fig.  5 ). The 
transparent three-dimensional projection of the Z-stack 
shown in  figure 5 a was merged from 28 single layers, the 
distance between layers being 7   m. Therefore, the thick-
ness of the tubule network was 196   m. The close-up of 
the tubule network ( fig. 5 b) shows multilayered tubules 
crossing each other. Some of the crossing points are indi-
cated with arrows.
 Discussion  
 We developed an inductive prevascular-like network 
support based on adipose stromal cells and endothelial 
cells for in vitro tissue models and for tissue engineering 
constructs. Our specific aim was to develop a completely 
 Fig. 2. hASC+GFP-HUVEC coculture model. Cells were cultured for 6 days in the growth factor-enriched 
EGM-2 medium and immunostained with anti-GFP (GFP, 1: 100, Abcam; TRITC-conjugated secondary anti-
body, 1: 100, Sigma) and anti-vWf (1: 100, Sigma; FITC-conjugated secondary antibody, 1: 500, Acris Antibodies). 
Cell nuclei were visualized with Hoechst staining (shown in the merged image, 1   g/ml, Sigma).  
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human-based, simplified and improved angiogenesis 
model, a tubular network with properties of maturing 
vessels, which could be used for studying angiogenesis in 
vitro, and that would aid in the development of tissue 
models by improving target cell proliferation, survival 
and differentiation. In this tubular network model cells 
are induced with natural growth factors and allowed to 
self-assemble into a prevascular-like network and vascu-
lar supporting structures. We studied a hASC+HUVEC 
coculture model by combining some properties and anal-
yses from the previously described model [Merfeld-
Clauss et al., 2010] and the fibroblast-HUVEC coculture 
angiogenesis assay previously validated in our laboratory 
[Sarkanen et al., 2011]. The maturity of the developed 
model was evaluated with markers that indicated the 
maturation of the tubules by quantitative RT-PCR and 
immunocytochemical staining. We also studied whether 
hASC alone could be induced to endothelial cell differen-
tiation and tubule formation with the addition of these 
naturally occurring stimulating growth factors.
 Merfeld-Clauss et al. [2010] created a similar hASC+
HUVEC coculture model with no exogenous growth fac-
tors added in cell culture. Contrary to their study, we spe-
cifically wanted to investigate tubule formation in a sim-
ilar coculture system by adding growth factors that are 
secreted in vivo and that naturally stimulate angiogene-
sis, e.g. in adipose tissue [Hausman and Richardson, 
2004; Mehta and Besner, 2007]. This selection of growth 
factors would provide a close to natural-like cell culture 
environment and presumably therefore favor the tubule 
network induction and allow sustained vessel formation 
and long-term stability of the tubular network, a feature 
that is often required in the development of complex tis-
sue or organ models. 
 When hASC were combined with HUVEC (hASC+
HUVEC) and cultured in EGM-2, a remarkable enhance-
ment in cell proliferation, capillary formation and induc-
tion of maturation was seen with both cells. However, if 
the hASC were allowed to attach and proliferate in cul-
ture for a prolonged time period prior to HUVEC seed-
ing, only modest tubule formation was seen (data not 
shown). Therefore, only simultaneous plating of cells ef-
fectively induced the self-assembly of the multilayered tu-
bule network. The growth factor stimulation induced tu-
bule formation that seemed not to be passage dependent 
(up to passage 7 tested) with either HUVEC or hASC, a 
result contrary to previous studies on these cell types cul-
tured alone by us [Sarkanen et al., 2011] and others [Hey-
darkhan-Hagvall et al., 2008] that have shown that the 
differentiation capability is passage dependent.
 hASC monoculture, on its behalf, had clearly passage 
and donor-dependent differentiation capacity towards 
endothelial-like cells despite the use of the growth factor-
enriched medium. hASC alone often formed short cords 
in culture, but only occasionally massive tubule network 
formation. In addition to the current study, the tubule for-
mation in hASC monoculture has only been shown previ-
ously by Miranville et al. [2004] and Heydarkhan-Hagvall 
et al. [2008]. Several groups have reported cord formation 
of hASC in Matrigel for example, but it has also been re-
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 Fig. 3. The relative mRNA expression of  PECAM-1 ,  Caldesmon 
and  Angiopoietin 1 in hASC monoculture or hASC-HUVEC co-
culture at 3 and 6 days after angiogenesis induction with growth 
factor-enriched EGM-2 medium. The expressions were compared 
to their respective control (hASC, plated at 20,000 cells/cm 2 , 
grown in hASC culture medium). The statistical analysis was per-
formed with one-way ANOVA. The results are reported as mean 
 8  SD and differences considered significant when  *  p  ! 0.05, 
 * *  p  ! 0.01 and  * * *  p  ! 0.001.  
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 Fig. 4. The expression of pericytic and 
smooth muscle cell differentiation mark-
ers in tubule structures after angiogenic 
induction with growth factor-enriched 
EGM-2 medium. For detection of tubule 
formation, cell cultures were immuno-
stained with vWf  antibody (anti-vWf,
1: 500, Sigma; red fluorescence shown with 
TRITC-conjugated secondary antibody,
1: 100, Sigma). For detection of tubule mat-
uration, cultures were immunostained 
with  either anti-  SMA (1: 200, Sigma), an-
ti-COLIV (1: 500, Sigma),  anti-PDGFR  
(1: 500, Sigma), anti-SMMHC (1: 800, Sig-
ma) or  anti-calponin (1: 800, Sigma), all of 
these green fluorescence, FITC-conjugat-
ed secondary antibody (1: 100, Sigma). The 
images shown are merged images of dou-
ble immunofluoresence at day 6, except for 
anti-PDGFR  , which is at day 3, and ex-
cept for anti-COLIV and anti-calponin for 
which both the merged image of staining 
( insets ) and the FITC-conjugated second-
ary antibody – anti-COLIV/anti-calponin 
staining – are shown. 
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ported that the cord formation observed by different cells 
in Matrigel is an unspecific phenomenon [Donovan et al., 
2001] and, therefore, not a reliable or comparable endo-
thelial tubule formation assay to coculture assays. 
 To further evaluate which cells contribute to the tu-
bule formation and whether the hASC mainly stimulate 
endothelial cell proliferation or take part in the endothe-
lial cell differentiation itself, we created a GFP-infection 
model. In the hASC+GFP-HUVEC coculture, the tu-
bules were seen to consist of a mosaic of GFP-HUVEC 
and of other cells that were GFP-negative, although vWf-
positive. This finding, with our other result that hASC 
monoculture is able to form tubular networks, suggests 
that hASC not only stimulate the tubule formation and 
maturation, but also differentiate into endothelial-like 
cells in this system. Moreover, the significant increase in 
the expression of the endothelial marker  PECAM-1 in 
hASC monoculture between days 3 and 6 supports this 
finding. 
 Although freshly isolated hASC, or more precisely, 
stromal-vascular fraction cells, may contain microvascu-
lar endothelial cells [Rehman et al., 2004; Wosnitza et
al., 2007], we have previously thoroughly characterized 
hASC [Lindroos et al., 2009, 2010] and shown that hASC, 
cultured in several different proliferation media, lack the 
expression of hematopoietic and angiogenic markers 
such as CD31, CD106 and CD146 (surface marker expres-
sion 0.6  8 0.7, 0.7  8 0.7 and 0.4  8 0.2, respectively). 
However, the extent whereby hASC differentiate into en-
dothelial-like cells in this model, especially in higher pas-
sages, and the functional and metabolic competency of 
these differentiated endothelial-like cells need careful 
further evaluation and characterization. In our opinion, 
the advantage of this current coculture model is, in fact, 
the heterogeneity of the hASC, creating and inducing a 
natural-like environment for the formation of a self-as-
sembling tubule network. 
 The HUVEC isolated from umbilical cords and used 
in the assay were previously carefully quality controlled 
for their tubule formation capacity with low variation be-
tween cell batches [Sarkanen et al., 2011], and the surface 
marker expression profile of HUVEC that has been char-
acterized here corresponds with previous reports [Fuka-
sawa et al., 2006; Ichikawa et al., 2006; Korbling et al., 
2006; Schmidt et al., 2006]. However, the flow cytometry 
results indicate low expression of VE-cadherin (0.9%) 
and relatively low expression of vWf (14.5%). VE-cad-
herin is reported to be low in HUVEC in normal cell cul-
ture, whereas significantly upregulated in HUVEC dur-
ing tubule network formation [Kiran et al., 2011]. vWf 
expression, on its behalf, is reported to be heterogeneous 
in endothelial cells and to show regional variations in 
mRNA levels [Zanetta et al., 2000]. Expression of vWf is 
reported to be upregulated by the angiogenic growth fac-
a b
 Fig. 5. The confocal laser scanning microscopy of a multilayered 
precapillary-like tubule network. For detection of the tubule for-
mation, the hASC+HUVEC cocultures were immunostained 
with vWf antibody (anti-vWf, 1: 500, red fluorescence, shown with 
TRITC-conjugated secondary antibody, 1: 100, Sigma). For detec-
tion of basement membrane, cultures were immunostained with 
anti-COLIV (1: 500, Sigma green fluorescence, FITC-conjugated 
secondary antibody, 1: 100, Sigma). The images shown are merged 
images of double immunofluoresence at day 6.  a Transparent 
three-dimensional projection of the Z-stack built from 28 layers 
with a threshold of 13; distance between layers: 7 um; scale bar = 
200   m.  b A close-up of the tubule network, multilayered tubule 
formation seen in several areas, some of the crossing points of the 
tubules are indicated with arrows. 
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tors bFGF and VEGF [Zanetta et al., 2000], which may 
explain the difference in our flow cytometry and immu-
nofluoresence results.  
 Blood vessel formation involves not only endothelial 
tubule formation, but also the maturation of vessels by 
basement membrane formation and pericyte and vascu-
lar smooth muscle cell recruitment and differentiation 
[Kalluri, 2003]. Therefore, the maturation stage of hASC-
induced vascular structures was evaluated. Our study 
supports the earlier studies [Merfeld-Clauss et al., 2010; 
Planat-Benard et al., 2004; Rubina et al., 2009; Traktuev 
et al., 2008] and demonstrates that hASC are able to con-
tribute to vessel formation maturation in vitro by differ-
entiating into vessel supporting structures with pericyt-
ic and smooth muscle cell properties. PDGFR  , an
important receptor in pericytic cell recruitment to
developing tubules [Nishishita and Lin, 2004], was al-
ready extensively seen at 3 days in hASC+HUVEC. In 
contrast to a previous study [Merfeld-Clauss et al., 2010], 
we detected  that hASC monoculture expressed COLIV 
colocalized with the tubules expressing vWf. hASC also 
widely expressed   SMA and occasionally other markers, 
even when capillaries were not present, which is well in 
line with the known vessel supporting role of hASC [Ver-
seijden et al., 2010]. COLIV, an important basement 
membrane component defining integrity, stability and 
functionality of the basement membrane [Bonanno et 
al., 2000; Poschl et al., 2004], was intensively expressed 
in hASC+HUVEC, both at days 3 and 6, and surrounded 
all of the tubules completely, indicating well-formed 
basement membrane. COLIV staining also revealed the 
multilayered structures where the tubules were orga-
nized into three-dimensional networks ( fig. 4 and  fig. 5 ). 
hASC+HUVEC also expressed widely   SMA and 
SMMHC, the major contractile proteins in smooth mus-
cle cells [Frid et al., 1992].  Angiopoietin 1 , a molecule reg-
ulating blood vessel stabilization [Nishishita and Lin, 
2004] and indicating late stages of tubule maturation and 
stabilization, as well as  Caldesmon, a smooth muscle cell 
contraction regulator indicating higher differentiation 
of smooth muscle cells [Frid et al., 1992], were signifi-
cantly expressed in both hASC and hASC+HUVEC at 
day 6. Another regulator of muscle cell contraction, cal-
ponin, was rarely seen in hASC monoculture, but often 
in hASC+HUVEC at the sites of the tubule formation. 
However, the maturation stage of the tubule networks 
needs further study, especially with endothelial nitric 
oxide synthase, an important regulator of angiogenesis, 
as well as by testing the VEGF independency of the 
formed tubule network.
 Most tissue-engineered constructs are limited in 
thickness to 1–2 mm due to inadequate vascularization 
[Norotte et al., 2009]. However, scaffolds, which are often 
used to create multilayered tissue constructs, may inter-
fere with the cell-to-cell interactions and the cell assem-
bly [Norotte et al., 2009]. The growth factor induction 
induced a high proliferation of both cell types in 
hASC+HUVEC coculture. Therefore, this supporting 
prevascular-like network model could allow for the cre-
ation of multilayered, yet scaffold-free, soft tissue con-
structs. The three-dimensional nature of hASC+
HUVEC coculture could be seen in confocal scanning 
microscopy three-dimensional projection, where the to-
tal thickness of the tubule network was nearly 200   m. 
This network model would be especially suitable for en-
gineering tissue constructs that need an intense tubular 
network. Moreover, due to a high proliferation rate, the 
cell number used in our study was only one fourth of the 
number used by Merfeld-Clauss et al. [2010], for example. 
A lower cell number provides a higher capacity, e.g. for in 
vitro drug screening studies. The xeno-free modification 
of hASC+HUVEC coculture allows the use of this tubu-
lar network culture model in tissue engineering applica-
tions. As suggested by Merfeld-Clauss et al. [2010], the 
endothelial cells could possibly be replaced with any tis-
sue-specific endothelial cells (e.g. microvascular endo-
thelial cells in adipose tissue) with no effect on tubule 
formation capability. Therefore, we can suspect that this 
developed tubular network platform is easily modified to 
be suitable in several different tissue model applications 
where a dense tubular network is needed. However, when 
this coculture system is aimed at human use in tissue 
constructs, the origin of endothelial cells must meet the 
need of the target tissue. Moreover, if hASC monoculture 
tubule network induction could be improved to be re-
peatable, this would allow an even more simplified tubu-
lar network model. However, the tubule formation of 
hASC alone in growth factor-enriched medium needs 
further study and more optimization, e.g. through an in-
crease in cell seeding density.
 By combining the present knowledge of potential 
properties of hASC in angiogenesis induction and fea-
tures from the presently available tubule network assays, 
we could generate a natural-like angiogenesis in vitro 
with an excellent prevascular-like network formation ca-
pability, reproducibility and stability, and minimal limi-
tations in technical performance (i.e. passaging and cul-
ture conditions). The tubule network had morphological 
and genetic features of maturing capillaries. This tubular 
network model mimics especially well the naturally oc-
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curring angiogenesis in adipose tissue. The hASC mono-
culture or hASC+HUVEC coculture model provides an 
ideal platform for tissue engineering applications, both 
for developing tissue models in vitro or for the develop-
ment of implantable tissue structures. Clinically relevant 
in vitro angiogenesis models are also valuable tools for 
investigating the in vivo angiogenesis process [Lai et al., 
2009; Ucuzian and Greisler, 2007], e.g. for the treatment 
of cancer, macular degeneration or peripheral and coro-
nary vascular diseases [Nillesen et al., 2007; Ucuzian and 
Greisler, 2007].
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Summary
The formation of blood vessels is a vital process in embryonic development and in normal physiology. Current vascular 
modelling is mainly based on animal biology leading to species-to-species variation when extrapolating the results 
to humans. Although there are a few human cell based vascular models available, these assays are insufficiently 
characterized in terms of culture conditions and developmental stage of vascular structures. Therefore, well characterized 
vascular models with human relevance are needed for basic research, embryotoxicity testing, development of therapeutic 
strategies and for tissue engineering.
We have previously shown that the in vitro vascular model based on co-culture of human adipose stromal cells (hASC) 
and human umbilical vein endothelial cells (HUVEC) is able to induce an extensive vascular-like network with high 
reproducibility. In this work we developed a defined serum-free vascular stimulation medium (VSM) and performed 
further characterization in terms of cell identity, maturation and structure to obtain a thoroughly characterized in vitro 
vascular model to replace or reduce corresponding animal experiments.
The results showed that the novel vascular stimulation medium induced an intact and evenly distributed vascular-like 
network with morphology of mature vessels. Electron microscopic analysis assured the three-dimensional microstructure 
of the network containing lumen. Additionally, elevated expression levels of the main human angiogenesis-related genes 
were detected.
In conclusion, with the newly defined medium the vascular model can be utilized as a characterized test system for 
chemical testing as well as in creating vascularized tissue models.
Keywords: serum-free media, angiogenesis, mesenchymal stromal cells, coculture techniques
this is an Open Access article distributed under the terms of the Creative 
Commons Attribution 4.0 International license (http://creativecommons.org/
licenses/by/4.0/), which permits unrestricted use, distribution and reproduction 
in any medium, provided the original work is appropriately cited. 
1  Introduction#
The formation of the blood vessel network is a vital process in 
growth and organ development (Carmeliet and Jain, 2011; Car-
meliet, 2005). In the embryo, endothelial precursor cells form 
new vessels that differentiate into a primitive vascular network 
(vasculogenesis) (Carmeliet and Jain, 2011). Subsequent ves-
sel sprouting (angiogenesis) creates a network of arteries and 
veins as well as capillaries that facilitate the exchange of gases 
and metabolites (Carmeliet and Jain, 2011; Adams and Alitalo, 
2007). To reach this level of complex organization, the imma-
ture vascular network must mature at the level of the vessel wall 
*Authors contributed equally to this work.
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AA, ascorbic acid; APC, allophycocyanin; BSA, bovine serum albumin; CD144, vascular endothelial cadherin; eGF, epidermal growth factor; eGM-2, endothelial 
cell growth medium-2; FBS, fetal bovine serum; FItC, fluorescein isothiocyanate; FGF-2, basic fibroblast growth factor; hASC, human adipose stromal cells; 
He, heparin sodium salt; HS, human serum; HUVeC, human umbilical vein endothelial cells; HY, hydrocortisone (cortisol); IGF-I, insulin-like growth factor I; 
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basal serum-free medium; αSMA, alpha smooth muscle actin; TRITC, tetramethyl rhodamine isothiocyanate; VEGF, vascular endothelial growth factor; VSM, 
vascular stimulation medium; vWf, von Willebrand factor
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morphology and as a whole network. Morphological maturation 
involves recruitment of mural cells, deposition of extracellular 
matrix and organ-specific specialization of cells, such as inter-
endothelial junctions and surface receptors. Maturation of the 
network involves branching and expanding the network to meet 
local, tissue-specific demands (Jain, 2003).
Since the formation and maintenance of the vascular network 
is a complex process, problems related to its regulation are com-
mon (Ucuzian and Greisler, 2007). Inadequate vessel mainte-
nance or growth causes ischemia in myocardial infarction and 
neurodegenerative or obesity-associated disorders, whereas 
excessive vascular growth or abnormal remodeling promotes 
cancer, inflammatory disorders and eye diseases (Potente et 
al., 2011). Moreover, genetic studies have shown that perturb-
ing embryonic vascular development can have adverse conse-
quences from benign vascular malformation to embryolethality 
and congenital defects (Knudsen and Kleinstreuer, 2011).
Angiogenesis models are important tools for studying the 
mechanisms of angiogenesis and the therapeutic strategies to 
modulate neovascularization (Ucuzian and Greisler, 2007). Due 
to an increasing amount of compounds affecting the vascular 
system, accurate vasculogenesis and angiogenesis models are 
needed for chemical safety testing and for drug development 
(Sarkanen et al., 2011; Bishop et al., 1999). Currently, preclini-
cal animal models are dominantly used for angiogenesis testing 
although they are not considered optimal in efficacy or relevance 
to humans. The most commonly used in vivo angiogenesis as-
says include the chick chorioallantoic membrane (CAM) assay, 
Matrigel plug assay, zebrafish embryo system, corneal micropo-
cket assay, rat/mouse hind limb ischemia model and rat aortic ring 
assay (Norrby, 2006; Auerbach et al., 2003). Despite the advan-
tage of providing more information on complex cellular interac-
tions compared to in vitro models, animal models are burdened 
by several disadvantages, such as variability, animal-specificity 
and ethical concerns (Norrby, 2006). Human cell based models 
have the potential to be valuable tools in predicting effects in 
man. However, the human relevance of these in vitro models 
needs to be confirmed in terms of cell identity, physiological ar-
chitecture and functionality (Bale et al., 2014; Hartung, 2011). 
In addition, the developmental stage of the model system and a 
defined medium composition are critical, especially when toxi-
cological applications are considered. Serum-free medium with 
xeno-free and defined supplements is considered essential for in 
vitro models to decrease the variation between experiments due 
to unknown components in the medium, and further, unknown 
binding properties of these components (Shen et al., 2013; Brun-
ner et al., 2010; van der Valk et al., 2010). Currently, culture 
media are still commonly supplemented with serum, although 
it has a highly uncharacterized composition, including various 
cytokines and growth factors, as well as a lot-to-lot variability 
(Lindroos et al., 2011; Brunner et al., 2010). 
We and others have shown that adipose stromal cells and um-
bilical vein endothelial cells are capable of self-assembling into a 
dense, three-dimensional vascular-like network (Sarkanen et al., 
2012; Merfeld-Clauss et al., 2010; Verseijden et al., 2010). While 
adipose stromal cells secrete factors that induce endothelial cell 
(EC) sprouting and lumen formation (Rubina et al., 2009; Trak-
tuev et al., 2008; Rehman et al., 2004; Kilroy et al., 2007; Bishop 
et al., 1999), the supporting stromal cells also enhance vascular 
basement membrane and lumen formation (Merfeld-Clauss et 
al., 2010; Newman et al., 2013; Stratman et al., 2009). 
The aim of this study was to develop a defined medium and 
further characterize the in vitro vascular model developed by us, 
which is composed of human adipose stromal cells (hASC) and 
human umbilical vein endothelial cells (HUVEC) (Sarkanen et 
al., 2012). Our results showed that the new vascular stimula-
tion media (VSM) developed in this study produces an exten-
sive vascular-like network with mature properties and provides 
a valid alternative to commercial EGM-2 medium when com-
paring vascular-like network formation capacity. This vascular 
model has the potential to be used in the safety and efficacy 
assessment of angiogenic compounds. In addition, the vascular-
like network combined with target cells, such as cardiomyocytes 
(Vuorenpää et al., 2014), can be used as a tissue engineering 
platform to create vascularized tissue models. 
2  Materials and methods
This study conforms to the principles outlined in the Declaration 
of Helsinki. The human adipose tissue samples were obtained 
from surgical operations and human umbilical cords were re-
ceived from caesarean sections with individual written informed 
consent at Tampere University Hospital, Tampere, Finland. The 
use of hASC and HUVEC were approved by the Ethics Com-
mittee of the Pirkanmaa Hospital District, Tampere, Finland 
with permit numbers R03058 and R08028, respectively. 
Isolation and culture of human adipose stromal cells
hASC were isolated from human adipose tissue by using a me-
chanical and enzymatic procedure described previously (Sar-
kanen et al., 2012). Briefly, human adipose tissue specimens 
were mechanically cut into small pieces and enzymatically di-
gested with 0.15% collagenase I (Invitrogen, Paisley, Scotland, 
UK) in Dulbecco’s Modified Eagle’s Medium Nutrient Mixture 
F-12 (DMEM/F12, Gibco, Invitrogen, Carlsbad, CA, USA). 
hASC were cultured in DMEM/F12 supplemented with 10% 
human serum (HS, Lonza Group Ltd, Basel, Switzerland) and 
1% L-Glutamine (Gibco). The cells were tested for mycoplasma 
contamination (MycoAlert® Mycoplasma Detection Kit, Lonza 
Group Ltd) before experimental use. 
Isolation and culture of human umbilical vein endothelial cells
HUVEC were isolated from human umbilical cord veins using 
0.05% collagenase I as described previously (Sarkanen et al., 
2011). The cells were cultured in EGM™-2 Endothelial Cell 
Growth Medium-2 (EGM-2, Lonza Group Ltd). Before use the 
cells were tested for mycoplasma contamination (MycoAlert® 
Mycoplasma Detection Kit, Lonza).
Establishment of the co-culture forming the vascular-like 
network
Co-culture of hASC and HUVEC was established as described 
previously (Sarkanen et al., 2012). Briefly, hASC were seeded in 
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EGM-2 (Lonza) at 20,000 cells/cm2. After 1-3 h HUVEC were 
seeded on top of hASC at 4,000 cells/cm2. The hASC were used 
at passage 2 and HUVEC at passage 4 in the co-culture (passage 
number increased at seeding). The day after plating, the stimula-
tion media were applied to the co-culture (see Tab. 1): 1) EGM-2 
containing epidermal growth factor, vascular endothelial growth 
factor A (VEGF), fibroblast growth factor 2 (FGF-2), insulin-
like growth factor I (IGF-I), ascorbic acid (AA), heparin, hydro-
cortisone (HY), antibiotic mix: 30 µg/ml gentamicin and 15 ng/
ml amphotericin and 2% fetal bovine serum (FBS); 2) EGM-2/
HS, where 2% FBS was replaced with 2% HS; 3) serum free ba-
sal medium (SFM); 4) Vascular stimulation medium (VSM). 
In this first media comparison study, the AA, HY and heparin 
in VSM were taken from the EGM-2 kit and used according 
to the manufacturer’s protocol (concentrations of these are not 
publicly available). After that, concentrations of AA, heparin 
sodium salt from bovine intestinal mucosa (HE) and HY pur-
chased from Sigma were optimized for VSM. In the concentra-
tion optimization study the tested concentrations of AA were 0, 
50, 100, 200, 500, 1000 and 2000 µg/ml; of HY 0, 20, 200, 1000, 
and 2000 ng/ml and of HE 0, 50, 500, 10,000 and 50,000 ng/ml. 
The concentrations of 10 ng/ml VEGF and 1 ng/ml FGF-2, used 
for VSM, had been optimized in our previous study (Sarkanen 
et al., 2012). The co-cultures were grown for 6 days prior to 
immunocytochemistry or quantitative real-time PCR (qPCR) 
processing. Stimulation medium was changed once during the 
6 day culture. 
Quantitative real-time PCR 
Genes activated in co-culture of hASC and HUVEC in EGM-
2 medium versus co-culture in VSM were analyzed by qPCR. 
Total RNA was extracted at day 6 using the RNAeasy minikit 
(Qiagen) following the manufacturer’s protocol. A step to elimi-
nate genomic DNA contamination was included in the isolation 
and performed with RNase-free DNase set (Qiagen). Reverse 
transcription of total RNA to cDNA was performed using RT2 
First Strand Kit (Qiagen) following the manufacturer’s instruc-
tions. 
Human Angiogenesis RT2 Profiler™ PCR Array (Qiagen, Va-
lencia, California, USA) was used to profile the expression of 
84 key angiogenesis-related genes (the comprehensive list of 
genes included in the array can be found in http://www.sabio-
sciences.com). The array was performed according to the man-
ufacturer’s protocol using BioRad CFX96 Real Time System 
(BioRad Laboratories, USA). The array contained five house-
keeping genes and controls, including genomic DNA control, 
Reverse Transcription Control and Positive PCR controls. The 
co-culture of hASC and HUVEC grown in EGM-2 medium was 
used as a control. Three independent experiments with the array 
were performed using the same cells. 
Immunocytochemistry
To analyze the vascular-like network formation and different 
cell types present in hASC and HUVEC co-culture, immunocy-
tochemical staining was performed. In primary antibody stain-
ing, endothelial cell specific antibody for rabbit anti-human von 
Willebrand factor IgG (anti-VWF, 1:100, F3520, Sigma) with 
common pericytic marker α-human smooth muscle actin (mon-
oclonal anti-SMA clone 1A4, 1:200, M0851, DAKO), vascular 
smooth muscle cell marker smooth muscle myosin heavy chain 
(anti-SMMHC, clone hSM-V, 1:800, M7786, Sigma), contrac-
tile smooth muscle cell marker calponin (anti-calponin, clone 
hCP, 1:800, C2687, Sigma), pericytic and smooth muscle cell 
progenitor marker platelet derived growth factor receptor-β 
(anti-PDGFRβ, clone PDGFR-B2, 1:800, P7679, Sigma), vas-
cular endothelial cadherin (CD144,Clone 55-7H1, 1:50, 555661, 
BD Pharmingen), monoclonal occludin (clone 1G7, 1:300, 
WH0004950M1, Sigma) or basement membrane marker colla-
gen IV (anti-COLIV, clone COL-94, 1:500, C1926, Sigma), all 
anti-human and all produced in mouse, except vWf, were used. 
Co-culture was fixed with 70% ethanol at day 6. After fixa-
tion, the cells were permeabilized with 0.5% Triton-X100 (MP 
Biochemicals, Ohio, USA) and non-specific binding sites were 
blocked with 10% bovine serum albumin (BSA, Roche Diagnos-
tics Corporation, Indianapolis, USA). Primary antibody in 1% 
BSA was applied to the cells. Secondary antibodies used were 
polyclonal goat anti-rabbit IgG tetramethylrhodamine (TRITC, 
1:50, T6778 Sigma), anti-rabbit IgG A568 (1: 400, A11011, In-
vitrogen) and anti-mouse IgG fluorescein isothiocyanate (FITC, 
1:100, F4143, Sigma). After immunocytochemical staining the 
Tab. 1: Stimulation media tested in vascular model
Acronym Basal medium Serum Growth factors Supplementation
eGM-2 eBM-2 2% FBS VeGF, FGF-2, IGF-I,  hydrocortisone, ascorbic acid, heparin,  
   epidermal growth factor GA-1000
eGM-2/HS eBM-2 2% HS VeGF, FGF-2, IGF-I, hydrocortisone, ascorbic acid, heparin,  
   epidermal growth factor GA-1000
basal SFM DMeM/F12 –   ItS, BSA, NaP, l-glutamine, t3,
VSM DMeM/F12 – VeGF, FGF-2 ItS, BSA, NaP, l-glutamine, t3,  
    hydrocortisone, ascorbic acid,  
    heparin sodium salt
0.1% ItS (insulin-transferrin-sodium selenite media supplement), 1.28 mM l-glutamine, 1% BSA (bovine serum albumin),  
2.8 mM NaP (sodium pyruvate), 100 IU/ml P/0.1 mg/ml S, 0.1 nM t3 (3,3’,5-triiodo-l-thyronine sodium salt), HS (human serum),  
FBS (fetal bovine serum), VEGF (vascular endothelial growth factor A), FGF-2 (fibroblast growth factor 2), IGF-I (insulin-like growth  
factor I), GA-1000 (30 µg/ml gentamicin and 15 ng/ml amphotericin), VSM (vascular stimulation medium), SFM (serum free medium)
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vascular-like network was analyzed and photographed with 
Nikon Eclipse TS100 inverted fluorescence microscope (Nikon, 
Tokyo, Japan) and Nikon digital sight DS-U2 camera (Nikon). 
Images were further processed with NIS Elements (Nikon, To-
kyo, Japan) and Adobe Photoshop CS3-software (Adobe Sys-
tems Incorporated, San Jose, CA, United States). 
Flow cytometric surface marker expression analysis of  
HUVEC and hASC
hASC were cultured in hASC medium (passage 1) for 6-7 days 
and HUVEC were cultured in EGM-2 medium (passage 3) for 
3 days prior to surface marker expression analysis using a BD 
FACSCanto II flow cytometer (BD Biosciences, Erembodegem, 
Belgium). For the flow cytometry analysis cells were divided 
into 5 ml polystyrene round bottom FACS tubes (BD, New Jer-
sey, USA) at 250,000 cells per tube. The cells were washed once 
with warm staining buffer (1% BSA in PBS) and centrifuged 
at 131 x g for 5 min, after which they were stained either for 
surface markers or for intracellular markers. 
Fixation and permeabilization were only performed for stain-
ing of intracellular markers. The fixation was conducted by 
incubating the samples for 30 min in 2% paraformaldehyde 
in PBS at room temperature (RT). The cells were then centri-
fuged at 500 x g for 5 min. Permeabilization of the cells was 
performed by 10 min incubation in 0.1% Triton-X100 in PBS at 
RT after which the cells were centrifuged at 500 x g for 5 min 
and washed once or twice with staining buffer before addition 
of antibodies. 
The labelled mouse anti-human antibodies used were intra-
cellular vWf-A2-allophycocyanin IgG2b (APC, #IC27641A) 
and eNOS- phycoerythrin IgG1 (PE, #560103), and surface 
markers CD144-FITC IgG1 (#560411), CD73-Phycoerythrin-
Cyanine IgG1 (PE-CY7, #561258), CD309-PE IgG1 (#560872), 
CD68-FITC IgG2b (#562117), NG2-PE IgG1 (#FAB2585P), 
CD90-FITC IgG1 (#561969), CD105-V450 IgG1 (#561447), 
CD34-APC IgG1 (#561209), CD140b-PE IgG2a (#558821), 
CD31-V450 IgG1 (#561653), CD45-PE IgG1 (#560975), 
CD14-FITC IgG1 (#561712). Isotype controls mouse IgG2b-
APC (#IC0041A), Mouse IgG1-PE-CY7 (#557872), mouse 
IgG1-PE (#559320), mouse IgG1-FITC (#555748), mouse 
IgG2b-FITC (#556655), mouse IgG1-V450-(#642268), mouse 
IgG1-APC (#550854), mouse IgG2a-PE (#551438). All anti-
bodies and their corresponding isotype controls used in the flow 
cytometry analysis were purchased from BD except NG2, vWf 
and IgG2b-APC, which were purchased from R&D Systems. 
Labelled antibodies were added into cell suspension in cold 
staining buffer and incubated on ice for 30 min in the dark. After 
incubation the cells were washed once with staining buffer and 
twice with PBS. Surface marker stained cells were centrifuged 
at 200 x g for 5 min and intracellular marker stained cells were 
centrifuged for 5 min at 500 x g. 
Flow cytometry analysis was performed with cells suspended 
in ice cold PBS and 5,000 events were analyzed per sample. 
Compensation was done with compensation particles, i.e., BD™ 
CompBeads (BD) according to the manufacturer’s instructions. 
The results were analyzed with BD FACSDiva™ Software 
(BD). The positive expression was obtained by gating 98% of 
the events isotype control results and then inverting the gate to 
obtain a percentage of positively stained cells in the samples. 
The results were calculated as percentages with SD.
Electron microscopy
hASC and HUVEC co-culture was performed in 24-well UpCell 
plates (ThermoFisher) for transmission electron microscopy 
(TEM) and on glass cover slips coated with 0.1% gelatin for 
scanning electron microscopy (SEM). Co-culture was main-
tained for 6 days and washed twice with PBS prior to fixation. 
SEM specimens were fixed in 2% glutaraldehyde in 0.1 M 
phosphate buffer after which the SEM samples were dehydrat-
ed in alcohol and dried in Baltec critical point dryer (Baltec, 
CPD030, Balzers, Liechtenstein). A layer of platinum was sput-
tered onto the specimens with a sputter coater (Agar Scientific, 
Stansted, England). Specimens were examined in a Zeiss Ultra 
Plus scanning electron microscope, (Carl Zeiss MT – Nanotech-
nology System Division, Carl Zeiss NTS GmbH, Oberkochen, 
Germany) using 5 kV as an accelerating voltage.
TEM specimens were detached from the temperature sensi-
tive 24-well UpCell plate and transferred to fixative with 1% 
glutaraldehyde, 4% formaldehyde mixture in 0.1 M phosphate 
buffer for 10 min. The cell sheet was immersed in 2% agarose in 
distilled water and postfixed in 1% osmiumtetroxide, dehydrat-
ed in acetone and embedded in Epon LX 112 (Ladd Research 
Industries, Vermont, USA). Thin sections were cut with Leica 
Ultracut UCT ultramicrotome, stained in uranyl acetate and lead 
citrate and examined in a Philips CM100 transmission electron 
microscope. Images were captured by a Morada CCD camera 
(Olympus Soft Imaging Solutions GMBH, Munster Germany).
Quantitative analysis of vascular-like network formation
Vascular-like networks, i.e., vWf-positive tubule structures 
formed in different stimulation media, were imaged using Cell-
IQ (Chipman tech., Tampere, Finland) with 10x objective and 
5x5 grid. The quantitation of the area of the vascular-like net-
work was performed using ImageJ software (National institutes 
of health, NIH, Maryland, USA) for the image analysis. Im-
ages were first converted to 8-bit gray scale, then background 
was subtracted and finally the binary threshold function was 
adjusted to obtain the best contrast of the vascular-like network 
against the background. With these settings, the total area of 
vascular-like network was calculated as the total number of pix-
els in images with set threshold.
Statistical analysis
Statistical analyses were performed and graphs processed with 
GraphPad Prism 5.0 (GraphPad Software, Inc., San Diego, CA, 
USA). The results concerning vascular-like network forma-
tion were subjected to one-way ANOVA followed by Dunnett’s 
post-test when applicable. The results were reported as total 
area ± SD and differences were considered significant when 
p < 0.05*, p < 0.01** and p < 0.001***. 
PCR results were analyzed with the PCR Array Data Analy-
sis Web Portal (http://www.SABiosciences.com/pcrarraydataa-
nalysis.php). The following formula was used to calculate the 
relative amount of the transcripts of the co-culture of hASC and 
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CD144 and CD31 and macrophage/monocyte markers CD68 
and CD14 were very low (< 1.4%). 
HUVEC were shown to express endothelial marker CD31 
and a specialized vascular endothelial marker CD144 at a high 
level (> 70%). Angiogenic endothelial marker CD105 and cell 
surface enzyme CD73 were found in the HUVEC population 
(57-68%). Markers for macrophages/monocytes (CD68) and 
mural cells (NG2) were low (≤ 2%). 
3.2  VSM induced optimal vascular-like  
network formation
Of the different stimulation media (Tab. 1), VSM induced an 
optimal vascular-like network formation (Fig. 1). The imaging 
analysis showed morphological differences in the vascular-like 
network in VSM compared to EGM-2 medium. VSM produced 
a uniformly distributed vascular-like network with connected 
branches and fewer cell aggregates. Low serum (2%) and se-
HUVEC in the VSM compared to transcripts of the co-culture 
in EGM-2 medium: ΔΔCT = ΔCT (VSM) − ΔCT (EGM-2). A 
two-fold change compared to housekeeping gene GAPDH was 
considered significant. 
3  Results
3.1  Phenotypic characterization 
Phenotypic characterization of the cells used in the vascular 
model was performed by analyzing the surface and intracellular 
markers of hASC and HUVEC separately (Tab. 2). The mesen-
chymal stem cell markers CD73, CD90 and CD105 were highly 
expressed (> 64%) in hASC. Also, pericyte marker PDGFR-β 
(CD140b) was strongly expressed (> 52%) in the hASC popu-
lation. Hematopoietic marker CD34 was moderately expressed 
(< 40%), whereas the expression levels of endothelial markers 
Tab. 2: Phenotypic characterization of human adipose stromal cells (hASC p1) and human umbilical vein  
endothelial cells (HUVEC p3)  
The expression of surface and intracellular markers was analysed by flow cytometry (5000 events per sample).  
Results are shown as percentage of positive cells.
Cells Protein Antigen Positive cells % SD n
hASC vWf von Willebrand factor 7.5 4.3 11
 CD144 vascular endothelial cadherin 1.4 2.9 9
 eNOS endothelial nitric oxide synthase 0.7 1.1 8
 CD140b PDGF Receptor b 52.8 16.0 6
 CD45 leukocyte common antigen 16.4 14.9 6
 CD14 expressed on monocytes/macrophages 0.7 0.8 7
 CD68 expressed on macrophages and monocytes 1.1 1.4 8
 CD309 VeGF receptor 2 1.2 3.5 6
 CD31 platelet endothelial cell adhesion molecule 0.9 3.1 6
 NG2 chondroitin proteoglycan 31.8 29.1 8
 CD90 thy-1 82.9 15.5 10
 CD105 endoglin 64.1 27.1 7
 CD73 ecto-5'-nucleotidase 88.8 6.7 12
 CD34 sialomucin-like adhesion molecule 40.9 34.3 10
HUVEC vWf von Willebrand Factor 45.6 13.2 13
 CD144 vascular endothelial cadherin 70.6 14.7 17
 CD309 VeGF receptor2 31.4 17.0 10
 CD73 ecto-5'-nucleotidase 68.7 17.1 14
 CD68 expressed on macrophages and monocytes 1.9 10.1 11
 eNOS endothelial nitric oxide synthase 48.4 18.4 13
 CD105 endoglin 57.4 26.6 9
 CD34 sialomucin-like adhesion molecule 43.1 18.6 9
 CD31 platelet endothelial cell adhesion molecule 81.3 13.7 8
 CD140b PDGF Receptor b 7.2 8.7 8
 NG2 chondroitin proteoglycan 2.0 1.1 7
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HUVEC in EGM-2 medium (control) and in VSM. Moderate 
differences in the expression of angiogenesis-related genes were 
detected between EGM-2 and VSM. In VSM, nine genes were 
up-regulated (Angpt1, F3, FIGF, IGF-I, LEP, MDK, MMP2, 
MMP9, PGF) and nine (CCL11, CXCL9, FN1, IL6, IL8, SER-
PINE1, TGFB2, THBS2, TIMP1) were down-regulated in com-
parison to EGM-2 medium. Fold changes and statistical sig-
nificances of the up- and down-regulated angiogenesis-related 
genes are shown in Table 3. 
3.4  Maturation stage, extracellular matrix 
production and 3D properties of the vascular-like 
network formed in VSM
Immunocytochemical staining of the vascular-like network 
formed in VSM showed the presence of platelet derived growth 
factor receptor-β (PDGFRβ) positive cells (Fig. 3D). Also, 
smooth muscle actin (SMA), smooth muscle myosin heavy 
chain (SMMHC) and contractile smooth muscle calponin posi-
tive cells surrounded the tubule structures (Fig. 3A-C). CD144 
and occludin positive staining indicated the presence of adher-
ence junctions between endothelial cells (Fig. 3E-F).
rum-free medium enabled stable cell attachment and induced a 
dense, connected vascular-like network with intact tubule walls. 
Human serum was found to induce a denser and more connected 
vascular-like network than FBS (Fig. 1).
In the supplement optimization several different concentra-
tions of ascorbic acid, heparin sodium salt and hydrocortisone 
were tested and compared to vascular-like network formed 
in EGM-2 medium. An optimal vascular-like network for-
mation was obtained with the AA concentration 100 µg/ml 
(Fig. 2A), HE concentration 0-500 ng/ml (Fig. 2B) and HY 
concentration 0.2 µg/ml (Fig. 2C). The results showed that a 
vascular-like network was formed in the absence of HE sup-
plement with minor morphological differences. However, low 
concentrations of HE (50-500 ng/ml) increased the total area 
of the vascular-like network significantly compared to EGM-
2 medium (Fig. 2B). 
3.3  Expression of angiogenesis-related genes  
in VSM compared to EMG-2
Expression of 84 angiogenesis-related genes was analyzed 
from a vascular-like network formed in co-culture of hASC and 
Fig. 1: Morphology of vascular-like network in 
different stimulation media with different serum 
concentrations 
Vascular-like networks were stained against Col IV (FItC, 
green) and vWf (tRItC, red). Co-localization is shown in 
the merged image. Vascular-like network formed in (A) 
commercial eGM-2 medium with 2% FBS, (B) serum-free 
VSM, (C) eGM-2 with 2% HS and (D) basal SFM. Scale 
bars 100 µm in each figure. Col IV= collagen type IV, 
VWF= von Willebrand factor, VSM= vascular stimulation 
medium, FBS= fetal bovine serum, HS= human serum, 
SFM=basal serum free medium.
Fig. 2: Vascular-like network formation (area in pixels) in different 
concentrations of (A) ascorbic acid, (B) heparin sodium salt and  
(C) hydrocortisone in VSM
Vascular-like network formed in VSM supplemented with different 
concentrations of ascorbic acid, heparin sodium salt or hydrocortisone were 
compared to eGM-2 medium and differences presented as follows:  
p < 0.05*, p < 0.01** and p < 0.001***. An optimal vascular-like network 
formation was obtained with 100 µg/ml ascorbic acid and 0.2 µg/ml 
hydrocortisone. Heparin sodium salt could be used in concentrations 
0-500ng/ml. Results are depicted as total area with standard deviations,  
n = 5 in each supplement and concentration. 
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The phenotypic analysis of the building blocks of the vascular 
model, i.e., the hASC and HUVEC, was performed using flow 
cytometry. HUVEC showed a strong expression of CD105 (en-
doglin), suggesting an active rather than quiescent state of the 
cells (Bernabeu et al., 2009). Interestingly, a recent study report-
ed a minor role of endoglin in vasculogenesis whereas VEGF-
induced angiogenesis was severely impaired in an endoglin de-
ficient mouse embryonic stem cell model (Liu et al., 2014). The 
high expression of CD144 and CD31 supports the active status 
of HUVEC in the formation of intercellular junctions. The level 
of CD73, a 5'-ectonucleotidase that normally suppresses pro-
inflammatory responses in human endothelial cells (Grunewald 
and Ridley, 2010) was high in our HUVEC analysis. Pericyte 
markers NG2 and CD140b (PDGFRβ) were low, indicating the 
absence of mural cells in the HUVEC population. 
This study confirms the earlier results shown by us (Sarkanen 
et al., 2012) and others (Lindroos et al., 2010; Traktuev et al., 
2008) that the stromal-vascular fraction extracted from adipose 
tissue is heterogenic. hASC expressed mesenchymal stem cell 
markers CD90, CD105 and CD73 at high levels, showing the 
Electron microscopic analysis confirmed the microstructure 
of the tubules formed in VSM. Tubules were shown to have 
a lumen, basement membrane and junctions (Fig. 4A-C). The 
three dimensional structure of the vascular-like network and 
shape of the tubules can be seen in the close-up image Figure 
4D.
4  Discussion
Present chemical safety testing and non-clinical drug develop-
ment rely mainly on animal biology although relevant safety 
testing data should be of human origin. Further, in vitro test 
systems should be thoroughly characterized in their human rel-
evance and functionality. In this study, we developed a novel 
vascular stimulation medium (VSM) and further characterized 
the in vitro human vascular model developed by us (Sarkanen et 
al., 2012). This defined in vitro vascular model has the potential 
to be used for safety assessment of compounds and for tissue 
engineering applications.
Tab. 3: Fold changes and statistical significance of expression of angiogenesis-related genes in vascular-like network formed 
in VSM compared to EGM-2 medium
Genes Target Fold change 2^(- ΔΔCT) Statistical significance
Up-regulated genes    
ANGPT1 angiopoietin 1 2.964 *
F3 coagulation factor III 3.255 *
FIGF vascular endothelial growth factor D 3.043 ns
IGF-I insulin-like growth factor I 16.555 ns
LEP leptin 2.932 ns
MDK neurite growth-promoting factor 2 2.06 ns
MMP2 matrix metallopeptidase 2 2.011 *
MMP9 matrix metallopeptidase 9 3.919 *
PGF placental growth factor 2.319 *
ANGPT2 angiopoietin 2 1.769 **
Down-regulated genes   
CCL11 chemokine ligand 11 2.613 ns
CXCL9 chemokine ligand 9 2.197 ns
FN1 fibronectin 1 2.295 *
IL6 interleukin 6 2.331 ns
IL8 interleukin 8 2.546 ns
SERPINE1 serpin peptidase inhibitor 3.465 **
TGFB2 transforming growth factor beta 2 2.080 ns
THBS2 thrombospondin 2 2.085 **
TIMP1 tIMP metallopeptidase inhibitor 1 5.01 **
VEFG-A vascular endothelial growth factor A 1.804 ns
TGFβ1 transforming growth factor beta 1 1.807 *
FGF-2 fibroblast growth factor 2 1.917 ns
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there is a moderate expression of CD34; these are markers for 
mesenchymal stem cells and endothelial progenitors. A hASC 
population of CD90+/CD34+ cells was shown to be capable 
of differentiating into endothelial cells and form capillary-like 
structures (De Francesco et al., 2009). 
The expression of mature endothelial cell markers CD31 and 
CD144 in the hASC population was very low. Interestingly, 
there is a report suggesting that adipose stromal cells may en-
hance endothelial differentiation of progenitor cells (Rubina et 
al., 2009). However, another essential marker for endothelial 
progenitor cells, CD309 (VEGFR2) (Yoder, 2012), showed very 
low expression in the six hASC lines that were analyzed in this 
study. Therefore, the presence of an endothelial progenitor cell 
population in the stromal-vascular fraction needs to be studied 
further. 
Serum-free VSM was shown to produce a reproducible, ex-
tensive mature vascular-like network and provide a suitable al-
ternative to the commercial EGM-2 medium (previously used 
in the model, containing 2% FBS). Serum had a strong corre-
lation with vascular-like network formation. At higher serum 
(10%) concentrations the network was shorter with broken tu-
bule walls, and random detachment of the cell layer occurred 
(data not shown). In low- or serum free (0-2%) environment, 
presence of a cell population with multilineage differentiation 
potential. Pericyte markers CD140b (PDGFRβ) and NG2 were 
expressed at high to moderate level, supporting the finding that 
pericytes from the hASC population are lining the vascular-like 
network in our model. 
We also analyzed whether the population of endothelial pro-
genitor cells capable of vasculogenesis could be found in hASC 
as suggested by some earlier reports (Sarkanen et al., 2012; 
Miranville et al., 2004; Heydarkhan-Hagvall et al., 2008). The 
results showed that, in addition to the high expression of CD90, 
Fig. 3: Vascular-like network formed in serum-free VSM 
shows vascular maturation markers at day 6
α-vWf-staining is shown in red in all figures. (A) Calponin-,  
(B) SMA- and (C) SMM-positive cells surrounding the vascular-like 
network. (D) α-PDGFRβ stained pericytes are located along  
the tubules. (e) CD144- and (F) occludin-positive junctions can be 
found in the tubule structures. Scale bar 100 μm in each image. 
VSM= vascular stimulation medium, vWf = von Willebrand factor, 
SMA = smooth muscle actin, SMM = smooth muscle myosin  
heavy chain, PDGFRβ = platelet derived growth factor receptor β, 
CD144 = vascular endothelial cadherin.
Fig. 4: Transmission (A, B, C) and scanning (D) 
electron microscopy images of the vascular-like 
network cultured in VSM
(A) Mature tubule with lumen = L and extracellular matrix 
= ECM. The lumen is filled with debris from the apoptotic 
cells. Scale bar 2 µm. (B) Close-up image with basement 
membrane = BM, adherence junction = AJ and lumen of 
the vascular-like tubules. Scale bar 2 µm. (C) tubule in 
earlier stage of vascular development showing endothelial 
cell with large nucleus (white arrow), lumen, adherence 
junctions and eCM. Scale bar 2 µm. D) Scanning electron 
microscopy image shows the 3D structure and the tubule 
shape of the vascular-like network. Scale bar 2 µm.  
VSM = vascular stimulation medium. 
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cular-like network. However, it produced cell aggregates at 
high concentrations whereas a lack of hydrocortisone induced 
a sparse vascular-like network. Our results suggest that hydro-
cortisone acts as a mitogen in the vascular model. Other sup-
plements of the VSM included ITS (insulin, transferrin, selenic 
acid medium supplement), BSA, sodium pyruvate, L-glutamine 
and T3 (3,3',5-triiodo-L-thyronine). The concentrations of these 
supplements were reported earlier by us (Vuorenpää et al., 2014) 
and were used in this study with minor modifications. 
Lumen formation is critical for the transformation of cords in-
to a perfusable vascular system (Charpentier and Conlon, 2014). 
Electron microscopic analysis assured the formation of 3D vas-
cular microstructure including lumen in the novel VSM. Tubules 
at different stages of lumen development were detected, indicat-
ing the ongoing process of network formation at day 6. The ini-
tiation of lumen development is triggered by apical-basal polar-
ity of the endothelial cells in which CD144 plays a critical role 
in promoting the localization of polarity markers (Charpentier 
and Conlon, 2014). The electron microscopic analysis as well as 
immunocytochemistry results of this study showed that hASC 
and HUVEC co-culture actively produces extracellular matrix 
(ECM) components, including fibrillins, thus creating natural 
3D scaffold around them. The reciprocal interaction between 
ECM stroma and vascular network is important in directing ves-
sel growth (Hoying et al., 2014; Du et al., 2014). The hASC and 
HUVEC co-culture gives mechanical support for other target 
cells, e.g., cardiomyocytes, and, additionally, the microenviron-
ment formed by the co-culture enhances target cell viability as 
reported previously (Vuorenpää et al., 2014). This 3D vascular 
model provides a more in vivo-like test system without an artifi-
cial scaffold that may interfere with the cell-cell interactions or 
affect the toxicological applications of the model.
In the genotypic analysis 84 human angiogenesis-related 
genes were studied. Nine genes were down-regulated and nine 
genes up-regulated in VSM compared to EGM-2 medium. The 
expression of angiopoietin 1, a marker for mature tubules, was 
significantly higher in VSM compared to EGM-2 medium, 
whereas angiopoietin 2, a marker for the early stage, i.e., sprout-
ing angiogenesis, was slightly upregulated in VSM. VEGF-A and 
FGF-2, indicators of early stage angiogenesis, were moderately 
yet not significantly down-regulated in VSM compared to EGM-
2. Since both media included VEGF and FGF-2, the expression 
of these growth factors was apparently unnecessary for the 
cells. On the contrary, placental growth factor (PGF) showed 
modest up-regulation in VSM. PGF and its receptor VEGFR-1 
are minimally expressed in adult quiescent vasculature, but are 
markedly up-regulated during pathological conditions (Carme-
liet et al., 2001). TGFβ1, a marker for tubule maturation, was 
slightly down-regulated in VSM. Vessel maturation relies partly 
on TGF-β signaling and TGF-β stimulates mural cell prolif-
eration and migration and production of ECM (Potente et al., 
2011). The gene expression analysis confirms the finding that 
VSM enhances the maturation of the vascular-like network.  
Interestingly, the expression of insulin like growth factor 
(IGF-I) showed the highest up-regulation in VSM. IGF-I treat-
ment in myocardial infarction has been shown to increase cir-
culating angiogenic growth factors, thus providing protection 
network formation increased, tubules were highly branched and 
tubule walls remained intact. In serum-free conditions we de-
tected thinner and more branched tubules as also reported by 
Yang and Xiong (Yang and Xiong, 2012). Serum-free medium 
is ideal for use in drug development, since serum is a complex 
mixture of components with unknown composition and protein 
binding affinities (Shen et al., 2013). Furthermore, a tissue con-
struct aimed for clinical therapy should be cultured in human 
serum or, preferably, in a serum-free environment to avoid the 
risk of infection and severe immune reactions in the recipient 
(Patrikoski et al., 2013; Lindroos et al., 2011, 2010; Holm et 
al., 2010). 
Fetal bovine serum (FBS), although being the most widely 
used growth supplement, holds ambiguous, unknown effects for 
cell culture and also raises ethical concerns due to the number 
of bovine fetuses needed for serum production (Gottipamula 
et al., 2013; Brunner et al., 2010). In this study, microscopical 
analysis showed that HS was more inductive for vascular-like 
network formation than FBS. Replacement of FBS with HS has 
been reported to support equal or higher proliferation rates and 
differentiation capacity of adipose stromal cells (Lindroos et al., 
2011; Brunner et al., 2010). Furthermore, human mesenchymal 
stem cells have been shown to maintain their immunophenotype 
and multilineage potential in serum-free medium (Patrikoski et 
al., 2013; Mark et al., 2013).
In this study we developed a defined vascular stimulation 
medium since commercial media producing companies do not 
necessarily publish the specific composition of their media. 
This might complicate the use of commercial media in toxico-
logical studies as medium components may interact with test 
compounds. In addition to commonly used VEGF and FGF-2 
defined by us earlier (Sarkanen et al., 2011), we found that the 
network formation can be further improved by addition of AA, 
HE and HY. Ascorbic acid (vitamin C) is an essential nutrient for 
human endothelial cells necessary for their effective migration 
and for the synthesis of collagen type IV, an important compo-
nent of basement membrane (Telang et al., 2007). In this study, 
the formation of basement membrane around the tubules was 
impaired in the absence of AA (data not shown). However, AA 
inhibited angiogenesis at high concentrations (1000-2000 µg/
ml) as reported previously (Mikirova et al., 2008). Therefore, 
AA is essential for collagen IV formation in basement mem-
brane at low concentrations.
Although HE is needed for the attachment of some growth fac-
tors to their cell surface receptors (Ashikari-Hada et al., 2005) 
and was found to be beneficial for the network formation, it did 
not induce a significant advantage to the morphology or branch-
ing of the tubules. Since HE is an animal derived substance it 
should rather be avoided where clinical applications are con-
cerned. The lack of need for added HE can be explained by the 
secretion of perlecan by HUVEC (Murikipudi et al., 2013; Sch-
lessinger et al., 2000). Our results correlate with earlier studies 
(Khorana et al., 2003; Jung et al., 2001) showing that HE inhib-
its vascular-like network formation at high concentrations.
Hydrocortisone, although not pro-angiogenic itself, has a 
beneficial effect on angiogenesis (Goding, 2009). In this study, 
hydrocortisone increased the number of branches in the vas-
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inflammatory responses in human endothelial cells. J Inflamm 
against myocardial ischemia in rats (Mathews et al., 2011). In 
vitro IGF-I stimulates migration and tube-forming activity of 
endothelial cells (Shigematsu et al., 1999; Nakao-Hayashi et 
al., 1992). Also leptin, a hormone secreted by adipocytes, was 
found to be up-regulated. Leptin signaling acts as a link between 
adipocytes and the vasculature (Sierra-Honigmann et al., 1998). 
It also increases the production of VEGF and enhances the ex-
pression of MMP-2 and MMP-9 (matrix metallopeptidases) in 
HUVEC (Park et al., 2001). This was seen as an up-regulation 
of MMP-2 and MMP-9 enzymes that are involved in degrada-
tion of the ECM at the early stages of angiogenesis (Kasper et 
al., 2007; Cornelius et al., 1998). 
In vivo studies in mice have revealed that the adult quiescent 
vasculature becomes less dependent on VEGF for its mainte-
nance (Gerber et al., 1999). However, during pathological con-
ditions – such as ischemia, inflammation or malignancy – an-
giogenic endothelial cells are stimulated by increased VEGF 
levels (Carmeliet et al., 2001). The VEGF signaling pathways 
have been conclusively identified as central for the processes of 
vasculogenesis, angiogenesis and lymphangiogenesis. VEGF-
D induces sprouting lymphangiogenesis when overexpressed 
in transgenic mice and also in various tumor models (Lohela 
et al., 2009). The up-regulation of vascular endothelial growth 
factor D (FIGF) as a marker for lymphangiogenesis suggests 
the versatile modifications of our vascular model. In future ap-
plications, it may be possible to replace HUVEC with lymphatic 
endothelial cells to form a lymphangiogenesis model.
5  Conclusion
The vascular model characterized in this study forms a vascular-
like network with mature properties. The developed novel medi-
um provides a valid alternative to commercial EGM-2 medium 
and benefits the use of the model in toxicological studies as well 
as in efficacy studies in drug development. This characterized 
vascular model is currently under intra-laboratory validation 
that is performed according to OECD guidance document No. 
34 (OECD, 2005) to verify the reliability and human relevance 
of the test system with known reference chemicals. The vali-
dated vascular model will be used in toxicity testing and can be 
combined with other target cell types from different tissues to 
create complex, vascularized tissue models. 
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Abstract The interaction between different cardiac cells has
shown to be important for critical biological properties includ-
ing cell survival, proliferation, differentiation and function.
The improvement of culture conditions with different cell
types and to study their effects on cardiomyocyte viability
and functionality is essential. For practical applications includ-
ing general toxicity testing, drug development and tissue engi-
neering it is important to study whether co-cultures have
additional advantages over cardiomyocyte monoculture. Two
multicellular in vitro cardiovascular constructs devoid of added
biomaterial were developed in this study. In the first construct,
neonatal rat cardiomyocytes (CM) were seeded on vascular-
like network formed by human umbilical vein endothelial cells
(HUVEC) and human adipose stromal cells (hASC). In the
second construct, CMs were seeded on vascular-like network
formed by HUVECs and human foreskin fibroblasts. The
ability of these two vascular-like networks to support the
viability and functionality of CMs was analyzed. Different
culture media compositions were evaluated to support the
development of optimal cardiovascular construct. Our results
demonstrate that both vascular-like networks markedly im-
proved CM viability and functionality. In the constructs, co-
localization of CMs and vascular-like networks was seen.
Multicellular constructs also allowed synchronized contractil-
ity of CMs. Serum-free medium supplemented with vascular
endothelial growth factor and basic fibroblast growth factor
was found to provide the most optimal conditions for cardio-
vascular construct as an entity. In conclusion, when combining
a vascular-like network with CMs, the viability and function-
ality of CMs was markedly improved. The results suggest that
the cardiovascular constructs developed provide a promising
new tool for the assessment of toxicological and safety phar-
macological effects of compounds in vitro.
Keywords Angiogenesis . Primary cardiomyocytes . Human
adipose stromal cells, in vitro cardiotoxicity
Introduction
The heart is a complicated organ having multiple cell types
and highly organized structure and function. The major cell
types present in the human heart are cardiomyocytes (CMs),
smooth muscle cells, endothelial cells (ECs) and fibroblasts
(Nag 1980; Banerjee et al. 2007). In adaptation to in vitro
culture conditions, primary CMs have a tendency to change in
morphology, dedifferentiate, and stop beating (Montessuit
et al. 2004; Banyasz et al. 2008).
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The interactions between coronary vasculature and myo-
cardium are bidirectional (Bhattacharya et al. 2006) and active
through the adult life affecting cardiac growth, function, and
rhythmicity (Brutsaert 2003). Vascular ECs produce a variety
of auto- and paracrine agents including VEGF, angiopoietin,
and nitric oxide that influence cardiac metabolism, growth,
contractility, and rhythmicity of the heart (Brutsaert 2003).
Previously, it has been shown that ECs and fibroblasts assist
the generation of a functional heart tissue construct and form
vascular networks among CMs (Caspi et al. 2007; Radisic
et al. 2008). Also CM proliferation has been found to increase
in the presence of ECs and fibroblasts (Stevens et al. 2009;
Lesman et al. 2010; Kreutziger et al. 2011). As the importance
of other cardiac cells to the viability and functionality of CMs
has been shown, there are recent reports of several tissue
engineering constructs based on co-culture of main cell types
present in heart tissue (Sekine et al. 2008; He et al. 2012;
Hussain et al. 2013). However, in spite of the extensive
research the effect of medium with optimal serum concentra-
tion and additional supplements to support the growth of
cardiac tissue constructs has not been studied thoroughly
(Sekine et al. 2008; Valarmathi et al. 2010; He et al. 2012;
Hussain et al. 2013).
The heart has been shown to be particularly prone to toxic
effects of both cardiac and noncardiac drugs. Cardiotoxic
substances can cause severe effects on heart functions includ-
ing decreased contractility and increased arrhythmia and is-
chemia (Lasser et al. 2002; Redfern et al. 2003; Lexchin
2005). Therefore, there is a need for reliable in vitro cardiac
model for assessment of toxicological and safety pharmaco-
logical potential of human pharmaceuticals in drug develop-
ment (Kettenhofen and Bohlen 2005). Functional in vitro
cardiac construct would also benefit the generation of future
transplantable cardiac tissue implants.
We have previously developed a three-dimensional
vascular-like network comprised of co-culture of human
umbilical vein endothelial cells (HUVEC) and human adi-
pose stromal cells (hASC) (Sarkanen et al. 2012). Adipose
stromal cells (ASCs) have shown to produce significant
amounts of angiogenic factors and cytokines including
VEGF, hepatocyte growth factor and angiopoietin
(Rehman et al. 2004; Rubina et al. 2009; De Siena et al.
2010). Although several tissue engineering strategies rely on
the use of scaffolds, these scaffolds may interfere the cell–
cell interactions and induce inflammatory reaction (Shimizu
et al. 2003; Norotte et al. 2009). The three-dimensional and
intense vascular-like network of our HUVEC+hASC co-
culture could serve as a natural scaffold for in vitro tissue
models (Sarkanen et al. 2012). In addition, we have present-
ed another human cell-based in vitro angiogenesis assay
based on co-culture of fibroblasts and HUVECs that can be
used for standardized testing of modulators of angiogenesis
(Sarkanen et al. 2011).
In this study, we developed two cardiovascular constructs,
consisting of two different previously developed vascular-like
networks (Sarkanen et al. 2011; 2012) of different origin
(HUVEC+hASC and HUVEC+fibroblast) and neonatal rat
CMs. Both constructs are based on co-cultures of three cell
types naturally resident in the heart, devoid of added bioma-
terials. The aim was to evaluate the capability of these two
different vascular-like networks to support CM viability and
functionality in an optimal medium. The results demonstrated
that both vascular-like networks provided substantial benefit
for the development of functional cardiovascular construct as
the networks led to extended viability and contractile capacity
of CMs.
Materials and Methods
Cells Ethics statement. This study conforms to the principles
outlined in the Declaration of Helsinki. The human adipose
tissue samples were obtained from surgical operations at
Tampere University Hospital, Tampere, Finland with individ-
ual written informed consents. The use of human adipose
tissue derived cells (hASCs) in this study was approved by
Ethics Committee of the Pirkanmaa Hospital District,
Tampere, Finland (permit number R03058). Human umbilical
cords were received from caesarean sections at Tampere
University Hospital, Tampere, Finland with individual written
informed consent. The use of HUVECs in this study was
approved by the Ethics Committee of the Pirkanmaa
Hospital District, Tampere, Finland (permit number
R08028). All animal experiments in this study were per-
formed according to the Finnish animal protection laws and
approved by the Department for Social Welfare and Health
Services of State Provincial Office of Western Finland.
Euthanasia was performed by decapitation, a method ap-
proved in Directive 2010/63/EU.
Isolation and culture of human adipose stromal cells. HASC
were isolated from human adipose tissue by using mechan-
ical and enzymatic procedure as described previously
(Gimble and Guilak 2003; Sarkanen et al. 2012). Briefly,
human adipose tissue specimens were cut into small pieces,
enzymat ical ly diges ted with 0.05% col lagenase
I (Invitrogen, Paisley, Scotland, UK) in Dulbecco’s
Modified Eagle’s Medium Nutrient Mixture F-12
(DMEM/F-12, Gibco, Invitrogen, Carlsbad, CA) for
60 min at 37°C in a gyratory water bath. Then the digested
tissue was centrifuged at 600×g for 10 min in room tem-
perature (RT). Then the digested tissue was filtered through
a 100 μm filter (Sarstedt, Nümbrecht, Germany), centri-
fuged and filtered through a 40 μm filter (Sarstedt). The
Cells were seeded into 75 cm2 flasks (Nunc EasyFlask™,
Nunc, Roskilde, Denmark) in DMEM/F-12 supplemented
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with 1% L -glutamine (L -glut, Gibco), 1% antibiotic–
antimycotic mixture (AB/AM, Gibco) and 10% human serum
(HS, Cambrex, East Rutherford, NJ). The next day, the cells
were washed several times with PBS. HASCmedium (Table 1)
was changed three times a wk and cells were subcultured when
confluent. Cells were tested for mycoplasma contamination
(MycoAlert® Mycoplasma Detection Kit, Lonza Group Ltd,
Basel, Switzerland) before experimental use.
Isolation and culture of human umbilical vein endothelial
cells . HUVECs were isolated from human umbilical cord
vein by using enzymatic procedure as described previously
(Jaffe et al. 1973; Sarkanen et al. 2011). Briefly, the cord was
separated from the placenta and the umbilical vein was can-
nulated with a 20G needle. The needle was secured by
clamping the cord over the needle with a surgical clamp.
The vein was perfused with PBS to wash out blood and then
the opposing end of the umbilical vein was clamped with a
surgical clamp. Subsequently, the vein was infused with
0.05% collagenase I. The umbilical cord was incubated in a
water bath at 37°C for 15 min. After incubation, the collage-
nase I solution containing HUVEC was flushed from the cord
by perfusion with PBS into a 50-ml polypropylene tube
(Sarstedt). The cells were centrifuged at 200×g for 10 min,
washed once with medium and centrifuged again. After last
centrifugation the cells were resuspended in EGM-2 BulletKit
Table 1. Culture media used for
cell culture set ups
HS human serum, AB/AM antibi-
otic–antimycotic mixture, EBM-2
endothelial cell basal medium,
FBS fetal bovine serum, hFGF-β
human basic fibroblast growth
factor beta, hVEGF human vas-
cular endothelial growth factor,
IGF insulin-like growth factor,
hEGF human epidermal growth
factor, GA-1000 gentamycin,
NEAA non-essential amino acids,
P/S penicillin/streptomycin, BSA
bovine serum albumin, ITS insu-
lin–transferrin–sodium selenite
media supplement, T3 3,3′,5-
triiodo-L-thyronine sodium salt
aDMEM/F-12 Dulbecco’s Modi-
fied Eagle’s Medium Nutrient
Mixture F-12
b Dulbecco’s Modified Eagle’s
Medium/Ham’s Nutrient Mixture
F-12
Culture media Basal medium Supplements
hASC medium DMEM/F-12 (Gibco,
Invitrogen, USA)a
10% HS (Cambrex, USA)
1% L-glutamine (Gibco)
1% AB/AM (Gibco)
EGM-2 BulletKit medium
(Lonza Group Ltd,
Switzerland)
EBM-2 (Lonza) SingleQuots supplements
(Lonza Group Ltd, Switzerland)
with unknown concentrations of:
FBS
hydrocortisone
hFGF-β
hVEGF
IGF
ascorbic acid
hEGF
GA-1000
heparin
Fibroblast medium Minimum Essential Medium
with
Earle’s salts, w/o L-
glutamine
10% FBS (Gibco)
1% L-glutamine
1% NEAA (Gibco)
1% AB/AM
CM seeding medium (SM) DMEM/F-12 (Sigma-Aldrich,
USA)b
10% FBS (Invitrogen, USA)
100 IU/ml P/0.1 mg/ml S (Lonza,
Belgium)
2.56 mM L-glutamine (Sigma-Aldrich)
CM serum-free medium
(SFM)
DMEM/F-12 (Sigma-Aldrich)b 10% BSA (Sigma-Aldrich)
2.8 mM NaPyruvate (Lonza)
2.56 mM L-glutamine
ITS (1 μM insulin, 5.64 μg/ml
transferrin,
32 nM selenium, Lonza)
100 IU/ml P/0.1 mg/ml S
0.1 nM T3 (Sigma-Aldrich)
Vascular-like network
(HUVEC+fibroblast)
medium
EBM-2 2% FBS
0.1% GA-1000 (Lonza)
1 mM L-glutamine
10 ng/ml hVEGF (Sigma-Aldrich)
1 ng/ml hFGF- β (Sigma-Aldrich)
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medium (Lonza Group Ltd) (Table 1) consisting of EBM-2
basal medium and SingleQuots supplements including fetal
bovine serum (FBS), hydrocortisone, human FGF-β, VEGF,
insulin-like growth factor (IGF), ascorbic acid, human epider-
mal growth factor (hEGF), GA-1000 and heparin (Lonza
Group Ltd) and seeded into 75 cm2 flasks. The medium was
changed three times a week and cells were subcultured
when confluent. Cells were tested for mycoplasma contam-
ination (MycoAlert® Mycoplasma Detection Kit, Lonza)
before experimental use.
Isolation and culture of human foreskin fibroblasts . Human
foreskin fibroblasts were purchased from American Type
Culture Collection (CRL-2522; ATCC, Manassas, VA). The
Cells were cultured in fibroblast medium (Table 1) consisting
of Minimum Essential Medium with Earle’s salts, w/o L-
glutamine supplemented with 10% FBS, 1% L-glutamine,
1% NEAA, and 1% antibiotic–antimycotic mixture in
75 cm2 flasks. Medium was changed three times a wk and
cells were subcultured when confluent. Cells were tested for
mycoplasma contamination (MycoAlert® Mycoplasma
Detection Kit, Lonza) before experimental use.
Isolation of neonatal rat cardiomyocytes. Neonatal rat
cardiomyocytes were harvested from 1- to 4-d-old Sprague–
Dawley rat pups hearts as described by Uusimaa et al. (1992).
Briefly, the hearts were perfusedwith collagenase solution and
cut into 1–2-mm pieces. The heart pieces were incubated at
37°C for 5 min and the supernatant was discarded. Fresh 5 ml
of collagenase solution was added and this step was repeated
five times. The supernatants were collected and filtered
(100 μm) into 20 ml of seeding medium [SM, DMEM/F-12
(Sigma-Aldrich, St. Louis, MO), 10% FBS (Invitrogen,
USA), 100 IU/ml penicillin/0.1 mg/ml streptomycin (P/S,
Lonza, Belgium), 2.56 mM L-glutamine (Sigma-Aldrich)].
The cells were preplated for 45 min to reduce the number of
non-muscle cells and to achieve more pure neonatal rat car-
diomyocyte (NRC) population.
Cell culture set ups Neonatal rat cardiomyocyte monoculture.
After the preplating, the CMs were collected and seeded in
CM seeding medium (SM, Table 1) into 48-well plates
(Nunc, Thermo Fisher Scientific, Waltham, MA) at a den-
sity of 0.1–0.4×106 cells/cm2. The serum-free medium
(SFM, Table 1) consisting of DMEM/F-12, 2,5 mg/ml
bovine serum albumin (BSA, Sigma-Aldrich), 2.8 mM
sodium pyruvate (Lonza), 2.56 mM L-glutamine, insulin–
transferrin–sodium selenite media supplement (ITS,
Lonza; 1 μM insulin, 5.64 μg/ml transferring, 32 nM se-
lenium) and 100 IU/ml P/0.1 mg/ml S 0.1 nM 3,3′,5-
triiodo-L -thyronine sodium salt (T3, Sigma-Aldrich) was
changed five day after plating and thereafter every second
or third day.
Vascular-like network from co-culture of hASC and
HUVEC. The co-culture was constructed as described previ-
ously by Sarkanen et al. (2012). hASCs were seeded (p1–3) in
EGM-2 BulletKit medium (Table 1) into 48-well plates
(Nunclon™Multidishes, Nunc, Roskilde, Denmark) at a den-
sity of 20,000 cells/cm2. After 1–3 h HUVECs, were carefully
seeded (p4) on top of hASCs at a density of 4,000 cells/ cm2 in
EGM-2 BulletKit medium (Table 1). The seeding densities of
hASCs and HUVECs were chosen according to our previous
study (Sarkanen et al. 2012). The control medium inducing
vascular-like network formation was changed every second or
third day.
Vascular-like network from co-culture of HUVEC and
fibroblast. The co-culture was constructed as described pre-
viously by Sarkanen et al. (2011). Fibroblasts (p6–7) were
seeded at a density of 20,000 cells/cm2 in fibroblast medium
(Table 1) and grown for 1–3 d. HUVECs were carefully
seeded on top of the fibroblast culture at a density of 4,000
cells/cm2 in EGM-2 BulletKit medium (Table 1). The seeding
densities of fibroblasts and HUVECs were chosen according
to our previous studies (Sarkanen et al. 2011, 2012). The
following day and thereafter every second or third day
vascular-like network control medium (Table 1) was changed
to induce vascular-like network formation.
Cardiovascular constructs. CMs were carefully seeded on
top of the co-culture of hASC+HUVEC and HUVEC+fibro-
blast approximately after 24 h at a density of 0.1−0.4×106
cells/cm2. Cardiovascular construct 1 included HUVECs,
hASCs and CMs and cardiovascular construct 2 included
HUVECs, fibroblasts and CMs. The viability of cardiovascu-
lar constructs was assessed visually under phase contract
microscope inspecting the contraction of the cardiomyocytes
and tubule formation of the HUVECs, hASCs and fibroblasts
three to five times a wk.
Culture media. For the cardiovascular constructs, the media
were changed on the day after seeding of CMs. Altogether six
different media were tested (Table 2) all in at least duplicate
wells. The media were chosen to represent optimal culture
media for either CMs (culture media 1–2), co-culture of
HUVEC and fibroblasts (culture media 3–4) or co-culture of
hASC and HUVEC (culture media 5–6) (Sarkanen et al. 2011,
2012). In addition to cardiovascular constructs, all culture
media were tested also with CMs as monocultures. Cells were
cultured for either 10 or 14 d and the culture media were
changed three times a week.
Analysis Functionality of cardiac cell. The functionality of
CMs in the cardiovascular construct was studied with micro
electrode array (MEA). Cells are growing on top of the
electrodes on MEA well containing 60 titanium nitride-
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coated electrodes with which the field potential can be mea-
sured (Reppel et al. 2004).
The MEAwells were first hydrophilized with FBS for 30 min at
RTand then coatedwith 0.1%gelatin typeA (Sigma-Aldrich) for
1 h at RT. The co-culture of HUVEC and hASC forms thicker
vascular-like network [approximately 200 μm (Sarkanen et al.
2012)] than the co-culture of fibroblasts andHUVECs and is thus
more likely to isolate the electrical signal. Therefore, the ability of
this tissue construct to conduct electrical signal of CMs was
analyzed. hASCs and HUVECs were first plated on MEAwells
and the following d 400,000CMswere plated on top. The culture
medium 1 was used in MEA experiments.
The measurements were performed as described in Kujala
et al. (2011). Briefly, an MEA1060-Inv- BC amplifier, a 20-
kHz sampling rate and MC_Rack software (all from Multi
Channel Systems MCS GmbH) were used. The recordings
were performed at room air keeping the temperature at +37°C
with MEA amplifier’s heating element. To maintain the ste-
rility of the cultures the MEAs were covered with a
gas-permeable membrane (ALA Scientific, Farmingdale,
NY). The field potential signals were recorded twice during
each culture and for three minutes at a time. The measure-
ments were performed with MC_Rack, files converted with
MC_DataTool and signals analyzed with AxoScope.
Immunocytochemistry. The tubule formation was visualized
with EC specific antibody anti-von Willebrand factor (anti-
vWf, 1:100, F3520, Sigma) and CMswith an antibody against
cardiac troponin T (anti-Tnt 1:500, ab33589, Abcam). The
cells were washed three times with PBS, fixed with ice-cold
70% ethanol for 20 min, permeabilized with 0.5% Triton X-
100 (JT Baker, Phillipsburg, NJ) for 15 min and blocked for
unspecific staining with 10% BSA (Sigma) for 30 min. After
blocking, the cells were incubated with the primary antibody
pairs at 1 h at RT or in +4°C o/n. The cells were then washed
three times with PBS, incubated 30 min with secondary anti-
body polyclonal anti- rabbit IgG TRITC (1:50, Sigma) for
anti-vWf and polyclonal anti-mouse IgG FITC (1:100, Sigma)
for anti-Tnt at RT. Fluorescence was visualized with Nikon
Eclipse Ti-S microscope (Nikon, Tokyo, Japan) and the
images were further processed with NIS D.2 Elements
Table 2. Culture media (1–6)
used for development of in vitro
cardiovascular constructs
DMEM/F12 Dulbecco’s modi-
fied Eagle’s medium/Ham’s nu-
trient mixture F12, hVEGF hu-
man vascular endothelial growth
factor, hFGF-β human basic fi-
broblast growth factor beta, T3 3,
3′,5-triiodo-L-thyronine sodium
salt, BSA bovine serum albumin,
ITS insulin–transferrin–sodium
selenite media supplement, P/S
penicillin/streptomycin, EBM-2
endothelial cell basal medium,
FBS fetal bovine serum, HS hu-
man serum, IGF insulin-like
growth factor, hEGF human epi-
dermal growth factor, GA-1000
gentamycin
a Unknown concentration
(SingleQuots supplements,
Lonza)
Culture media Basal medium Serum Growth factors Additional supplements
1 DMEM/F12 – 10 ng/ml hVEGF
1 ng/ml hFGF-β
T3
NaPyruvate
BSA
L-glutamine
ITS
P/S
2 DMEM/F12 – 10 ng/ml hVEGF
1 ng/ml hFGF-β
T3
NaPyruvate
BSA
L-glutamine
ITS
P/S
Hydrocortisone
Heparin
Ascorbic acid
3 EBM-2 2% FBS 10 ng/ml hVEGF
1 ng/ml hFGF-β
Gentamicin
L-glutamine
4 EBM-2 2% HS 10 ng/ml hVEGF
1 ng/ml hFGF-β
Gentamicin
L-glutamine
5 EBM-2 2% HS hVEGFa
hFGF-βa
IGFa
hEGFa
Hydrocortisone
Ascorbic acid
GA-1000
Heparin
6 EBM-2 – hVEGFa
hFGF-βa
IGFa
hEGFa
Hydrocortisone
Ascorbic acid
GA-1000
Heparin
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(Nikon, Tokyo, Japan) and Adobe Photoshop CS3-software
(Adobe Systems Incorporated, San Jose, CA).
Analysis of vascular-like network formation. After immuno-
cytochemical staining, the vascular-like network formation was
analyzed with Nikon Eclipse TS100 microscope (Nikon,
Tokyo, Japan) from 48-well plate wells with ×40 magnifica-
tion. The analysis and grading was based on vascular-like
network formation, the length and the branches of tubules.
The vascular-like network formation was estimated visually
and compared to the control medium that gave value of 100%
vascular-like network formation. The chosen control media,
medium number 5 in cardiovascular construct 1 and medium
number 3 in construct 2 (Table 1) induced optimal vascular-like
network formation in HUVEC+hASC (Sarkanen et al 2012)
and HUVEC+Fibroblast co-culture (Sarkanen et al 2011),
respectively. In order to see the differences in vascular-like
network formation in control versus other media a linear
mixed-effect model was used. A linear mixed-effect model with
estimation as a dependent variable was fitted separately for
HUVEC+Fibroblast and hASC+HUVEC co-culture using
function lme in R (Software environment for statistical com-
puting and graphics, version 2.13.0, The R Foundation for
Statistical Computing). Experiments and media were used as
independent variables. Random intercept for parallel wells was
used together with independent random errors.
Analysis of cardiomyocyte contractility. After producing the
cardiovascular construct, the CM contractility was microscop-
ically assessed three to five times a wk. The contractility was
estimated as 10–30% (only few separate beating
cardiomyocytes or cardiomyocyte clusters per cm2,
Electronic supplementary materials (ESM), 30–50% (at most
half of the cardiomyocytes are beating per cm2, ESM), or 50–
70% (large areas of synchronously beating cardiomyocytes
per cm2, ESM).
Results
Op t ima l c u l t u re med i um f o r c a rd i o v a s c u l a r
construct. Different culture media (Table 2) were tested in
order to primarily support CM functionality and secondarily
to induce adequate vascular-like network formation. The re-
sults showed that the culture medium 1 (serum-free culture
medium supplemented with 10 ng/ml VEGF and 1 ng/ml
FGF) and 2 (serum-free culture medium supplemented with
10 ng/ml VEGF, 1 ng/ml FGF, ascorbic acid, hydrocortisone
and heparin) improved most efficiently the cell viability in
cardiovascular constructs as an entity (Table 3). Culture me-
dium 1 provided 50–70% contractility of CMs and the
vascular-like network formation was 34.7% and 68.9% in
cardiovascular construct 1 and 2, respectively. Culture medi-
um 2 provided a 111.4% and 114.3% induction for vascular-
like network formation in cardiovascular construct 1 and 2,
respectively, but the amount of contractile CMs was more
diverse (30–70%). Since medium 1 provided a stronger, more
synchronic and more repeatable cardiac contractility, it was
chosen for further experiments. Media 3–6 were optimal for
vascular-like network formation but only 10–30% of CMs
were contractile. Moreover, the contractility decreased after
7 d in vitro culture.
Functionality of cardiomyocytes in the absence and presence
of vascular-like network. In this study, two different vascular-
like networks as a supporting platform for CMs were evalu-
ated. The results demonstrated that both vascular-like
networks were able to support CM viability. In the
Table 3. Cardiomyocyte contractility and vascular-like network formation in different culture media
Culture media Cardiovascular construct 1 (HUVEC+hASC+CM) Cardiovascular construct 2 (HUVEC+fibroblast+CM)
Cardiomyocyte
contractility (%)a
Vascular-like network formationb n Cardiomyocyte
contractility (%)a
Vascular-like network formationb n
Mean (%) COV (%) p value Mean (%) COV (%) p value
1 50–70 34.69 22.01 0.00 7 50–70 68.89 15.30 0.00 9
2 30–70 111.40 5.73 0.13 5 30–70 114.3 13.23 0.32 7
3 10–30 17.86 40.00 0.00 4 10–30 106.7 9.68 6
4 10–30 21.43 38.49 0.00 4 10–30 126.7 12.89 0.057 6
5 10–30 97.62 11.02 6 10–30 84.00 31.04 0.18 5
6 10–30 105.7 12.09 0.12 5 10–30 86.67 26.65 0.09 3
COV coefficient of variation
p >0.05 differences are not significant
a 10–30% = only few separate beating cardiomyocytes or cardiomyocyte clusters/cm2 , 30–50% = at most half of the cardiomyocytes are beating/cm2 ,
50–70% = large areas of synchronously beating cardiomyocytes/cm2
b Compared to the control medium 5 (or 3) with value of 100% vascular-like network formation in construct 1 (or 2)
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cardiovascular construct 2 (HUVEC+fibroblast+CM), the
formation of vascular-like structures was less dense compared
to construct 1 (HUVEC+hASC+CM) (Fig. 1). The orienta-
tion of vascular-like network seemed more parallel in
Figure 1. The formation of
vascular-like network in
cardiovascular construct 1 in (A)
culture medium 1, (B) culture
medium 2, (C) culture medium 3
and (D) culture medium 4, (E)
culture medium 5 and (F) culture
medium 6. The formation of
vascular-like network in
cardiovascular construct 2 in (G)
culture medium 1, (H) culture
medium 2, (I) culture medium 3,
(J) culture medium 4, (K) culture
medium 5 and (L) culture
medium 6. The vascular-like
structures were stained against
von Willebrand Factor. Scale bar
is 500 μm in each image.
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cardiovascular construct 2, whereas in cardiovascular con-
struct 1 a tight, branching 3D like network was formed
(Fig. 1).
The capability of two different vascular-like networks to sup-
port the functionality of CMs was compared to CM monocul-
ture (Table 4). In monoculture, the CMs were contractile
approximately for 7 d in any of the tested media. However,
in the presence of vascular-like network, the CMs were func-
tional, and maintained their contractile capacity for at least
14 d. Differences in the time of contractility were not detected
between the two constructs and a synchronized contractility
was visually observed in both constructs. However, the areas
which were beating were larger in co-cultures (50–70%) than
in monoculture (30–50%). The number of CMs was less
critical when they were cultured with the vascular-like net-
works compared to monoculture and the contractility was
stronger even with a fewer number of CMs (Table 4).
Cardiomyocyte morphology and orientation in the absence
and presence of vascular-like network. CM morphology and
orientation were studied inmonoculture and with the vascular-
like networks. The results showed that the rod-shape mor-
phology of mature CMs could be detected in the presence of
both vascular-like networks after 14 d. However, CMs in the
monoculture remained rounded and less organized in their
phenotype (Fig. 2).
The results also showed that when CMs were cultured in
the presence of vascular-like network they co-localized with
the vascular structures in all culture media tested. Orientation
of the CMs could not be detected in monoculture.
Furthermore, CMs were co-localized longitudinally and par-
allel with the vascular-like network structure that was formed
in cardiovascular construct 2. In cardiovascular construct 1,
the CMs seemed more randomly oriented with the branching
vascular-like structures (Fig. 2).
Electrophysiology of the cardiovascular construct. The
MEA system was used to analyze the functionality of
cardiovascular construct. In addition, the conductivity of
the vascular-like network was proven. Vascular-like net-
work in construct 1 (HUVEC+hASC) was chosen due to
its thicker structure (Sarkanen et al. 2012) and potential
to isolate the signal of CMs. However, the results
showed that cardiovascular construct 1 conducted the
signal and electrical activity was detectable (Fig. 3).
There were no differences detected in the beating fre-
quency in CM monoculture (Fig. 3A) compared to CMs
in cardiovascular constructs (Fig. 3B). MEA measure-
ments also showed that the contractility of CMs was
synchronous in cardiovascular construct 1 (Fig. 3C) as
already observed visually.
Table 4 CM cell number and contractility area in the absence and
presence of two vascular-like networks (HUVEC+hASC) and
(HUVEC+fibroblasts)
Cell number CM contractility
in monoculturea
CM contractility in the presence
of vascular-like networka
0.1×106 7 d, 30–50% (n =27) 14 d, 50–70% (n =30)
0.4×106 12 d, 50–70% (n =13) 14 d, 50–70% (n =7)
a Using visual inspection
Figure 2. CM morphology at day 14 in vitro in (A) cardiovascular
construct 2 in culture medium 1, (B) cardiovascular construct 1 in culture
medium 1 and (C ) monoculture in control medium (SFM).
Cardiomyocytes (cardiac troponin T, green) were co-localized with the
vascular-like network(von Willebrand Factor, red) in (D) cardiovascular
construct 2 in culture medium 4, (E) cardiovascular construct 1 in culture
medium 5 and (F) cardiovascular construct 1 in culture medium 1. Scale
bars are 300 μm.
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Discussion
To reliably mimic the in vivo environment of heart the in vitro
construct should include all critical cardiac cells including
cardiomyocytes, endothelial cells and stromal cells (pericytes,
smoothmuscle cells, and fibroblasts). Constructs composed of
single target cells are lacking the crucial microenvironment
and cell–cell contacts. In addition, the cells should preferably
be characterized in genotypical and phenotypical level in
order to develop a high-quality in vitro construct.
In this study, two different in vitro cardiovascular con-
structs were developed. The constructs are based on
supporting and interacting platform of vascular-like networks
and NRCs. First construct is composed of NRCs, HUVECs,
and human adipose stromal cells. The second construct is
composed of NRCs, HUVECs, and human foreskin fibro-
blasts. NRCs were used in the constructs for proof of concept
purposes as they can be obtained in larger amounts, and are
more easily available than human CMs. Both cardiovascular
constructs in this study are based on quality-controlled prima-
ry HUVECs with fixed passage (Sarkanen et al. 2011). In
regards to the angiogenic and anti-apoptotic potential hASCs
used in the cardiovascular constructs are well defined by us
(Sarkanen et al. 2012) and others (Miranville et al. 2004;
Rehman et al. 2004; Kilroy et al. 2007; Traktuev et al. 2008;
Rubina et al. 2009: De Siena et al. 2010).
In the previous studies, the importance of stromal cells and
endothelial cells to the viability and functionality of CMs has
been shown (Narmoneva et al. 2004, Hsieh et al. 2006, Sadat
et al. 2007, Tulloch et al. 2011). However, to our knowledge,
the effects of premature vascular-like network formed by
HUVEC+fibroblast or by HUVEC+hASC on cardiomyocyte
viability and functionality without artificial scaffold has not
been studied earlier. Our results showed that the contractility
of rat CMs remained longer in culture with HUVEC+hASC/
fibroblasts. Vascular-like network enabled a prolonged func-
tionality of the CMs up to 14 d while the functionality of CMs
in monoculture was approximately seven days with optimized
cell amount. Furthermore, in both constructs, a synchronized
contractility, an essential quality for properly functioning heart
tissue, was visually detected also suggesting properly func-
tioning junctional proteins.
Present tissue engineering strategies often rely on the use of
scaffolds that may, however, interfere with the cell-cell inter-
actions, cell assembly, and induce inflammatory reaction
(Shimizu et al. 2003; Norotte et al. 2009). In this study, no
artificial scaffolds were used. The 3D nature of HUVEC+
hASC co-culture and intense vascular-like network provides
mechanical support and inductive growth factors, thus acting
as a natural scaffold. When the structure of the cardiovascular
constructs was studied in different culture media the CMswere
seen to co-localize with the vascular-like structures in both
constructs. Based on earlier microscopic analysis HUVEC+
hASC vascular-like network is densely branched and three-
dimensional [approximately 200 μm thick (Sarkanen et al.
2012)] thus leading CMs to distribute throughout the network
without organization into anymajor direction. HUVEC+fibro-
blast forms a less dense (approximately 50 μm thick, unpub-
lished data) network and enhanced parallel organization of
vascular-like structures and co-localization of CMs. In both
constructs we could detect elongated phenotype of CMs re-
sembling mature morphology. The co-localization of CMs
and HUVEC+fibroblast vascular-like network may mimic
more closely native heart (Kyösola et al. 1983), as we believe
that cardiovascular construct 2 resembles more closely
Figure 3. MEA measurements of CMs (A) in monoculture (n=3), (B)
on top of the vascular-like network formed by HUVEC+hASC in car-
diovascular construct 1 (n=5). (C) The measurements showed synchro-
nous contraction of CMs on top of the construct 1.
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the in vivo cardiomyocyte alignment shown by Narang
et al. (2004). However, this needs to be further studied.
Our results suggest that already premature vascular-like
network with short tubules, i.e., not completely matured vas-
cular structures, is sufficient for enhanced viability and con-
tractile capacity of CMs. Premature vascular-like network is
missing some features of mature tubules, including lack of
mural cells thus leading to incompletely developed basement
membrane and unstable tubule structure (Rivron et al. 2008).
The paracrine effects of the co-cultured cells seem to be
critical. Activated hASC and HUVEC produce several angio-
genic and anti-apoptotic factors (Rehman et al. 2004; De
Siena et al. 2010) and may therefore increase the viability
and functionality of CMs. Cell–cell contacts including endo-
thelial–cardiomyocyte contacts are known to be crucial in
maintaining the rhythmic and synchronous contraction of
CMs (Brutsaert 2003). The vascular-like network in our car-
diovascular construct might assist in the formation of cell-cell
contacts thus enabling the formation of gap junctions. This
could explain our finding that strong contractility was ob-
served with fewer CMs in the presence of the vascular-like
network than without it. The co-localization of CMs and
vascular-like network may also enable better conduction of
electrical signals.
There is lack of information about medium including opti-
mal serum concentration, growth factors and additional sup-
plement in in vitro cardiac construct (Sekine et al. 2008;
Valarmathi et al. 2010; He et al. 2012; Hussain et al. 2013).
In cardiomyocyte culture, the medium is essential for mainte-
nance of cell morphology, growth characteristics, and pheno-
typic modulations (Li 2002). In our study, the results revealed
that serum-free medium supplemented with VEGF, FGF, and
additionally with ascorbic acid, heparin, and hydrocortisone
provided the best results for cardiovascular construct.
However, in order to get an optimal construct, a compromise
between contractile function of the CMs and amature vascular
network formation was needed. VEGF and FGF are well-
known angiogenic factors that stimulate ECs to form new
vessels (Cao et al. 2004). Moreover, VEGF regulates the
development of vascular endothelium and the endocardium
by inducing multiple angiogenic cellular responses, including
promotion of survival, migration, and differentiation, through
the activation of Akt signaling in ECs (Ferrara et al. 1996).
Therefore, the designed growth factor combination in our
construct supported not only vascular-like network formation
but also the prolonged functionality of CMs.
The concentration of serum in the medium plays an essen-
tial role in determining the phenotype of the cultured CMs.
More mitogenic medium stimulates cell proliferation whereas
CMs cultured in lower serum concentrations (0–5% FBS)
maintain the cell number, phenotype, and contractile proper-
ties. (Li 2002) We tested the cardiovascular constructs in low
(2%) serum as well as in serum-free conditions aiming at
in vivo-like environment with mature CMs. The results
showed that serum was not needed in order to produce func-
tional cardiovascular construct. CM contractility could be
maintained in serum-free conditions and, additionally, obtain
more mature, rod-shaped phenotype of the cells.
Engineered cardiac tissue should have functional and mor-
phological properties similar to that of native myocardium
(Iyer et al. 2011). Cardiac grafts should be thick and compact,
and contain physiologic density of metabolically active, dif-
ferentiated cells (Radisic et al. 2006). The constructs devel-
oped here consisted of the cell types naturally resident in heart
thus providing the essential components needed for in vitro
modeling of myocardium. The results of the current study can
be further utilized in development of a human heart tissue
model. This is a first step towards physiologically relevant and
clinically predictive in vitro cardiovascular model.
Conclusions
In this study, the ability of two different vascular-like networks
to support the viability and functionality of CMs was assessed.
When combining a vascular-like networkwith CMs the viability
and functionality of CMswasmarkedly improved.Multicellular
constructs also allowed synchronized contractility of CMs. The
results suggest that the cardiovascular constructs developed
provide a promising new tool for the assessment of toxicological
and safety pharmacological effects of compounds in vitro.
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ABSTRACT 
 
In vitro cardiac models should include vascular structures to mimic the highly vascularized 
myocardium and to provide interactions between endothelial cells, stromal cells and cardiomyocytes. 
Currently, human pluripotent stem cell derived cardiomyocytes have been shown to present immature 
morphology and fetal-like electrophysiological properties that may limit their use as physiological 
test  platform.  The  aim of  this  study  was  to  develop  multicellular  in vitro cardiovascular construct 
modeling human heart tissue for cardiac safety and efficacy testing.  
In the cardiovascular construct, human pluripotent stem cell-derived cardiomyocytes (CM) were 
cultured with vascular-like network formed by human foreskin fibroblasts and human umbilical vein 
endothelial cells that served as a supporting platform in the construct.  CM orientation, maturation, 
electrophysiological properties and drug responses of the cardiovascular construct were characterized 
and compared to CM monoculture. 
CM in cardiovascular construct showed elongated morphology and aligned with the vascular-like 
network. Electrophysiological properties and calcium metabolism of CM as well as response to E-
4031 and adrenalin demonstrated normal physiological behavior. Gene expression studies 
demonstrated increased expression of cardiac structural proteins and ion channels in cardiovascular 
construct compared to CM monoculture. 
In conclusion, vascular-like network supports the structural and functional maturation of CM. Our 
results suggest that cardiovascular construct presents more mature in vitro cardiac model compared 
to CM monoculture and could therefore serve as an advanced test system for cardiac safety and 
efficacy assessment.  
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INTRODUCTION 
 
In mammalian cardiogenesis, atrial and ventricular cardiomyocytes, conduction system with 
pacemaker cells as well as smooth muscle and non-muscle cell types including endothelial, valvular, 
and endocardial cells are generated 1. Cardiomyocytes account 20-40% of all cardiac cells in adult 
heart with the majority of cells being highly adaptive cells including fibroblasts, vascular smooth 
muscle cells and endothelial cells 2, 3. In cardiac microenvironment, cardiomyocytes are embedded in 
an aligned extracellular matrix (ECM) that facilitates the coordinated contractile function of the heart 
1. Cells and ECM proteins, mainly produced by fibroblasts, are connected via cell–cell and cell–
matrix interactions to maintain the structural organization and functionality of the heart 4, 5. In mature 
myocardium, each cardiomyocyte has physical contact with at least one capillary blood vessel 6. The 
interactions between vasculature and myocardium are bidirectional 7, and active through the adult life 
affecting cardiac growth, function and rhythm 3. Vascular endothelial cells produce several 
angiogenic and anti-apoptotic factors including vascular endothelial growth factor (VEGF), 
angiopoietins and nitric oxide that influence cardiac metabolism, growth and functionality of the heart 
3. Beside to endothelial cells, also fibroblasts secrete angiogenic factors in addition to growth and 
differentiation factors with autocrine and paracrine effects. Fibroblasts have also been shown to give 
mechanical support and produce factors that promote the organization of cardiomyocytes into 3D 
structures in collagen matrices. 5, 8 
 
Cardiotoxicity is one of the leading causes of failure for new therapeutic molecules in preclinical 
development 9. Presently, pharmaceutical industry relies upon animal testing although there are 
fundamental differences in the electrophysiological properties of animal and human cardiomyocytes 
10. In particular, the differences in ion channels and currents impact the transferability of drug 
screening and toxicity studies from murine to humans 11. In addition to animal models, transfected 
non-cardiac cells have been used. However, these cells express usually only one cardiac ion channel 
of interest and all the other characteristics of human cardiomyocyte are lacking 12. Therefore, there is 
a need for improved preclinical drug screening test system especially for assessment of cardiotoxic 
effects and for evaluation of the efficacy of new drug candidates 10, 13.   
 
Functional cardiomyocytes derived from human pluripotent stem cells could provide a significant 
advantage over the previously used cardiac models. Human pluripotent stem cell derived 
cardiomyocytes (hPSC-CM) contract spontaneously and respond appropriately to cardioactive drugs 
14. These cells could be useful in early efficacy and toxicity screening, improving the selection of lead 
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candidates and the reduction of adverse outcomes in clinical stages of drug development 15. However, 
since  hPSC-CM have  been  shown to  display  functional  properties  typical  to  human fetal  CM,  the  
immature state of hPSC-CM may complicate their utilization 14, 16. Ventricular cardiomyocytes in the 
adult human heart are large and brick-shaped whereas hPSC-CM are markedly smaller with round or 
triangular morphology 17. Although the expression of cardiac structural proteins, such as Į-myosin 
heavy chain (MYH6), is shown to be very low in undifferentiated hPSC-CM, it is strongly 
upregulated during in vitro differentiation 18. This has been further supported by the finding that 
hPSC-CM do mature electrophysiologically over time in vitro but  without  reaching  the  adult  CM 
maturity 19. In addition to the increased time in culture, other methods have been utilized in the 
production of more mature hPSC-CMs such as electrical stimulation 20 and 3D culture environment 
4, 6, 21-23. However, the use of scaffolds to enable 3D environment has been associated with reduced 
cell-cell contacts, as well as incorrect deposition and alignment of extracellular matrix in cardiac 
constructs 24.  
 
 
 
In this study, a multicellular in vitro cardiovascular construct without artificial scaffold was 
developed to mimic adult human heart. In the construct, hPSC-CM were co-cultured with vascular-
like network composed of human fibroblasts and human umbilical vein endothelial cells (HUVEC). 
Vascular-like network served as a supporting platform to create natural microenvironment with cell-
cell and cell-matrix interactions. The effects of the vascular-like network on cardiomyocyte 
morphology, gene expression and functionality were studied. 
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MATERIALS AND METHODS 
 
Ethics 
This study conforms to the principles outlined in the Declaration of Helsinki. The use of human 
umbilical  cord  derived  cells  (HUVEC)  and  iPSC  were  approved  by  Ethics  Committee  of  the  
Pirkanmaa Hospital District, Tampere, Finland (approval numbers R08028 and R08070, respectively) 
and a written informed consent was obtained from all the participants.  
 
Cell culture and differentiation 
 
Isolation and culture of human umbilical vein endothelial cells 
HUVEC were isolated from human umbilical cord vein by using enzymatic procedure as described 
previously by us 25. Cells were cultured in EGM-2 medium (Lonza Group Ltd, Table 1) and tested 
for mycoplasma contamination (MycoAlert® Mycoplasma Detection Kit, Lonza Group Ltd) before 
experimental use. 
 
Culture of human foreskin fibroblasts 
Human foreskin fibroblasts were purchased from American Type Culture Collection (CRL-2522; 
ATCC, Manassas, VA, USA). Cells were cultured in fibroblast medium consisting of Minimum 
Essential Medium with Earle’s salts, w/o l-Glutamine (Gibco) supplemented with 10% FBS (Gibco), 
1% l-glutamine (Gibco) and 1% NEAA (Gibco). Cells were tested for mycoplasma contamination 
(MycoAlert® Mycoplasma Detection Kit, Lonza) before experimental use. 
 
Generation of Patient-Specific iPSC line and Cell culture of pluripotent stem cells   
Patient-specific iPSC line UTA.04602.WT was established from a healthy individual as described 
earlier 26. Results of the characterization of UTA.04602.WT cell line have been described earlier 27. 
H7 is a commercial hESC line purchased from WiCell Research Institute, Madison, WI, USA.  
UTA.04602.WT cells and H7 hESC were cultured on mitomycin C inactivated mouse embryonic 
fibroblasts (MEF) in KSR medium (Table 1) which consisted of DMEM/F-12 (Invitrogen) 
supplemented with 20% KnockOut serum replacement (Invitrogen), 1% non-essential amino acids 
(Lonza), 2 mM Glutamax (Invitrogen), 50 U/ml penicillin/streptomycin (Lonza), 0.1 mM beta 
mercaptoethanol (Invitrogen), and 7.8 ng/ml basic fibroblast growth factor (R&D Systems). The 
medium was refreshed daily, and the stem cell colonies were passaged onto a new MEF layer once a 
week using 1 mg/ml collagenase IV (Invitrogen). 
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Differentiation of cardiomyocytes 
Differentiation of pluripotent stem cells into cardiomyocytes was carried out with either by co-
culturing hESC or iPSC with murine visceral endoderm-like (END-2) cells (Humbrecht Institute, 
Utrecht, The Netherlands) as described earlier 28 or with small molecule differentiation method via 
temporal modulation of canonical Wnt signaling 29. Both differentiation methods formed beating 
cardiomyocyte aggregates. These were mechanically excised and treated with collagenase A (Roche 
Diagnostics) to dissociate beating aggregates to single cell level. 
 
Development of cell models 
 
Human cardiomyocyte monoculture 
 
After dissociation human CM were seeded in EB 5 % medium (Table 1) at density of 0,01-0,04 x 106 
cells/cm2. EB 5 % medium was changed 1-2 days after cell seeding and thereafter every second or 
third day. CM monoculture was used as a control to cardiovascular construct throughout the study. 
 
Vascular-like network from co-culture of HUVEC and fibroblast 
The co-culture was established as described earlier 25. Briefly, fibroblasts (p 6-7), 20 000 cells/cm2 
were seeded in fibroblast medium (Table 1) and grown for 2-3 days to confluency. HUVEC were 
seeded on top of fibroblasts at 4000 cells/cm2 in EGM-2 medium (Table 1). The day after cell seeding, 
angiogenic stimulation medium (EBM-2, Lonza), 2 % FBS, 1 mM L-glutamine, 10 ng/ml vascular 
endothelial  growth  factor  (VEGF,  Sigma)  and  1  ng/ml  fibroblast  growth  factor  2  (FGF-2,  Sigma)  
(Table 1) was changed. The angiogenic stimulation medium was changed twice during the 6 day co-
culture prior to CM seeding.  
 
Cardiovascular construct  
EB 5  % medium (Table  1)  was  changed  to  HUVEC+fibroblast  co-culture  before  seeding  of  CM.  
Dissociated human iPS- or hESC-derived CM were seeded on top of the HUVECௗௗfibroblast co-
culture at day 6, when the  vascular-like network was already formed, at a density of 0,01-0,04 x 106 
cells/cm2 in EB 5 %  medium (Figure 1). 1-2 days after CM seeding first EB medium change was 
performed and thereafter three times in a week. The viability of cardiovascular constructs was 
evaluated visually under microscope by assessing the contraction of the cardiomyocytes and vascular-
like network formation of the HUVECs and fibroblasts at least three times in a week. 
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Media development 
In cardiovascular construct medium was designed to primarily support CM functionality and 
secondarily to induce vascular-like network formation. Minimum serum concentration for CM 
monoculture was tested due to our objective to have low-serum or serum-free culture conditions.
  
Immunocytochemistry 
Cardiomyocytes were stained either with goat anti-cardiac-troponin-T (anti-Tnt, 1:1500, Abcam) or 
with mouse anti-Tnt (1:500, Abcam) and the vascular-like formation was visualized with basement 
membrane marker mouse collagen IV (anti-ColIV, 1:500, Sigma) for 1 hour at RT or in+ 4 °C o/n.  
Polyclonal IgG Alexa Fluor 568 (Abcam) for goat anti-Tnt and polyclonal IgG FITC (1:100, Sigma) 
for anti-ColIV and mouse anti-Tnt were used as secondary antibodies for 30 min in RT. Fluorescence 
was visualized with Nikon Eclipse Ti-S microscope (Nikon) or with confocal laser scanning 
microscope Zeiss LSM780 Laser Scanning Confocal Microscope (ZEISS) and the images were 
processed with Zen2009 (confocal images, Carl Zeiss) and with Adobe Photoshop software 7.0 
(Adobe Systems). 
 
Quantitative Real Time-PCR 
Gene expression in CM monoculture, vascular-like network and cardiovascular construct were 
analyzed. The total RNA was extracted at day 1, 6, 7 and 18 (Figure 1) using using PureLink RNA 
Mini Kit (Life Technologies) following the manufacturer’s protocol. Concentration and purity of 
RNA was assessed using spectrophotometry with microplate reader in Varioskan Flash 
Spectrophotometer (ThermoScientific) before further use.  Reverse transcription of the total RNA to 
cDNA was performed using iScript cDNA synthesis kit (Bio-Rad) following manufacturer’s 
instructions.  qRT-PCR was performed according to standard protocols on Abi Prism 7300 instrument 
(Applied  Biosystems)  or  on  Bio-rad  CFX96  Real  Time  System  (BioRad).  The  expression  of  
angiogenesis related genes including VEFG-A, FGF-2, PDGFȕ, TGFȕ1, Angiopoietin1, 
Angiopoietin2 and cardiac related genes including CACNA1C, TNNT2, KCNJ2, CX-43, MYH-6, 
MYH-7 were studied with SYBR chemistry. In addition, the expression of cardiac related genes 
ADRB1and SCN5a as well as reference genes RPLP0 and GAPDH were studied using Taqman 
chemistry with Taqman Universal PCR Master Mix (Applied Biosystems). The following Taqman 
assays (x20) were used: Hs02330048_s1 for ADRB1, Hs00165693_m1 for SCN5A, Hs04189669_g1 
for RPLO0 and Hs02758991_g1 for GAPDH (Applied Biosystems). SYBR primer sequences can be 
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found in supplemental data. The relative expression levels were determined by using the comparative 
method (ǻǻCt) 30. 
 
Functional analyses 
Micro electrode array (MEA) measurements 
The ability of cardiovascular construct to conduct electrical signal was analyzed using the MEA 
system (Multi Channel Systems MCS GmbH). The MEA wells (8x8 standard MEAs or 6-well MEAs) 
were first hydrophilized with FBS and then coated with 0.1 % gelatin type A (Sigma-Aldrich).  
Field potentials were recorded at day 10 or 18 (Figure 1) at 37°C, and signals were recorded for 2 
min. The sampling frequency was 20 kHz. Field potentials were recorded during spontaneous baseline 
beating, and with 1µM adrenaline (Sigma-Aldrich) or 300nM E-4031(Sigma-Aldrich). Drugs were 
diluted and measurements performed in EB medium with 5% FBS. The field potentials were recorded 
with MC_Rack v.4.5.7 software (Multi Channel Systems MCS GmbH). Signals were analyzed with 
Cardiomyocyte MEA Data Analysis (CardioMDA) software (Pradhapan et al. 2013). 
 
Analysis of  Ca2+ cycling 
Cardiovascular constructs were loaded with 4 µmol/L Fura-2 AM (Invitrogen, Molecular Probes) for 
30 minutes in HEPES based medium. Measurements were assessed in 37°C and the extracellular 
solution and consisted of (in mmol/L): 137 NaCl, 5 KCl, 0.44 KH2PO4, 20 HEPES, 4.2 NaHCO3, 5 
D-glucose, 2 CaCl2, 1.2 MgCl2 and 1 Na-pyruvate (pH was adjusted to 7.4 with NaOH) 
Ca2+ measurements were recorded at day 10 or 11 (Figure 1) and conducted on an inverted IX70 
microscope (Olympus Corporation) with a UApo/340 x20 air objective (Olympus). Images were 
acquired  with  an  ANDOR  iXon  885  CCD  camera  (Andor  Technology)  synchronized  with  a  
Polychrome  V  light  source  by  a  real  time  DSP  control  unit  and  TILLvisION  software  (TILL  
Photonics). Fura-2 in CMs was excited at 340 nm and 380 nm light and the emission was recorded at 
505 nm. For Ca2+ analysis, regions of interests were selected for spontaneously beating cells and 
background noise was subtracted before further processing. The Ca2+ levels are presented as 
ratiometric values of F340/F380. The changes in Ca2+ were recorded during spontaneous baseline 
beating and spontaneous beating during 1µM adrenaline (Sigma-Aldrich) perfusion.  
 
Statistics 
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qPCR data is expressed as mean values +/- SD. Statistical analysis for the qPCR data was performed 
by IBM SPPS Statistics 22-software and by using Mann-Whitney U-test for independent samples. 
Bon ferroni -correction was included when more than two groups were analyzed. A p-value less than 
0.05 was considered statistically significant.  
In MEA and Ca2+ imaging data, the significance of differences between the two groups (CM 
monoculture and cardiovascular construct) was evaluated with the unpaired Student’s t-test. The 
significance of changes within a group was evaluated with the paired Student’s t-test. MEA and Ca2+ 
imaging data are expressed as average ± S.E.M. In Ca2+ imaging data n refers to the number of cells 
and  in  MEA  data  n  refers  to  number  of  MEA  chips.  A  p-value less than 0.05 was considered 
statistically significant.  
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RESULTS 
Vascular-like network serves as a supporting and interactive platform for cardiovascular 
construct 
Expression levels of angiogenesis related genes were analyzed at days 1, 6 and 18 in vascular-like 
network to assess the production of growth factors and maturation state of vascular structures (Figure 
2). During the first six days the expression of fibroblast growth factor 2 (FGF-2), transforming growth 
factor  ȕ (TGFȕ) and Angiopoietin-1 (Ang-1) had an increasing trend. Furthermore, statistically 
significant increase in the expression level was observed in Angiopoietin-2 (Ang-2) and platelet 
derived growth factor ȕ (PDGF-ȕ). During the days 6 - 18, the expression of aforementioned genes 
remained constant except for Angiopoietin-2 which had significantly increased expression level also 
during this time period. 
 
The expression levels of the angiogenesis related genes were also assessed from the cardiovascular 
construct at day 6 and 18 (Figure 2). The expression levels of FGF-2, TGFȕ and Angiopoietin-1 
were at the similar level in cardiovascular construct compared to the vascular-like network. However, 
the expression levels of VEGF and PDGF-ȕ were significantly higher in the cardiovascular construct. 
 
Vascular-like network enhances mature cardiac phenotype and orientation of pluripotent stem 
cell derived cardiomyocytes in cardiovascular construct 
 
Compared to the round morphology of CM in monoculture (Figure 3.A), more mature morphology 
with elongated CM was detected in the presence of vascular-like network (Figure 3.C-D). Moreover, 
2D and 3D projections showed that CM co-localized longitudinally and parallel with tubular 
structures (Figure 3.E-F). On the contrary, CM in monoculture remained rounded, less organized and 
orientation of the cells could not be detected (Figure 3.B).  
Expression levels of cardiac related genes were analyzed in cardiovascular construct on the day after 
CM seeding (day 7) and at day 18. The expression was similarly assessed from CM monoculture at 
the same time points (Figure 4). Results showed that the cardiac muscle myosin transcripts MYH6 
and MYH7 as well as cardiac troponin T were significantly upregulated in cardiovascular construct 
over this time period whereas they remained constant or decreased in CM monoculture. Also 
expression level of gap junction marker connexin 43 was shown to increase significantly in 
cardiovascular construct while remaining low in CM monoculture. Furthermore, at day 18, MYH6, 
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MYH7, troponin T and connexin 43 were all expressed at significantly higher level in the 
cardiovascular construct compared to the CM monoculture (Figure 4).  
 
In the cardiovascular construct, the expression levels of ion channels CACNA1C, KCNJ2 and 
SCN5A did not increase significantly between days 7 to 18 (Figure 4). However, similarly to 
structural genes, there was statistically significant difference when expression levels were compared 
between cardiovascular construct and CM monoculture at day 18. The expression of beta-1 adrenergic 
receptor (ADRB1) increased at statistically significant manner from day 7 to day 18 in the cardiac 
construct. Moreover, the expression was significantly higher at day 18 in the cardiovascular construct 
compared to CM monoculture. 
 
 
Electrophysiological changes in pluripotent stem cell derived cardiomyocytes in cardiovascular 
construct suggest functional improvement of cardiomyocytes 
 
The electrical activity of the cardiovascular construct was detectable with MEA and the contractility 
was synchronous (Figure 5.A). Adrenaline increased the beating frequency of CM (Figure 5.B-C) 
thus decreasing the field potential duration (FPD) in cardiovascular constructs as well as in CM 
monoculture (Figure 5.D). The increase in beating frequency and decrease in FPD was statistically 
significant between baseline and adrenaline only in cardiovascular construct. 
 E4031, a hERG blocker, was shown to significantly prolong the FPD in cardiovascular construct and 
in CM monoculture compared to the baseline but there was no significant difference between the 
groups (Figure 5. E-F). Prolongation of FPD due to E4031 exposure resulted in additional adverse 
effects including pausing beating and/or arrhythmias. These adverse effects were seen in CM 
monoculture as well as in cardiovascular construct (Figure 5.G).  
 
Ca2+ transients of pluripotent stem cell derived cardiomyocytes in the absence and presence of 
vascular-like network 
Cardiovascular construct and CM monoculture were shown to respond similarly to adrenaline 
exposure (See supplemental figure S1.A). When compared to baseline, adrenalin caused significant 
increase in beating frequency (Figure 6.D) and decrease in peak duration in both systems (Figure 6.B) 
and, additionally, a significant decrease in amplitude in cardiovascular construct (Figure 6.C). The 
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amplitude in cardiovascular construct was significantly lower at baseline as well as during adrenaline 
perfusion compared to those in CM monoculture (Figure 6.C).  
The diastolic Ca2+ increased significantly in CM monoculture and in cardiovascular construct due to 
the adrenaline exposure (Figure 6.A). Ca2+ transient changes were also analysed separately for each 
cell as the ratio of adrenaline response divided by baseline response. The results showed that in 
cardiovascular construct adrenaline caused significant increase in beating frequency and significant 
decrease in amplitude when compared to CM monoculture (see supplemental figure S1.B).  
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DISCUSSION 
Since in vitro assays aim at translating preclinical data into the clinical studies, it is crucial to use 
physiologically relevant model system 31. In preclinical cardiotoxicity studies, the assessment of the 
risk for QT interval prolongation is part of the standard evaluation of new compounds as defined by 
the International Conference of Harmonization (ICH) Expert Working Group 9. It has been stated that 
human pluripotent stem cell derived cardiomyocytes (hPSC-CM) based test systems could improve 
the early detection of QT prolongation with the benefit of being of human origin 32. However, at the 
same time, it is widely acknowledged that hPSC-CM possess fetal-like characteristics, i.e. 
contractility with some proliferative capacity and with embryonic like electrophysiology. Although 
the factors affecting maturity remain largely unknown, cell line, time in culture, co-cultured cells and 
culture conditions appear to have an effect on the maturity. 14  
 
We have previously developed cardiovascular constructs based on co-culture of neonatal rat 
cardiomyocytes and two different vascular-like networks formed either by human adipose stromal 
cells+human umbilical vein endothelial cells (HUVEC) or HUVEC+fibroblasts. In the previous 
study, CM viability and functionality was maintained longer in co-culture with vascular-like network 
and, furthermore, morphological maturation with more elongated cardiomyocytes compared to CM 
monoculture was detected 33.   In the present study, vascular-like network formed by HUVEC and 
fibroblasts was combined with hPSC-CM to develop completely human cell based cardiovascular 
construct for cardiac safety and efficacy assessment.  
 
Expression of cardiac structural protein coding genes MYH6 and MYH7 and cardiac troponin t 
increased markedly in cardiovascular construct whereas they remained constant or decreased in 
hPSC-CM monoculture. Also expression level of gap junction marker connexin 43 was shown to 
increase in cardiovascular construct. In CM monoculture, the overgrowth of non-cardiomyocytes may 
explain the decreased expression of structural transcripts MYH6, MYH7 and troponin T. However, 
similar overgrowth of non-cardiomyocytes was not detected in cardiovascular construct. These results 
suggest that vascular-like network improves the cardiac specific phenotype of hPSC-CM. Similar 
phenomenon has been reported previously. Genes coding structural proteins were expressed at higher 
level  when  cardiomyocytes  were  cultured  with  endothelial  cells  and  fibroblasts  with  3D  
biodegradable scaffold as reported by Caspi et al. 34.   Burridge  et  al.  reported  a  similar  kind  of  
phenomenon in which troponin T expression at the protein level was significantly enhanced in the 
multicellular culture when compared to the CM monoculture 35. In these studies, however, a 3D 
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matrix was used in addition to the co-culture. Our results are in line with the previous studies without 
hydrogel or any other external scaffold. 
 
In heart, the extracellular matrix, mainly produced by the cardiac fibroblasts, guides cellular 
orientation and organization thus facilitating efficient cell contraction, force transduction and 
electrical transmission between the cells. The importance of alignment of CM in coordinated 
contraction is proven by the native cardiac structure, but also in in vitro studies. 4 In in vitro studies 
alignment of CM has been induced by microcontact printing demonstrating that alignment improves 
CM calcium handling and contractile properties when compared to randomly oriented cardiomyocyte 
monolayers 36, 37. Since the use of scaffolds in cardiac constructs has been associated with reduced 
cell-cell contacts, as well as incorrect deposition and alignment of extracellular matrix 24, artificial 
scaffolds were not used in the present in vitro cardiovascular construct. Our result demonstrated that 
seeding of hPSC-CM to already formed vascular-like network orientates the CM mostly parallel with 
tubule structures. Moreover, as detected in 3D projection, some CM were seen to surround the tubule 
structures. Fibroblasts are known to produce extracellular matrix components and enhance alignment 
of cardiomyocytes 5. Also in our cardiovascular construct the presence of fibroblasts was likely to 
enhance orientation of hPSC-CM with vascular-like structures.   
 
As  already  reported  in  our  previous  study,  the  vascular-like  network  formed  by  HUVEC  and  
fibroblasts served as a supporting platform for the cardiomyocytes 33. Our new results showed that 
the expression of several growth factors including vascular endothelial growth factor (VEGF), 
fibroblast growth factor 2 (FGF-2), angiopoietin 1, platelet derived growth factor beta (PDGF-ȕ)  and 
transforming growth factor beta (TGF-ȕ) was active in vascular-like network throughout the 
experiment. In addition, angiopoietin 2, a marker of early stage tubule formation, was shown to 
increase from day 1 to day 18 suggesting an ongoing tubule formation process in vascular-like 
network. In cardiovascular construct, expression of growth factors had a similar trend. However, 
expression of VEGF and PDGF-ȕ was increased in cardiovascular construct suggesting an active 
production of these growth factors.  
After seeding of CM (day 6), vascular-like network was shown to regress in the absence of VEGF 
and FGF-2. This was detected in gene expression studies with the low expression of angiopoietin 2 
in cardiovascular construct compared to vascular-like network at day 18. It has been previously 
reported that in the absence of angiogenic stimulatory signals, such as VEGF, regression of the vessels 
occurs 38. However, the regression of vascular-like structures did not seem affect to the cardiomyocyte 
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viability or contractility as detected in the MEA and calcium metabolism measurements that were 
performed 4-12 days after seeding of hPSC-CM. These results suggest that cell-cell as well as cell-
matrix interactions, instead of completely developed vascular structures, are critical for 
cardiomyocyte viability and functionality.  
Beside to cell-cell and cell-matrix contacts, the paracrine effects of the co-cultured cells are most 
likely important. Vascular endothelial cells have been shown to produce several angiogenic and anti-
apoptotic factors compounds including VEGF and angiopoietins that influence cardiac metabolism, 
growth and contractility 3. Fibroblasts also secrete angiogenic factors in addition to growth and 
differentiation factors that have autocrine and paracrine effects 5,  8. Furthermore, endothelial-
cardiomyocyte contacts are known to be crucial in maintaining the rhythmic and synchronous 
contraction of cardiomyocytes 3. All these earlier findings support our results indicating that mature 
vascular-like structures are not necessary for the development of functional cardiovascular construct. 
 
Although the major ionic currents normally present in adult CM are expressed also in hPSC-CM 14 
differences are seen in the expression levels of cardiac ion channels and in calcium handling genes 
39. Our gene expression data showed that in the presence of vascular-like network the expression of 
transcripts of sodium (SCN5A) and calcium (CACNA1C) channels were increased during the days  
7-18, while the level of a potassium channel (KCNJ2) remained constant. More importantly, all these 
genes were expressed at higher level in the cardiovascular construct compared to CM monoculture at 
the end of the experiment. SCN5A gene codes the cardiac sodium channel NaV1.5 which functions 
in the fast depolarization phase of the cardiac action potential. The expression level of SCN5A has 
been reported to increase when hPSC-CM were maturated upon electrical stimulation 20. In addition, 
the  expression  of  CACNA1C,  gene  coding  the  L-type  Ca+ -channel Cav 1.2, was also shown to 
increase in co-culture with hESC-derived endothelial cells and human amniotic mesenchymal stem 
cells 35. The expression level of KCNJ2 that codes the Kir2.1 channel responsible for the inward 
rectifier potassium current (IK1), has been reported to significantly increase during hESC-CM 
maturation 19 and in culture with endothelial cells 35. Despite the relative short co-culture time with 
vascular-like network, cardiomyocytes in cardiovascular construct expressed these ion channel-
coding genes at higher level compared to CM monoculture. The increased expression indicates that 
the aforementioned currents are increasingly present in the cardiovascular construct and the hPSC-
CM would therefore exhibit electrophysiologically more mature phenotype than the monoculture of 
CM. 
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MEA measurements showed that E-4031 increased significantly the field potential duration and 
arrhythmogenicity in the cardiovascular construct as well as in CM monoculture Calcium imaging 
analysis showed that Ca2+ transients were detectable and adrenaline responses evident in the 
cardiovascular construct. We detected that adrenaline increased significantly the beating frequency 
of cardiovascular construct compared to CM monoculture. This was evident in field potential 
recordings  as  well  as  in  Ca2+ cycling measurements and further confirmed by gene expression 
analysis.  A significantly higher expression of ADRB1, a gene encoding the ȕ1-adrenoreceptor, was 
detected in the cardiovascular construct compared to CM monoculture which further supports the 
conclusion that vascular-like network has positive effect on the maturation status of the hPSC-CM. 
 
Although earlier studies have shown that co-culture with endothelial cells and fibroblasts enhances 
the formation of more mature-like morphology of cardiomyocytes, increases the expression of cardiac 
specific genes and their electromechanical properties 34, 35, 40, they are based on the utilization of 
different artificial scaffolds. In the present study, vascular-like network served as a natural, supporting 
and interactive platform for the hPSC-CM. Enhanced maturation of hPSC-CM detected in already 12 
days suggests that the cardiovascular construct provides more rapid test system. In addition, we 
detected increased sensitivity in response to adrenalin that is likely due to higher expression of the 
ȕ1-adrenoreceptor in cardiovascular construct compared to CM monoculture.  
 
The specific mechanism which vascular-like network enhances the maturation state of hPSC-CM 
remains unknown. However, it can by hypothesized that neighboring non-myocytes could enhance 
the electrical maturation of hPSC-CM in cardiovascular construct by secreting paracrine factors or 
non-cardiac cells might enhance CM signal propagation through cell-to-cell contacts as also 
suggested by others 41, 42.  
In conclusion, the vascular-like network composed of HUVEC and fibroblasts improves the 
morphological and electrophysiological maturation state of hPSC-CM. Optimal microenvironment 
for CM is likely essential for proper functioning of the cells and the cardiovascular construct could 
serve as a more mature and advanced test systems in the cardiac safety and efficacy assessment.  
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Tables  
 
Table 1. Culture media used for development of cell models. 
 
Acronym           Basal medium Serum Growth factors  Supplementation 
Fibroblast medium      MEM  10 % FBS - 1% l-glutamine, 1% 
NEAA 
EGM-2 medium EBM-2 2 % FBS VEGF, FGF-2, IGF, 
EGF 
hydrocortisone, 
ascorbic acid, heparin 
Angiogenic 
stimulation 
medium 
EBM-2 2 % FBS 10 ng/ml VEGF, 
1 ng/ml FGF-2 
1 % l-glutamine 
EB 5%  DMEM/F12 5% FBS - 1 % NEAA, 
1 % Glutamax, 
0,5 % Pen/Strep 
VEGF, Vascular Endothelial Growth Factor 
FGF-2, Fibroblast Growth Factor 2 
IGF, Insulin-like Growth Factor 
EGF, Epidermal Growth Factor 
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Figures 
 
Figure 1. Establishment of cardiovascular construct and different end points.  
 
 
 
 
 
 
Figure 2. Expression levels of angiogenesis related genes vascular endothelial growth factor (VEGF), 
fibroblast growth factor 2 (FGF-2), transforming growth factor beta (TGF-ȕ), angiopoietin 1 (ANG-
1),  angiopoietin  2  (ANG-2) and platelet derived growth factor beta (PDGF-ȕ) in cardiovascular 
construct and in vascular-like network at time points 0, 6 and 18. * p<0.05. 
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Figure 3. Morphology of human stem cell derived cardiomyocytes in (A-B) cardiomyocyte 
monoculture and in  (C-D) cardiovascular construct. (E-F) Orientation of human stem cell derived 
cardiomyocytes (troponin t, red) with vascular-like network (collagen IV, red) in cardiovascular 
construct. Scale bars 50 µm. 
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Figure 4. Expression of levels of cardiac related genes troponin t (TNNT), cardiac muscle myosins 
(MYH6, MYH 7), connexin 43 (Cx43), calcium channel (CACNA1C), potassium channel (KCNJ2), 
sodium channel (SCN5A) and beta-1-adrenergic receptor (ADBR1) at time points 7 and day 18 in 
cardiomyocyte monoculture and in cardiovascular construct.* p<0.05. 
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Figure 5.  MEA measurements of the cardiovascular construct. (A) The electrical activity of the 
cardiovascular construct was detectable with MEA and the contractility was synchronous. (B) 
Representative field potential traces of the effect of ȕ-adrenergic agonist adrenaline (1 uM). (C) 
Beating frequencies and (D) field potential durations in MEA measurements. In (C) and (D) n=5 in 
CM monoculture and in cardiovascular construct. (E) Overlay plot showing the effect of 300nM E-
4031 on field potential duration. (F) E-4031 responses in CM monoculture (n=6) and cardiovascular 
construct (n=7). Change in the field potential duration was calculated as relative change from the 
baseline. No significant difference between CM monoculture and cardiovascular construct. (G) 
Adverse effects of E-4031. The number indicates how many replicates were affected. Normal: no 
arrhythmias, Normal+Pause: no arrhythmias but field potential activity terminates, Arrhythmia: 
arrhythmias affecting amplitude and frequency, Arrhythmia+Pause: arrhythmias leading to 
termination of beating activity. CM=cardiomyocytes; CvC=cardiovascular construct. * p<0.05. 
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Figure 6. Ca2+ measurements of the cardiovascular construct and cardiomyocyte monoculture in 
baseline and after adrenalin exposure represented as (A) diastolic Ca2+ levels; (B) peak duration; (C) 
amplitude and (D) frequency. CM monoculture n=16, cardiovascular construct n=26. * p<0.05.   
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Supplemental data 
 
Primer sequences for SYBR green qPCR. 
 
 
Figures 
 
 
 
Figure S1. Ca2+ measurements of the cardiovascular construct and cardiomyocyte monoculture (A) 
Ca2+ traces of cardiomyocyte monoculture and cardiovascular construct at baseline and after adrenalin 
exposure.  (B)  Diastolic  Ca2+ level and duration, amplitude and frequency of calcium transients in 
cardiomyocyte monoculture and in cardiovascular construct were analyzed separately for each cell as 
the ratio of adrenaline response divided by baseline response. CM monoculture n=16, cardiovascular 
construct n=26. * p<0.05. 
 
 
 
 
 
 
Gene Forward Primer Reverse Primer 
VEFG-A AGGGCAGAATCATCACGAAGT AGGGTCTCGATTGGATGGCA 
FGF-2 AGAAGAGCGACCCTCACATCA CGGTTAGCACACACTCCTTTG 
PDGFȕ CTCGATCCGCTCCTTTGATGA CGTTGGTGCGGTCTATGAG 
TGFȕ1 CAATTCCTGGCGATACCTCAG GCACAACTCCGGTGACATCAA 
Angiopoietin1 AGCGCCGAAGTCCAGAAAAC TACTCTCACGACAGTTGCCAT 
Angiopoietin2 ACCCCACTGTTGCTAAAGAAGA CCATCCTCACGTCGCTGAATA 
CACNA 1C TGACATCGAGGGAGAAAACT ACATTAGACTTGACTGCGGC 
TNNT2 TTCACCAAAGATCTGCTCCTCGCT TTATTACTGGTGTGGAGTGGGTGTGG 
KCNJ2 GAGCACAGCTCCTCAAATCC TTCCACTGTCAAACCCAACA 
CX-43 GGTCTGAGTGCCTGAACTTGCCT TGCCTGGGCACCACTCTTTTGC 
MYH6 AGGGATAACCAGGGGAAGCACC TGCGAATGTCAAAGGGCCGGG 
MYH7 GGCAAGACAGTGACCGTGAAG 
 
CGTAGCGATCCTTGAGGTTGTA 
 
